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Abstract 
New chemical entities that humans and animals are likely to be exposed to are 
tested using various in vitro and in vivo toxicological assays to understand the 
potential for harm. The increasing power of in silico analysis in combination with in 
vitro techniques is being exploited for the ability to predict in vivo outcomes such as 
toxicity, thereby reducing the requirement for animal testing. Previous studies in our 
laboratory have found that dietary phenobarbital treatment of rats results in 
dysregulation of the hepatic miRNAome, including prominent alteration of the 
expression of the miR-200a/b/429 cluster and miR-182/96 cluster. In this thesis I 
explore the use of a cell culture system, rat hepatocyte-like B13/H cells, to 
interrogate the underlying mechanisms of phenobarbital-mediated toxicity. Through 
this model I explore the function of phenobarbital-dysregulated microRNAs to 
determine their roles as markers of phenobarbital treatment in the rat. We find that 
the B13/H cells provide a useful system for studying the phenobarbital response in 
vitro, and how these responses relate to the effects of oral exposure to phenobarbital 
in vivo in the rat. In this respect, the B13/H cells appear representative of the rat 
response to phenobarbital, which is different to that of the mouse. With a focus on 
the phenobarbital-mediated dysregulation of the miR-182/96 cluster, I have explored 
the consequences of phenobarbital treatment on the B13/H cell model and related 
this to the in vivo effects. The data suggest that these microRNAs appear to control 
phenobarbital-mediated perturbation of glycolysis, cell transformation and 
methylation patterns.  
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If you don’t go after what you want, you’ll never have it.  
If you don’t ask, the answer is always no.  
If you don’t step forward, you’re always in the same place. 
 
Nora Roberts
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1. Introduction 
1.1 Chemical exposure  
Exposure to lipophilic chemical entities from foreign (xenobiotic) or endogenous 
(endobiotic) sources requires biotransformation and excretion to prevent harmful 
accumulation (Ennulat et al., 2010). Biotransformation refers to biologically-mediated 
chemical changes, for example by xenobiotic metabolising enzymes, which aim to 
reduce a chemical’s lipophilicity and aid elimination (Botts et al., 2010). Most tissues 
in the body are capable of xenobiotic biotransformation, however the liver has the 
largest capacity to produce xenobiotic metabolising enzymes and is the major 
defence of the body to chemical exposure (Ennulat et al., 2010; Hardisty & Brix, 
2005).  
 
1.1.1 Biotransformation 
The liver is a multifunctional organ involved in xenobiotic metabolism (Sturgill & 
Lambert, 1997), energy regulation (Bollen, Keppens, & Stalmans, 1998), bile 
production, fat absorption and cholesterol homeostasis (T. Li & Chiang, 2014). The 
liver is a heterogeneous mix of cells, dominated by parenchymal hepatocyte cells, 
which are the main cell type involved in expressing proteins for biotransformation 
(Decaens, Durand, Grosse, & Cassio, 2008) and make up to 60-70% of the cell 
population. The most abundant non-paranchymal cell populations consist of 
cholangiocytes, sinusoidal cells, Kupffer cells and hepatic stellate cells. There are 
variable reports on their density within the liver, but each have been reported to be 1-
20% of the total cell population (Damm et al., 2013; Malarkey, Johnson, Ryan, 
Boorman, & Maronpot, 2005). The cholangiocytes are epithelial cells, which line the 
liver bile ducts and are important in the transport of bile from hepatocytes into the 
1. Introduction 
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bile canaliculi to the bile duct (N. Kanno, LeSage, Glaser, Alvaro, & Alpini, 2000) 
(Figure 1.1). Kupffer cells are resident macrophages and are involved in mediating 
the liver immune response (Damm et al., 2013). Sinusoidal endothelial cells form 
capillaries that facilitate the transport of molecules between hepatocytes and the 
blood (Figure 1.1), which is enabled by the sinusoidal cell’s porous structure, known 
as  fenestrations (Damm et al., 2013). Finally, hepatic stellate cells, which are 
located in the space of Disse (between the basolateral membrane of hepatocytes 
and anti-luminal surface of sinusoidal cells (Figure 1.1)), are involved in liver 
regeneration, retinol storage and immune regulation (Y.-S. Lee & Jeong, 2012). 
  
Figure 1.1: Liver architecture 
Figure 1.1 depicts the human liver architecture, demonstrating the cellular 
arrangement and blood and bile flow. Adapted from Kang et al., (Kang, Mars, & 
Michalopoulos, 2012). 
 
The architecture of the human liver is arranged as many hexagonal-like hepatic 
lobules, where blood flows into the liver lobule from the portal triad (Figure 1.1 and 
Figure 1.2). Blood flows into the liver from the intestine, stomach, spleen and 
1. Introduction 
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pancreas via the portal vein, and from the heart via the hepatic artery. Blood flow 
leaves the liver through the central vein where it travels back to the heart (Malarkey 
et al., 2005) (Figure 1.1 and Figure 1.2). Bile flows in the opposite direction towards 
the portal triad; produced by the hepatocytes and leaves via the bile duct to the gall 
bladder (Malarkey et al., 2005) (Figure 1.1 and Figure 1.2). The hepatic lobule is split 
into 3 zones, (1) the outer periphery, or periportal zone, containing the portal triads, 
(2) the pericentral zone and (3) the inner transitional, or centilobular, zone (Figure 
1.2). The periportal zone is associated with highest oxygen context, transitioning to 
the centrilobular zone, which is linked to the highest levels of metabolised 
xenobiotics and lowest oxygen levels (Kang et al., 2012; Malarkey et al., 2005).  
  
 
 
 
 
 
 
Figure 1.2: Hepatic lobule structure 
Figure 1.2 demonstrates the layout of the human hepatic lobule structure as 
hexagonal units that repeat throughout the liver. In the left panel, blood flow and bile 
flow are represented using yellow and black arrows respectively. Adapted from Kang 
et al., (Kang et al., 2012). 
 
Xenobiotic biotransformation can be split into 3 distinct phases. Phase 1 metabolism 
refers to the creation of a functional group on a lipophilic xenobiotic (such as an 
1. Introduction 
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hydroxyl group by oxidation from cytochrome P450 monooxygenases (Cyps)), which 
allows the subsequent conjugation of a polar moiety (phase 2) (such as glucuronide 
formation by UDP-glucuronosyl transferases (Ugt)). Addition of the polar group 
increases the hydrophilicity of the xenobiotic for transport and excretion (phase 3) 
(by transporter proteins such as, organic anion transporter (Oat)) (B. D. Wallace & 
Redinbo, 2013). 
 
1.1.2 In vitro toxicology testing 
In order to interrogate the underlying molecular mechanism(s) of a chemical’s 
potential for harm, one needs to investigate and characterise an appropriate in vitro 
model. Hepatic models will be discussed herein due to the hepatic effects of 
phenobarbital.  
 
Cultured primary hepatocytes are the current gold standard for hepato-toxicology 
testing. However primary hepatocytes are unstable and rapidly lose their hepatic 
phenotype (within 48-72 hours of culturing) and data is not easily reproducible due to 
donor variation and health. Liver slices can be used but they are also subject to 
similar problems associated with primary cells (Soldatow, LeCluyse, Griffith, & 
Rusyn, 2013). Maintenance of the primary hepatocyte cell phenotype are reported to 
be improved through co-culture with additional cell types (Khetani, Szulgit, Del Rio, 
Barlow, & Bhatia, 2004) or by 3D spheroid culture (Chang & Hughes-Fulford, 2014) 
when compared to monolayer cultures. However, it remains difficult to maintain 
appropriate oxygen and nutrient flow in 3D cultures, which are key effectors of 
spheroid formation and hepatocyte differentiation (Nugraha et al., 2011; Soldatow et 
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al., 2013). One way to circumvent these hurdles is through the use of microfluidics 
based approaches. In systems such as this, hepatocytes can be cultured either as 
mono- or co-cultures, or even as spheroids, and cell medium with or without 
xenobiotics can be perfused over the cells producing a dynamic and zonal 
environment (Soldatow et al., 2013). Results demonstrate that the functional life 
span of primary hepatocytes can be improved with these methods (Legendre et al., 
2013). It is thought that these above 3D methods improve upon primary cell mono-
cultures due to the formation of cell polarity and inter cell contacts and 
communication, which is believed to be key in the pleiotropic functionality of 
hepatocytes (Decaens et al., 2008; Treyer & Musch, 2013).  
 
Other more readily available cell systems have been extensively used to understand 
hepatic responses to chemical exposure such as immortalised human cells: HuH7 
(Nakabayashi, Taketa, Miyano, Yamane, & Sato, 1982), HepG2 (Knowles, Howe, & 
Aden, 1980) and HepaRG (Gripon et al., 2002) cells. HuH7 cells are derived from a 
well differentiated hepatocellular carcinoma, which are Cyp450 inducible as 
demonstrated by increased enzyme activity of CYP2B6 and CYP3A4 when treated 
with PB or rifampicin respectively (Choi et al., 2014). HepG2 cells are human 
hepatoblastoma derived cells that are also Cyp450 inducible, and to a greater 
degree than Huh7 cells (Choi et al., 2014). HepG2 cells are useful in studying phase 
1 (oxidative) detoxication of a parent compound but have lower metabolic capacity 
for the metabolites (phase II metabolism) (Gerets et al., 2012) and have been shown 
to exhibit altered phenotypic changes with increased passage (Soldatow et al., 
2013). Equivalent hepatoma derived cells from the rat have also been used to 
understand xenobiotic metabolism, such as the Reuber H35 rat hepatoma derived: 
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Fao, 2sFou and C2Rev7 cells (Pitot, Peraino, Morse, & Potter, 1964; Reuber, 1961). 
These cell lines exhibit aldrin epoxidase activity in response to PB treatment (Wiebel, 
Kiefer, & Murdia, 1984), which is suggestive of Cyp2b activation (Khan et al., 1998). 
Increased Cyp2c6 mRNA has been reported in Fao cells after PB treatment (Shaw, 
Adesnik, Weiss, & Corcos, 1993) and Fao cells treated with benzo[b]fluoranthene 
also demonstrate increased Cyp1a activity (Alessandro Chiarolini, Maria Teresa, 
1997). More recently the HepaRG cell line, a bipotent human hepatocellular 
carcinoma cell line, has been shown to display enhanced Cyp450 inducibility 
compared to HepG2 cells (Gerets et al., 2012). Upon reaching confluency, HepaRG 
cells differentiate into hepatocyte-like and biliary-like cells and express liver function 
genes such as phase I and II drug metabolising enzymes and the nuclear receptors, 
Car and Pxr. Treating HepaRG cells with 2% DMSO and hydrocortisone has been 
reported to further improve their liver-like functions (Gripon et al., 2002). 
 
Hepatocytes or hepatocyte-like cells can be derived from stem cell populations, 
either from embryonic stem cells or from differentiated somatic cells as induced stem 
cells (Hu & Li, 2015). Induced pluripotent stem cells derived from differentiated cells 
allows expansion of patient specific cells for experimental manipulation (Lu et al., 
2015). Yet thus far, stem-cell derived hepatocyte models do not exhibit the full 
complement of normal hepatocyte activity and in particular the full range and 
inducibility of Cyp enzyme functionality and are also subject to dedifferentiation 
problems as well as typically requiring complex culture media (Soldatow et al., 
2013). However, unlike other stem-cell derived hepatocytes, the differentiated rat 
B13/H hepatocyte-like cells do express a range of inducible and constitutively 
expressed Cyp enzymes and have been demonstrated to act as a functional and 
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useful hepatic model (Philip M E Probert et al., 2014), and will be used herein as an 
in vitro model to assess responses to phenobarbital exposure. 
 
1.2 Phenobarbital (PB) 
Phenobarbital (PB) is a commonly prescribed antiepileptic drug that has been in use 
since its inception over 100 years ago (Brodie & Kwan, 2012). PB has a low cost-
efficacy ratio and is recommended by the World Health Organisation as a first-line 
treatment in countries with low resources (Ilangaratne, Mannakkara, Bell, & Sander, 
2012), demonstrating similar efficacy and tolerability as with other antiepileptic drugs 
such as phenytoin and carbamazepine (Brodie & Kwan, 2012). However, increased 
teratogenic effects have been reported in 1 year old infants whose mothers were 
treated with PB (>150mg/day compared to <150mg/day). Teratogenic effects were 
also noted with other antiepileptic drugs and all treatments demonstrated increased 
probability of congenital abnormalities if there was a parental history of such 
malformations (Tomson et al., 2011). 
Figure 1.3: Structure of phenobarbital 
Figure 1.3 shows the chemical structure of phenobarbital 
(PB).  
 
PB is a lipophilic barbiturate (Figure 1.3), which exerts its 
antiepileptic effects through binding γ-aminobutyric acid (GABA) ion channels in the 
neocortex. Through PB binding to GABAA receptors, PB potentiates the neuro-
suppressive effects of GABA by keeping the Cl- channel open and hyperpolarising 
the postsynaptic neuron (Löscher & Rogawski, 2012). PB is also known to cause a 
myriad of phenotypic effects beyond its original therapeutic outcomes. These are 
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typically mediated by PB’s interaction with the nuclear receptors, the constitutive 
androstane receptor (Car/Nr1i3) and the pregnane x receptor (Pxr/Nr1i2). 
 
Nuclear receptors are ligand-activated transcription factors whose activation are 
controlled by lipophilic compounds, such as hormones and xenobiotics and are 
involved in a variety of biological processes. They consist of a variable N-terminal 
trans-activation domain with a DNA binding domain and a hinge region linked to the 
C-terminal ligand binding and trans-activation domain (AF2) (Aranda, Aranda, 
Pascual, & Pascual, 2001; Y. Kanno & Inouye, 2008). Car and Pxr belong to the Nr1i 
family of nuclear receptors, which, including the 1,25-(OH)2-vitamin D3 receptor 
(Vdr/Nr1i1), are all functionally involved in regulating the expression of xenobiotic 
metabolising enzymes (Reschly & Krasowski, 2006). Car and Pxr control the 
expression of shared and unique genes involved in xenobiotic metabolism, as well 
as genes involved in apoptosis, inflammation and cell cycle control (Tojima et al., 
2012; Ueda et al., 2002).  
 
1.2.1 Car/Pxr functions  
Exogenous activators & functions The synthetic steroid, pregnenolone 16α-
carbonitrile (PCN) is an efficacious activator of mouse and rat Pxr (Kliewer et al., 
1998) while the antibiotic rifampicin is an human Pxr activator (Y. Chen, Ferguson, 
Negishi, & Goldstein, 2004; Kliewer & Willson, 2002). PB is typically regarded as the 
prototypical indirect activator of Car, although Car is also activated by 1,4-Bis[2-(3,5-
dichloropyridyloxy)]benzene (TCPOBOP) in the mouse (Omiecinski, Coslo, Chen, 
Laurenzana, & Peffer, 2011; Tzameli, Pissios, Schuetz, & Moore, 2000), and 6-(4-
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chlorophenyl)imidazo[2,1-b][1,3]thiazole-5-carbaldehyde O-(3,4-
dichlorobenzyl)oxime (CITCO) in humans (Maglich et al., 2003). Pxr possesses a 
large C-terminal ligand binding domain, which results in promiscuous activation by a 
variety of ligands. Whereas Car has a smaller repertoire of direct ligands due to a 
smaller ligand binding site, but can also be indirectly activated. Therefore Car/Pxr 
can be activated by, and induce the metabolism of, a wide range of chemicals 
(Honkakoski, Zelko, Sueyoshi, & Negishi, 1998; Omiecinski et al., 2011; Sueyoshi, 
Kawamoto, Zelko, Honkakoski, & Negishi, 1999; Suino et al., 2004). CAR/PXR 
induction of CYP2B6/3A4 (Lehmann et al., 1998; Sueyoshi et al., 1999) have been 
reported as involved in the metabolism of >50% of clinical drugs, highlighting the 
important role these nuclear receptors play in xenobiotic metabolism (Rendic, 2015). 
 
Endogenous activators & functions The bile acid, lithocholic acid, is a Pxr agonist 
and increases expression of the bile acid metabolising enzyme, Cyp3a11, and 
inhibits the cholesterol metabolising (and bile acid synthesising) enzyme, Cyp7a1 
(Staudinger et al., 2001). Increased bilirubin levels can also activate Car and Pxr 
resulting in the expression of genes involved in bilirubin metabolism (such as the 
carrier protein Slc12a6, which mediates bilirubin uptake, and Ugt1a1, which 
glucuronidates bilirubin) (Huang et al., 2003).  
 
Other functions Acute activation of Car and Pxr is reported to induce transient 
increases in cell cycle genes, such as cyclin A2, cyclin-dependent kinase 1 and 
cyclin B2 (Luisier et al., 2014). Car and Pxr activation is also associated with 
decreased glucose levels due to reduced activity of gluconeogenic genes, such as 
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forkhead box O1 (FoxO1) (Kodama, Koike, Negishi, & Yamamoto, 2004). Car and 
Pxr have been shown to reduce adiposity through induction of insulin induced gene 
1, which is involved in inhibiting the nuclear localisation of the lipogenic transcription 
factor, sterol regulatory element binding protein 1 (Roth et al., 2008).  It has also 
been reported that Pxr and the immune and inflammatory mediator, nuclear factor-
ĸB, regulate each other through a negative feedback loop (Zhou et al., 2006). Hence, 
as well as xenobiotic metabolism, Car and Pxr are also associated with bile acid and 
bilirubin metabolism, energy metabolism, regulation of adiposity and negative 
regulation of the immune response.       
 
1.2.2 Car/Pxr activation 
Coactivator binding Activated Car and Pxr form heterodimeric complexes with the 
retinoid x receptor α (Rxr) (Suino et al., 2004). Agonist activation and binding of 
Car/Pxr to Rxr via their ligand binding domain (Suino et al., 2004) is thought to 
stabilise subsequent binding of coactivators, such as steroid receptor co-activator- 
(Src-)3 (T. Chen et al., 2012). Coactivators bind to α-helix (H)12 (AF2) within the 
ligand binding domain of nuclear receptors (Dussault et al., 2002; Suino et al., 2004).  
 
In the absence of a ligand, corepressors bind H3 of the nuclear receptor’s ligand 
binding domain, via the repressor’s receptor interaction domain. Repressors are 
displaced upon ligand binding due to a conformational change of AF2, which also 
aids coactivator binding (Dussault et al., 2002). Uniquely among nuclear receptors, 
Car demonstrates constitutive activity due to a short AF2 helix, which is stabilised by 
surrounding helixes, allowing coactivator binding in the absence of a bound ligand 
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(Dussault et al., 2002; Suino et al., 2004). Coactivator binding is thought to facilitate 
DNA binding (Dussault et al., 2002). 
 
Car/Pxr DNA binding Car/Rxr bind response elements containing direct repeat- 
(DR)3, DR-4 and everted repeat- (ER)6 motifs, while Pxr/Rxr also bind DR-5, ER-8 
and inverted repeat- (IR)6 motifs (Dawson & Xia, 2012). The repeat sequences 
typically consist of the consensus sequence, AG(G/T)TCA, followed by:  
 a chronological repeat of this first consensus sequence (direct repeat),  
 the reverse complement of the first consensus sequence (inverted repeat) or, 
 the first sequence is the reverse complement of the consensus sequence, 
which is followed by the consensus sequence (everted repeat). 
The 2 sequences are separated by ‘n’ nucleotides as indicated in each case. For 
example, DR-3 represents 2 direct repeating sequences separated by 3 nucleotides 
(Beaudet, Desrochers, Lachaud, & Anderson, 2005; Horie-Inoue, Bono, Okazaki, & 
Inoue, 2004; Y.-M. Wang, Ong, Chai, & Chen, 2012).  
 
Cyp2b expression is often used as a marker of Car activation by PB (Honkakoski et 
al., 1998; Sueyoshi et al., 1999), and Cyp3a for Pxr (Kliewer et al., 1998; Lehmann 
et al., 1998); although both receptors have been reported to regulate both genes (B 
Goodwin, Moore, Stoltz, McKee, & Kliewer, 2001; Bryan Goodwin, Hodgson, 
D’Costa, Robertson, & Liddle, 2002). The mouse PB-inducible gene, Cyp2b10, has 
been shown to be regulated by an upstream enhancer sequence; the phenobarbital-
responsive enhancer module (PBREM) (Honkakoski et al., 1998) (also known as the 
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PB-responsive enhancer unit; PBRU (Czekaj, 2000)). The PBREM contains a 
nuclear factor (NF)1 binding site, surrounded by DR-4 nuclear receptor binding sites: 
NR1 and NR2 and a 5’ NR3 motif; of which, NR1 is conserved between the mouse, 
rat and human and thought to be the key component for PB-responsiveness (J. Kim, 
Min, & Kemper, 2001; Sueyoshi et al., 1999). Car/Rxr are thought to bind to the NR1 
site within the PBREM to increase target gene expression (Honkakoski et al., 1998), 
as well as nuclear factor 1 protein binding, which potentiates Car/Rxr binding to NR2 
(J. Kim et al., 2001).  
 
Car cellular localisation Due to Car’s constitutive activity, Car-mediated gene 
expression is controlled via its sequestration to the cytoplasm. Nuclear import of rat 
Car is dependent on a conserved C-terminal leucine rich peptide, the xenochemical 
response signal (XRS) (Zelko, Sueyoshi, Kawamoto, Moore, & Negishi, 2001), as 
well as nuclear localisation signals (NLS) 1 and 2, in the hinge region and ligand 
binding domain, respectively (Figure 1.4). While a cytoplasmic retention region 
(CRR) containing a nuclear export signal (NES) (NES2) within the ligand binding 
domain, and a second NES surrounding the XRS, are implicated in Car cytoplasmic 
localisation (Figure 1.4). Whereas for Pxr nuclear translocation it is reported that 
AF2, NLS and XRS are implicated (Y. Kanno et al., 2007; Y. Kanno, Suzuki, 
Nakahama, & Inouye, 2005).  
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Figure 1.4: Rat Car - linear structure 
Figure 1.4 shows the linear structure of rat Car, with domains reported to be 
important in cellular localisation labelled. The activation helix, H12/AF2, is shown as 
a white bar. Adapted from Suino et al., (Suino et al., 2004) Kanno et al., (Y. Kanno et 
al., 2007). Abbreviations: DBD, DNA binding domain; LBD, ligand binding domain; 
CRR, cytoplasmic retention region; XRS, xenochemical response signal; NLS, 
nuclear localisation signal; NES, nuclear export signal.  
 
1.2.3 PB-mediated indirect activation of Car 
Mutoh et al.,(Mutoh et al., 2013) demonstrated in the mouse that PB indirectly 
activates Car by binding and inhibiting the epidermal growth factor receptor (Egfr), 
decreasing phosphorylation of the receptor Tyrosine845 and Tyrosine1173 residues, 
and therefore decreasing phosphorylation of receptor for activated C kinase 1 
(Rack1), on Tyrosine52. De-phosphorylated Rack1 forms a complex with Car and the 
catalytic subunit of protein phosphatase 2A (Pp2ac) to stimulate de-phosphorylation 
of Car-Threonine38 (Figure 1.5). Hosseinpour et al.,(Hosseinpour, Moore, Negishi, & 
Sueyoshi, 2006) also identified Serine202 as a key residue in the de-phosphorylation 
and subsequent nuclear translocation of mouse Car.  
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Figure 1.5: Indirect activation of Car in the mouse 
 
Figure 1.5 depicts the proposed indirect activation 
of Car by PB in the mouse via antagonism of the 
Egfr. Adapted from (Mutoh et al., 2013)  
 
 
Under normal conditions Car is retained in the 
cytosol by cytoplasmic Car retention protein (Ccrp), 
which also aids recruitment of heat shock protein 90 
(Hsp90) (Kobayashi, Sueyoshi, Inoue, Moore, & 
Negishi, 2003). Treatment-induced de-phosphorylation and nuclear translocation of 
Car is dependent on an intact microtubular network (Y. Kanno, Miyama, Ando, & 
Inouye, 2009) as well as cytosolic proteins such as Hsp90 (Yoshinari, Kobayashi, 
Moore, Kawamoto, & Negishi, 2003) and Rack1 (Mutoh et al., 2013), which aid in 
Pp2ac recruitment and de-phosphorylation of Car. Oligomerisation of the membrane 
bound subunit of protein phosphatase 1 (Ppp1r16a) and its association with Car 
have also been implicated in the nuclear receptor’s translocation into the nucleus 
(Sueyoshi, Moore, Sugatani, & Matsumura, 2008). Translocation into the nucleus is 
reported to be via a Ran-GTPase and importin 13-dependent process potentially 
through interactions with Car’s NLS2 domain (Y. Kanno, Miyazaki, & Inouye, 2010).  
 
Other kinases such as cAMP-dependent protein kinase, mitogen-activated protein 
kinase kinase (Mek)1/2, protein kinase c and extracellular regulated mitogen-
activated kinase (Erk) have been reported as negative regulators of PB-mediated 
gene transcription (F Joannard, Galisteo, Corcos, Guillouzo, & Lagadic-Gossmann, 
2000; Kawamura, Yoshida, Kimura, Oda, & Kakinuma, 1999; Koike, Moore, & 
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Negishi, 2007; Osabe & Negishi, 2011), while Ca2+/calmodulin-dependent protein 
kinase II has been reported as an enhancer of PB-mediated gene expression 
(Pustylnyak et al., 2005). Furthermore, Rencurel et al.,(Rencurel et al., 2005) 
showed that in the HepG2 cell derivative, WGA cells, dominant negative AMP-
activated protein kinase (AMPK) mutant cells exhibited reduced PB-mediated Cyp 
induction, and that PB (2.5mM) activated AMPK through reduced ATP levels in 
human WGA cells and rat primary hepatocytes. PB mediated increase in AMPK 
activity was also demonstrated in vivo for the mouse and rat (Shindo, Numazawa, & 
Yoshida, 2007). It has been proposed that PB-mediated AMPK activation is through 
the upstream kinase, LKB1 (Blättler, Rencurel, Kaufmann, & Meyer, 2007), which is 
proposed as a putative target of miR-122, a microRNA (miRNA) shown to be 
reduced by PB (100mg/kg) in vivo (Shizu, Shindo, Yoshida, & Numazawa, 2012), as 
a result of Car-mediated inhibition of hepatocyte nuclear factor 4α (Hnf-4α/Nr2a1) 
(Kazantseva, Yarushkin, Mostovich, Pustylnyak, & Pustylnyak, 2015). Dominant 
negative AMPK was also shown to reduce activity from the Car binding site, NR1 
(Rencurel et al., 2005). Furthermore, Pascussi et al., (Pascussi, Gerbal-Chaloin, 
Fabre, Maurel, & Vilarem, 2000) demonstrated that dexamethasone-mediated 
(100nM) nuclear translocation of Car did not induce CYP2B6, suggesting other 
nuclear activities are required for full activation. Taken together these data suggest 
that, once Car is in the nucleus, AMPK may mediate NR1 site binding of Car for full 
activation, which is further indicated by the fact that AMPK activation alone is not 
sufficient for PB induced gene expression (Shindo et al., 2007). However, AMPK-
mediated inhibition of Car target genes has also been demonstrated by others (H. 
Yang et al., 2014), which complicates the interpretation of such data.  
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1.2.4 PB is non-genotoxic  
The hallmarks of a non-genotoxic carcinogen include the ability to cause cancer 
without directly damaging DNA (Hernández, van Steeg, Luijten, & van Benthem, 
2009), and has been reported to be through diverse mechanisms such as endocrine 
modification, tumour promotion, inflammation, and epigenetic carcinogenesis 
(Hernández et al., 2009; Williams & Whysner, 1996). Epigenetics is defined as the 
adaptation of chromosomal arrangement to initiate or potentiate activity state, such 
as by DNA methylation (Bird, 2007). The DNA methyl modification, 5-methylcytosine, 
is found on the cytosine of cytosine–guanine pairs. Typically, gene promoters that 
are extensively methylated are associated with transcriptional silencing. This is 
thought to be due to recruitment of proteins, which bind the methylated sites and, in 
conjunction with other proteins, compact the chromatin and inhibit transcription. 
Whereas the de-methylated intermediate, 5-hydroxymethylcytosine, is associated 
with enhancer regions and transcription start sites of actively transcribed genes 
(Thomson, Moggs, Wolf, & Meehan, 2013).  MicroRNAs add to the complexity of 
epigenetic regulation through post-transcriptional and post-translational regulation of 
gene expression, and will be discussed later (Malumbres, 2012). 
 
Testing compounds for carcinogenic potential requires 2 approaches. The first is an 
assessment of the chemical as a genotoxin, a DNA reactive chemical, for example 
benzo[a]pyrene (Ling et al., 2004), in assays such as the Ames test (Ames, McCann, 
& Yamasaki, 1975). The second is an assessment of the chemical as a non-
genotoxic carcinogen. As mentioned above, non-genotoxic carcinogens are typically 
thought to cause cancer without damaging DNA. Due to these indirect methods of 
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carcinogenesis, genotoxicity assays do not positively identify such compounds. 
Therefore, the gold standard test for non-genotoxic chemicals requires treatment 
with the chemical of animals in a lifetime bioassay (Boobis et al., 2009). PB does not 
directly damage DNA, but when given to rodents after a DNA damaging event in a 
lifetime bioassay, does promote the progression of hepatic tumours and as such is a 
non-genotoxic carcinogen.  
 
PB is widely used as a model non-genotoxic carcinogen in rodents, whereby PB acts 
as a tumour promoter in the rat (Butler, 1978; Hagiwara et al., 1999), and induces 
hepatocellular carcinomas in mice predisposed to tumours, such as C3H and 
B6C3F, while C57BL appear resistant (Becker, 1982). Due to the different 
sensitivities of rats and mice, tumour promotion studies are often conducted with PB 
following a DNA damaging compound, such as N-diethylnitrosamine (DEN), which 
when given to mice at 6 weeks of age will increase tumour burden with PB compared 
to DEN alone (Braeuning, 2013). However, PB is not reported to cause cancer in 
humans (Elcombe et al., 2014) and is currently classified as a class 2B carcinogen; 
possibly carcinogenic to humans (Braeuning, 2014). 
 
Using genetic mouse models, research groups have tried to determine the relevance 
of PB as a human carcinogen. Wildtype and humanised Car/Pxr C57BL/6J mice 
treated with PB (80mg/kg/day) by intraperitoneal injection for 4 days showed that the 
PB treated humanised mice did not present with hyperplasia as seen in the wildtype 
mice (Ross et al., 2010). However, Luisier et al., (Luisier et al., 2014) demonstrated 
in the same model that PB treatment (0.05% w/v in drinking water) does induce 
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hyperplasia in humanised mice. This dose is roughly equivalent to 87mg/kg/day 
(0.05% w/v corresponds to 500mg/L, and the daily dose was subsequently 
calculated using a dose conversion factor for a subacute study with male mice; 
0.174, as determined by the European Food Safety Authority (Antunović et al., 
2011)) therefore suggesting that the disparity could be an issue of dose method. 
Furthermore, the authors show that the transcriptomic profile is similar between 
wildtype and humanised mice (Luisier et al., 2014). It has also been demonstrated 
that using the same strains, humanised Car/Pxr mice do develop tumours when 
treated with DEN (single intraperitoneal injection at 90mg/kg body weight) for 1 week 
followed by dietary PB (0.05% w/v) for 40 weeks, albeit at a lower tumour burden 
than in wildtype mice with the same treatment (Braeuning et al., 2014). These data 
suggest that rodent and human Car are capable of inducing tumours, but that 
receptor activity also needs to be considered in the context of other factors beyond 
the receptor. This is corroborated by Yamada et al., (Yamada et al., 2014) who 
demonstrate that chimeric CD1 mice with human hepatocytes do not show PB-
mediated hyperplasia (up to 1500 parts per million (ppm) for 7 days). 
 
1.2.5 PB-mediated tumourigenesis 
Acute PB exposure Treatment with PB is associated with a myriad of molecular and 
physiological changes in the liver. PB is a prototypical Cyp2b inducer via indirect 
activation of Car (Honkakoski et al., 1998; Sueyoshi et al., 1999) and Pxr (B 
Goodwin et al., 2001). PB induces adaptive hepatic responses, consolidated as 
hepatomegaly – liver enlargement (P. Carthew, Edwards, & Nolan, 1998; Waterman 
et al., 2010). In the rat, PB induces compensatory transient hyperplasia during the 
first 3 days of treatment (Waterman et al., 2010), which is associated with increased 
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Car activation and enhanced by concomitant Pxr activation (Shizu et al., 2013), 
followed by reversible hepatocyte hypertrophy (Isenberg et al., 2001). Within the first 
7 days of PB treatment there is an increase in growth factor expression in mice 
(Orton, Doughty, Kalinowski, Lord, & Wadsworth, 1996) and rats (Lindroos, Tsai, 
Zarnegar, & Michalopoulos, 1992), which are thought to be involved in mediating PB-
induced transient hyperplasia. Activation of Car is also associated with cell cycle 
progression (Osabe et al., 2008), and expression of cell cycle genes (Luisier et al., 
2014; Waterman et al., 2010). The induction of the transcription factor 
myelocytomatosis oncogene (c-Myc) in mice (Blanco-Bose et al., 2008) and transient 
hypermethylation in the promoter region of the tumour suppressor gene cyclin-
dependent kinase inhibitor 2A (p16) in the rat (Kostka, Urbanek, & Ludwicki, 2007) 
and decreased miR-199a-3p (Koufaris, 2011) have also been suggested as 
contributing to this proliferative response. Typically more than 7 days treatment with 
PB has been shown to reduce responsiveness to growth factors in both the mouse 
(Fletcher, Orton, Chipman, & Strain, 1997) and rat (Tsai & Michalopoulos, 1991; 
Tsai, Zarnegar, & Michalopoulos, 1991) potentially due to the phenotypic switch from 
hyperplasia to mitoinhibition (Fletcher et al., 1997). 
 
Chronic PB exposure It has been demonstrated in mice that chronic activation of 
Car is necessary for PB-induced tumours (Figure 1.6), potentially through 
upregulation of Mdm2 and inhibition of p53-mediated apoptosis (Huang et al., 2005; 
Yukio Yamamoto, Moore, Goldsworthy, Negishi, & Maronpot, 2004) and growth 
arrest and DNA-damage-inducible 45β- (Gadd45β) induced inhibition of apoptosis (Y 
Yamamoto & Negishi, 2008). Furthermore, several other signalling components have 
been identified as pertinent to the tumour promoting effects of PB. It has been 
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demonstrated in DEN/PB studies that PB promotes the growth of β-catenin activated 
tumours (Aydinlik, Nguyen, Moennikes, Buchmann, & Schwarz, 2001) (Figure 1.6) 
and that deletion of β-catenin results in loss of PB-induced tumours in the mouse 
(Rignall, Braeuning, Buchmann, & Schwarz, 2011). PB is known to interfere with 
gap-junction signalling, which is thought to promote neoplastic cell growth due to the 
impaired signalling. In fact, loss of connexin 32 suppresses PB-mediated tumour 
promotion, suggesting PB requires functional gap-junction signalling to induce 
tumours (Moennikes et al., 2000) (Figure 1.6). A comprehensive analysis of the liver 
methylome of PB-treated mice has shown that the level and type of methylation 
induced by long-term PB treatment are associated with sensitivity to PB-induced 
tumours in the mouse, as well as altered gene expression (Phillips, Burgoon, & 
Goodman, 2009; Phillips, Yamamoto, Negishi, Maronpot, & Goodman, 2007; 
Thomson et al., 2012; Thomson, Hunter, et al., 2013) (Figure 1.6). 
 
Figure 1.6: PB-mediated tumourigenesis in the mouse 
Figure 1.6 Depicts key molecular markers and components of PB-induced 
tumourigenesis in the mouse, as described in text. 
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Recent work has demonstrated that chronic exposure to PB also induces time- and 
dose-dependent changes in rat (Koufaris, Wright, Currie, & Gooderham, 2012; 
Koufaris, Wright, Osborne, Currie, & Gooderham, 2013) and mice miRNAomes 
(Lempiäinen et al., 2013). 
 
1.3 microRNAs 
The first miRNA to be discovered was lin-4 in Caenorhabditis elegans (R. C. Lee, 
Feinbaum, & Ambros, 1993), and was initially dismissed as a component of 
C.elegans genetics that was unrelated to other organisms. However, since then it 
has been established that miRNAs play an important role in gene regulation; being 
predicted to target >50% of human genes, as well as having been identified as 
biomarkers of different cancers, and a multitude of other diseases and even as 
therapeutic treatments (reviewed in Doxakis, (Doxakis, 2013) and Zhang et al.,  (B. 
Zhang, Pan, Cobb, & Anderson, 2007)).   
 
1.3.1 Biogenesis 
MiRNAs are found in the introns and exons of genes, where they are processed in 
tandem with the mRNA (Rodriguez, Griffiths-Jones, Ashurst, & Bradley, 2004), or 
miRNAs are found in intergenic regions being controlled by their own promoter 
(Saini, Griffiths-Jones, & Enright, 2007). MiRNAs can be transcribed as single units 
(monocytronic) or in clusters (polycistronic) (reviewed in (Doxakis, 2013).  
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Mammalian miRNAs are transcribed by DNA polymerase II into primary-miRNA (pri-
miRNA) transcripts, which are 3’ poly-adenylated and 5’ 7-methyl guanosine capped, 
forming hairpin secondary structures (Y. Lee et al., 2004) (Figure 1.7). Flanking pri-
miRNA nucleotides are cleaved to form the hairpin precursor-miRNA (pre-miRNA) 
containing a 2 nucleotide 3’ overhang, by the RNase III endonuclease Drosha, with 
the RNA binding protein Pasha (also known as DGCR8) (Han et al., 2004; Y. Lee et 
al., 2003) (Figure 1.7), and RNA helicases, dead box helicase- (DDX-)5 and DDX17 
and tumour suppressor, breast cancer 1, early onset (Kawai & Amano, 2012). Pre-
miRNAs can also be produced from the introns of mRNAs (Y.-K. Kim & Kim, 2007). 
After pre-miRNA processing, the nucleo-cytoplasmic receptor, Exportin-5, transports 
the pre-miRNA into the cytoplasm (Figure 1.7) through an interaction with the pre-
miRNA’s 3’ overhang, in a Ran-GTP dependent process (Yi, Qin, Macara, & Cullen, 
2003). Once in the cytoplasm, the pre-miRNA is bound by the miRNA loading 
complex (miRLC) comprising Argonaute2 (Ago2) (also known as elF2C2), and other 
proteins, including the RNase III endonuclease, Dicer, and trans-activating response 
RNA-binding protein (Maniataki & Mourelatos, 2005) (Figure 1.7). Dicer recognises 
the 3’ overhang of the pre-miRNA via Dicer’s PAZ (PIWI-AGO-Zwille) domain and 
cleaves ~22 base pairs (bp) from this site (Vermeulen et al., 2005). The miRNA is 
unwound and the guide strand is selected by Ago2, and the passenger strand is 
discarded. Generally, in the duplex the strand with lowest thermodynamic stability at 
its 5’ terminus is selected as the guide strand, which results in either retention of the 
5’ end of the miRNA (miR-5p) or the 3’ end (miR-3p) (Schwarz et al., 2003) (Figure 
1.7). It is thought that once the mature miRNA (guide strand) is selected, the 
accessory proteins dissociate leaving the miRNA and Ago2 as the functional RNA 
induced silencing complex (RISC) (Maniataki & Mourelatos, 2005). Ago2 secures the 
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miRNA seed sequence (discussed below) via an interaction with the miRNA 5’ 
terminus and the protein’s Mid domain, thereby exposing the seed region of the 
mature miRNA to enable target interactions (Lambert, Gu, & Zahler, 2011).  
 
Figure 1.7: MiRNA biogenesis 
Figure 1.7: depicts the pathway for miRNA biogenesis and formation of RISC as 
described in text. 
 
1.3.2 Activity/Function  
The mature miRNA transcript is approximately 22 nucleotides long and has a 
functional region known as the seed sequence in the 5’ terminal end of the miRNA, 
which exhibits homology to the mRNA target. The seed sequence can be between 
residues 2-7 (known as a 6mer site match to the mRNA) or 2-8 (known as a 7mer or 
7mer-m8 site match to the mRNA). Sequence complementarity as an extension of 
the seed sequence is also thought to influence miRNA-mRNA target interactions if 
the miRNA possesses a matching adenosine in the position of the first nucleotide, 
(therefore between nucleotides 1-7 of the miRNA; known as a 7mer-A1 site match of 
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the mRNA), or if the miRNA contains both matching residues in positions 1 and 8 
(known as an 8mer site match of the mRNA) (B. Lewis, Burge, & Bartel, 2005). 
 
MiRNAs silence gene expression based on the level of complementation between 
the miRNA seed sequence and its mRNA target, resulting in either mRNA target 
degradation or translation inhibition. It is still not fully understood what the 
mechanisms are that control these two outcomes, but it appears to be highly context 
specific and dependent on the diversity and proximity of miRNA binding sites 
(Doench & Sharp, 2004; Grimson et al., 2007). MiRNAs have been shown to target 
the mRNA within the 3’-untranslated region (UTR), as well as with the 5’-UTR (I. Lee 
et al., 2009), and introns (Tan et al., 2007).  
 
Typically, it is thought that complete sequence complementarity mediates Ago-
induced cleavage of the mRNA, while mismatches induces translation suppression 
(discussed in (R. W. Carthew & Sontheimer, 2009)). MiRNA target degradation or 
translation suppression is dependent on the recruitment of deadenylase and 
decapping complexes to the RISC via Ago interaction with the GW182 (TNRC6A-C) 
protein, and that the final outcome may also be dependent on which proteins are 
recruited (Behm-Ansmant, Rehwinkel, & Izaurralde, 2006).  
 
MiRNA down-stream regulation is becoming increasingly complex; with the ability of 
miRNAs to regulate gene expression of the parent cell, but also the secretion of 
miRNAs to act in inter-cellular communication as evidenced by the presence of 
miRNAs in many biological fluids (Boon & Vickers, 2013), the ability of miRNAs to 
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act as toll-like receptor ligands or “hormone miRNAs” (Fabbri, 2012), and even 
potentially cross-kingdom associations (L. Zhang et al., 2012). The roles of miRNAs 
are further complicated by the observation that RNAs can act as competing factors, 
pseudo-targets, to mediate miRNA function and availability, known as competing 
endogenous RNAs (ceRNAs) (Salmena, Poliseno, Tay, Kats, & Pandolfi, 2011). It 
has been suggested that microRNAs provide robustness to biological systems – the 
ability to maintain appropriate function when under intrinsic or extrinsic stresses 
(Ebert & Sharp, 2012).  
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1.4 Concluding statements 
This thesis is concerned with understanding the toxicity of PB in vivo and developing 
in vitro models to assess the mechanisms of toxicity. Furthermore, as the rat model 
is reported to be resistant to PB-induced tumourigenesis, when PB is treated in the 
absence of a DNA damaging compound, this thesis attempts to establish to what 
extent PB-inducible miRNAs in vivo impart robustness and maintenance of 
homeostasis, with a focus on miR-182/96. 
 
1.5 Hypothesis 
I hypothesise that the rat hepatocyte-like, B13/H, cell system can provide robust 
mechanistic insights into the PB phenotype. Additionally, that the regulation and 
function of PB-induced miRNAs can be explored using in vivo samples, and provide 
context-specific relationships relevant to chronic PB exposure.  
 
1.6 Aims 
1. Characterise the B13/H cell line and its response to PB and PB-like 
compounds. 
2. Explore the interaction with PB and growth factor signalling in vitro and in 
vivo. 
3. Identify potential regulators of PB-induced miRNAs in vivo. 
4. Elucidate the potential function of PB-induced miRNAs in vivo. 
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2. Characterising rat hepatocyte-like AR42J-B13/H cells as an in 
vitro model for phenobarbital treatment 
 
2.1 Introduction 
In this chapter I will evaluate the hepatocyte-like AR42J-B13/H (B13/H) cell as a 
model to characterise the in vitro effect of phenobarbital (PB) treatment. 
 
2.1.1 The rat AR42J-B13/H (B13/H) cell model - origin 
Wistar/Lewis rats were treated with azaserine (O-diazoacetyl-L-serine) to generate 
pancreatic tumour cells, which were subsequently harvested to form the acinar 
derived pancreatic adenocarcinoma AR42J cell line (Longnecker, Lilja, French, 
Kuhlmann, & Noll, 1979). Azaserine is a pancreatic carcinogen with potent DNA 
adduct forming abilities. AR42J cells possess exocrine and neuroendocrine 
properties and treatment with activin A plus betacellulin will convert approximately 
10% of cells from amylase production to insulin production (Hirosato Mashima et al., 
1996). This was also noted when AR42J cells were treated with activin A plus Hgf, 
and it is from this sub-population of cells that the AR42J-B13 (B13) cell line 
originated (H Mashima, Shibata, Mine, & Kojima, 1996). The switch to insulin 
producing β-cells is thought to be due to activation of neurogenin 3 and downstream 
transcription factors Nkx6.1 or MafA (Akinci, Banga, Greder, Dutton, & Slack, 2012; 
Ogihara et al., 2008). 
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2.1.2 The rat AR42J-B13/H (B13/H) cell model - differentiation 
It has been demonstrated in vivo that the pancreas can develop hepatic-like foci, for 
example as noted in Fisher rats following 60-72 weeks ciprofibrate treatment (Reddy 
et al., 1984), as well as after glucocorticoid treatment of Sprague-Dawley rats for 25 
days (K. Wallace, Marek, Currie, & Wright, 2009). This differentiation was also 
shown in B13 cells. Shen et al., (Shen, Slack, & Tosh, 2000) were able to 
demonstrate that B13 exocrine-like cells transdifferentiated into hepatocyte-like cells, 
AR42J-B13/H (B13/H), upon stimulation with 10nM dexamethasone for 2 weeks. The 
differentiated B13/H cells are no longer proliferative and display phenotypic and 
molecular markers of hepatocytes (Philip M. E. Probert et al., 2015). 
 
The current dogma is that the differentiation of B13/H cells is through 
dexamethasone-mediated activation of the glucocorticoid receptor and increased 
expression of the serine/threonine protein kinase serum- and glucocorticoid-
regulated kinase 1 (Sgk1), which when activated, phosphorylates and reduces the 
total levels of cellular β-catenin. Reduced levels of β-catenin transiently suppresses 
downstream components of WNT signalling, which results in activation of the 
transcription factor CCAAT enhancer binding protein-β (C/EBP-β) (Shen et al., 2000; 
K. Wallace, Long, Fairhall, Charlton, & Wright, 2011; K. Wallace, Marek, Hoppler, & 
Wright, 2010), followed by activation of Hnf-4α and phenotypic change of the cell 
towards an hepatic fate (Z. D. Burke, Shen, Ralphs, & Tosh, 2006). Furthermore, 
endogenous expression of insulin in B13 cells through activation of the Pi3k/Akt 
pathway augments the transdifferentiation of B13 to B13/H cells (Wu et al., 2010). 
This is likely the stimulus for activation of Sgk1 described by Wallace et al., due to 
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the sensitivity of Sgk1 phosphorylation to the Pi3k 
inhibitor, LY294002 (K. Wallace et al., 2011) 
(Figure 2.1) .  
 
Figure 2.1: Dexamethasone-mediated 
differentiation of B13 cells 
Figure 2.1 shows the proposed molecular 
pathway controlling dexamethasone-mediated 
differentiation of B13 cells to hepatocyte-like 
B13/H cells (Shen et al., 2000; K. Wallace et al., 
2011; K. Wallace, Marek, et al., 2010; Wu et al., 
2010). 
 
 
Furthermore, the Shen group later demonstrated that during transdifferentiation an 
intermediate cell type is generated, which express the stem/progenitor cell marker 
ABCG2 (Wu et al., 2010). Treatment with oncostatin M has been shown to improve 
the differentiated phenotype (Shen et al., 2000).  
 
Expression of hepatocyte markers has been extensively studied in B13/H cells, 
whereby B13 cell markers amylase, synaptophysin, and neuroﬁlament were 
suppressed, albumin is secreted and Cyp2e1, 3a1, 2b1, 7a1 and UGT (Z. D. Burke 
et al., 2006) and the hepatocyte marker transferrin, as well as ductal cell markers 
cytokeratin 7 and 19 are expressed (Al-Adsani et al., 2010). Further studies have 
demonstrated functional increases in phase I and II xenobiotic metabolism enzymes 
and drug transporter genes highlighting this model as a useful system to study 
chemical exposure (Marek, Cameron, Elrick, Hawksworth, & Wright, 2003; Philip M 
E Probert et al., 2014; Philip M. E. Probert et al., 2015). 
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2.1.3 Hypothesis 
That the AR42J-B13/H cell line can be used as an in vitro tool to further understand 
and mechanistically test cellular responses to phenobarbital treatment. 
2.1.4 Aims 
1. Characterising the differentiation of AR42J-B13 (B13) to hepatocyte-like 
AR42J-B13/H (B13/H) cells in response to dexamethasone. 
2. Assess the B13/H cell response to PB and PB-like compounds. 
3. Explore the effect of PB and PB-like compounds on miRNA expression in 
B13/H cells. 
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2.2 Methods 
2.2.1 Cell culture 
Unless stated otherwise, all cell culture consumables were bought from Life 
Technologies, Gibco & Invitrogen (Paisley, UK). All cell culture consumables and 
chemicals were sterile filtered or autoclaved before use. Rat pancreatic progenitor 
AR42J-B13 cells (B13) were a gift from Professor Matthew Wright (Newcastle 
University). Rat pancreatic progenitor B13 cells were cultured in standard conditions 
with GIBCO low glucose (1g/L) Dulbecco's Modified Eagle Medium and 10% foetal 
bovine serum (FBS), with L-glutamine (233.6μg/mL) and antibiotics, penicillin 
(80Units/mL) and streptomycin (80µg/mL). Rat pancreatic B13 cells were treated 
with dexamethasone (10nM) (Sigma-Aldrich, Dorset, UK) for 13 days, with media 
changes every 3-4 days to stimulate differentiation into hepatocyte-like (B13/H) cells 
(Shen et al., 2000). Dexamethasone was removed from the culture media for 24 
hours after 13 days continuous differentiation to control for potential confounding 
effects on Cyp2b (Audet-Walsh & Anderson, 2009). Undifferentiated B13 cells were 
maintained by trypsinization and subculture. Trypsin (0.25%) was used to detach 
cells, and an equal volume of serum-containing media to inactivate the trypsin. 
Seeding densities and treatments are detailed in the following sections. Cell culture 
plastics were purchased from Corning (NY, USA).  
 
2.2.2 Cyp450 enzyme activity - PROD 
All compounds used for PROD were purchased from Sigma-Aldrich (Dorset, UK), 
unless stated otherwise. To assess drug metabolising competency of the cell culture 
model, activity was assessed by the pentoxyresorufin-O-dealkylase (PROD) assay, 
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which is catalysed mainly by Cyp2b1/2, but also 2c11, Cyp26 and Cyp3a2 (M. 
Burke, Thompson, Weaver, Wolf, & Mayer, 1994; Langouët et al., 1997). B13 cells 
were seeded at 2x104 cells per well in 24-well plates and differentiated to B13/H cells 
as described above. B13/H cells were treated with phenobarbital-sodium (PB) (BDH 
Chemicals Ltd, UK) (solvated in media), benzophenone (BP) (Alfa Aesar, 
Lancashire, UK) (solvated in dimethyl sulfoxide [DMSO]), clotrimazole (solvated in 
ethanol), or 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP) (solvated in 
DMSO) for 1, 2, 3, 7 and 9 days. After treatments, cells were washed in serum-free 
media as assay activity is maintained at higher levels with cells in serum-free media 
(Hammond & Fry, 1992). Rat liver aroclor induced S9 (40µg) was used as a positive 
control for PROD. The PROD assay controls were run in a buffer containing Tris HCl 
(100mM), nicotinamide adenine dinucleotide phosphate (NADPH) (500µM), glucose-
6-phosphate (10mM), magnesium chloride (MgCl2) (2mM) and glucose-6-phosphate-
dehydrogenase (3 units) (based on (D. M. Burke & Mayer, 1974), whereas samples 
were run in serum-free media.  
 
A Synergy H1 Hybrid plate reader and Gen5 Data Analysis Software (BioTek, 
Swindon, UK) were used to collect data with optimized excitation (λ565nm) and 
emission (λ590nm) wavelengths (Figure 2.2) to measure the production of resorufin 
from the pentoxyresorufin  substrate (Figure 2.3 A). The assay was started by adding 
pentoxyresorufin (resorufin pentyl ether, final concentration of 6µM). It should be 
noted that Cyp450 activity might be underestimated in this assay due to potential 
incomplete pentoxyresorufin uptake into the cells, as well as phase 2 conjugation of 
resorufin resulting in a reduced fluorescence signal, such as through the activity of 
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glucuronidation and sulphation enzymes, which are reported to be highly expressed 
in the B13/H cells (Philip M. E. Probert et al., 2015). 
Excitation wave length 
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Figure 2.2: Excitation and emission wavelengths for resorufin detection 
Figure 2.2 shows optimised excitation and emission wavelengths of resorufin with 
relative fluorescence units (RFU) on the y-axis indicative of signal strength. 
 
Fluorescence readings were taken every 10 minutes for 2 hours and the rate of 
resorufin was calculated by normalising to a blank of pentoxyresorufin only. 
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Fluorescence was converted to pmol of resorufin using a set of known standards 
(Figure 2.3 B and C), then the linear rate of reaction was calculated per minute per 
mg of total protein. Total cellular protein was determined using the BCA assay 
described later. The two highest concentrations of the resorufin standard (Figure 2.3 
B) were not included in calculating the change in fluorescence with resorufin 
concentration due to the plateau in signal strength.  
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Figure 2.3: PROD substrate and resorufin fluorescence  
Figure 2.3 shows the structure of pentoxyresorufin and its O-dealkylated product, 
resorufin, and aldehyde (A) (adapted from Sigma-Aldrich) with resorufin 
fluorescence (B, C). Data are representative of 3 dilutions, shown as mean + SEM. 
The y-axis plots the relative fluorescence units.  
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2.2.3 BCA assay 
The bicinchoninic acid (BCA) assay protein quantification kit was from Pierce, 
ThermoScientific (IL, USA). A reaction mix of buffers B and A were made at 1:50, 
and 200µL was mixed with 10µL sample. The sample-buffer mixture was incubated 
at 37oC for 30 minutes. Cupric ions (Cu2+) in the buffer are reduced by and bind to 
protein molecules of >3 peptides in length, and the subsequent cuprous ions (Cu1+) 
chelate with BCA to produce a colour change that can be quantified by absorbance 
at 560nm (Goldring, 2012). Absorbance of each sample was compared to the 
absorbance of a set of standard BSA concentrations (25, 125, 250, 500, 750, 1000, 
1500, 2000µg/mL), using the equation:  
y = “gradient” x  where y = absorbance and x = protein concentration (µg/mL) 
 
2.2.4 Nuclear localisation - Subcellular fractionation 
Phenobarbital induces nuclear translocation of Car protein, and to assess this in the 
cell culture model used here, nuclear and cytoplasmic fractions were harvested and 
protein changes interrogated by immunoblot. B13 cells were seeded at 1x106 cells 
per T175 flask and differentiated to B13/H as described above. B13/H cells were 
treated with phenobarbital-sodium (PB) (dissolved in media), for 72 hours. After 
treatments, cells were detached using trypsin (0.25%), centrifuged at 250g for 8 
minutes and washed with ice cold phosphate buffered saline (PBS) (Fisher Scientific, 
PA, USA). The cell pellet was re-suspended in 500µL of buffer A containing 4-(2-
Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES) (10mM) pH 7.9, MgCl2 
(1.5mM), potassium chloride (KCl) (10mM), DL-Dithiothreitol (DTT) (500µM) (Sigma-
Aldrich, Dorset, UK) and Halt Protease Inhibitor (diluted in buffer mixture to 1:100) 
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(ThermoScientific, IL, USA), for 60-70 minutes on ice. All buffers were made up to 
the required volume using demineralised (dm)H2O.   
 
Typically a Dounce homogenizer is used to disrupt the cell membrane while leaving 
the nucleus intact. The B13/H cells however appear susceptible to the hypotonic 
conditions of the low KCl concentration used here and ruptured without the need of a 
Dounce homogenizer. The success of fractionation can be crudely tested at this 
stage by haemocytometer and trypan blue (Sigma-Aldrich, Dorset, UK), where 
successfully lysed cells fail to exclude the impermeable dye. Leaving the cells for 60-
70 minutes on ice as described above produced >90% lysis by trypan blue exclusion.  
 
Samples were centrifuged for 5 minutes at 250g and 4oC to pellet the intact nuclear 
material and the supernatant was collected as the cytoplasmic fraction. The nuclear 
pellet was re-suspended in 500µL of buffer B containing sucrose (250mM) (BDH 
Chemicals Ltd, UK) MgCl2 (10mM) and Halt Protease Inhibitor (diluted in buffer 
mixture to 1:100). The nuclear fraction was then layered over a sucrose gradient of 
1mL buffer C containing sucrose (862.5mM), MgCl2 (500µM) and 1x Halt Protease 
Inhibitor (diluted in buffer mixture to 1:100). In order to remove lighter, non-nuclear, 
contaminants samples were centrifuged for 10 minutes at 3500g and 4oC. The pellet 
was retained and re-suspended in buffer C (100µL) as the nuclear fraction. Samples 
were discarded if they showed signs of being insoluble as this is indicative of lysed 
nuclei and subsequent nuclear contamination in cytoplasmic fractions. Samples were 
stored at -20oC, or lysed directly using equal volumes of RIPA buffer (Sigma-Aldrich, 
Dorset, UK). Contamination was checked using protein markers when samples were 
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run on immunoblots; Lamin B1 as the nuclear marker, and β-actin as the cytoplasmic 
marker (Figure 2.4).  
 
 
Figure 2.4: B13/H subcellular fractionation markers 
Figure 2.4 shows the cytosolic and nuclear separation of B13/H cells and the 
respective compartment-specific markers. Abbreviations kDa, kilodaltons. 
 
This fractionation protocol was based on the Lamond Lab Protocol (2007): 
http://greproteomics.lifesci.dundee.ac.uk/webpage%20front%20page/dreamweaver
%20webpage/CellFractionation.pdf 
 
2.2.5 RNA extraction 
To avoid contamination and RNA degradation all surfaces and tips were cleaned 
with 70% ethanol and RNaseZAP (Sigma-Aldrich, Dorset, UK) prior to any handling 
of RNA/cDNA. RNA extractions were performed using MirVana PARIS RNA 
extraction kits (Life Technologies, Paisley, UK) following manufactures protocol. 
Tissue culture wells were washed with ice cold PBS followed by addition of ice cold 
kit disruption buffer for 10 minutes. Samples were then transferred to DNase/RNase 
free 2mL centrifuge tubes. An equal volume of kit 2x Denaturing Solution was added 
to the homogenate at room temperature and samples were incubated for 5 minutes 
on ice. Samples were mixed with an equal volume of Acid-Phenol:Chloroform (to 
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denature proteins) and then separated by high speed centrifugation for 10 minutes 
(20,000g) to isolate the protein into the lower phase. Acidic conditions reduces gDNA 
contamination in the upper aqueous phase, which contains the RNA (Chomczynski & 
Sacchi, 2006). A volume of 1.25x 100% ethanol was added to the aqueous phase 
aliquot and passed through a silica filter, which binds the RNA. A series of wash 
steps with kit washes were used to remove salt contamination and purified total RNA 
was eluted from the filter into clean collection tubes by adding 95oC DNase/RNase 
free water. RNA was quantified using the IMPLEN – nanophotometer (Implen, 
Gmbh, Munich, Germany). RNA was stored at -20oC until required. RNA quality was 
determined using absorbance at A260 (nucleic acids)/A280 (proteins) and 
A260/A230 (phenol and salts), with ratios of >1.8 indicative of good quality.  
 
2.2.6 qRT-PCR 
To assess mRNA and miRNA expression in cell samples, quantitative real time PCR 
(qRT-PCR) was used. Endogenous controls were used to control for loading 
differences – β-actin, 18S rRNA or glyceraldehyde-3-phosphate dehydrogenase 
(Gapdh) for mRNA and sno or U6 RNA for miRNA. mRNA reverse transcription (RT) 
was performed using RNA template (500ng-1µg) with random hexamers (300ng) 
(Life Technologies, Paisley, UK) made up to a final volume in DNase/RNase free 
water (15μL). To denature RNA secondary structures prior to RT, the samples were 
heated for 5 minutes at 65oC. RT was performed using Superscript II (Life 
Technologies, Paisley, UK) using a final volume of 23.5μL per sample including 
deoxynucleotide triphosphates (dNTPs) (425μM) (Sigma-Aldrich, Dorset, England), 
first strand buffer (diluted in reaction mixture to 1:5), DL-dithiothreitol (DTT) (8.5mM), 
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and superscript II enzyme (100 units). To check for contamination in the RT mixture 
a no template control was included and a no enzyme control to check for genomic 
DNA (gDNA) contamination in the RNA. The samples were run on a PTC-200 Peltier 
Thermal Cycler using conditions described in Table 2.1.  
 
MiRNA RT was performed using TaqMan MicroRNA Reverse Transcription Kit (Life 
Technologies, Paisley, UK) with a final volume of 7.5μL per sample containing: RNA 
(5ng), dNTP (1mM), reverse transcriptase (25 units), RT buffer (diluted in reaction 
mixture 1:10), RNase inhibitor (1.9 units) and RT primers (diluted in reaction mixture 
1:5), and run on a thermal cycler using conditions described in Table 2.1. Negative 
controls were not necessary for the miRNA RT as the primers used for this reaction 
are specific to the miRNA and do not amplify gDNA (C. Chen et al., 2005). Reverse 
transcription product was stored at -20oC until needed.  
 
Table 2.1: qRT-PCR conditions 
RT/PCR Step 1 Step 2 Step 3 Step 4 Step 5 
RT 
(miRNA) 
16oC 
30min 
42oC 
30min 
85oC 
5min 
4oC ∞  
RT 
(mRNA) 
25oC 
10min 
37oC 
120min 
85oC 
5min 
4oC ∞  
qPCR 95oC 
10min 
95oC 
15sec 
60oC 
60sec 
Repeat 
step 2-3 
x39 
4oC ∞ 
 
PCR amplification of the mRNA and miRNA RT product was performed using 
TaqMan Fast Universal PCR Master Mix, No AmpErase UNG (Life Technologies, 
Paisley, UK). PCR master mix was made to a final volume of 10μL with master mix 
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(diluted in reaction mixture to 1:2), primers (diluted in reaction mixture to 1:20), and 
mRNA cDNA (0.8μL) or miRNA cDNA (0.67μL). Samples were run as technical 
triplicates for each primer. PCR analysis was performed using the 96-well fast block 
setting on the 7500 Fast Real-Time PCR System (Applied Biosciences, Life 
Technologies, Paisley, UK) (Table 2.1) and quantified by the comparative Ct method 
(2-ΔCt) relative to an internal control (Schmittgen & Livak, 2008). Changes in 
housekeeping genes were assessed using the inverse log2 of the Ct values (2-Ct) 
(Schmittgen & Livak, 2008).  
 
TaqMan PCR signals are detected through conventional primer based amplification 
of target cDNA with addition of a target-specific 5’-FAM-labelled probe, which will 
only fluoresce after polymerase-mediated cleavage of the probe and subsequent 
release of the 3’ quencher from the probe (Figure 2.5). A tailed 5’ binding forward 
primer is used to adjust melting temperature. MiRNAs are specifically reverse 
transcribed by a 3’ binding stem-loop primer, which provides specificity and stability 
for amplifying short sequences (Figure 2.5). TaqMan PCR amplification is similar 
between mRNAs and miRNAs (C. Chen et al., 2005). 
 
 
 
Figure 2.5: TaqMan PCR 
Figure 2.5 details the TaqMan miRNA RT and 
universal PCR process; 5’-FAM-label (F) and 3’ 
quencher (Q) of the TaqMan probe are shown. 
Adapted from Chen et al., (C. Chen et al., 2005). 
 
         2.  Characterising rat hepatocyte-like AR42J-B13/H cells as an in vitro model for phenobarbital treatment 
59 
 
2.2.7 Semi-qPCR 
Semi-quantitative (semi-q) PCR was also used to assess cell type markers after 
differentiation of rat pancreatic B13 cells to the hepatocyte-like B13/H cell. RT 
reactions were performed as described above for mRNA in the qRT-PCR section 
(chapter 2.2.6).  
 
PCR amplification was performed using the Tfi polymerase kit to a final volume of 
20μL per sample, containing cDNA (2μL), Tfi polymerase (2.5 units), 1x reaction 
buffer (diluted in reaction mixture to 1:5), MgCl2 (3mM), dNTPs (200μM), and forward 
and reverse primers (200nM  each) (Life Technologies, Paisley, UK). Negative 
controls were included as described for mRNA qRT-PCR. Primer details & optimised 
PCR conditions can be found in Table 2.2 and Table 2.3 respectively. PCR products 
were resolved using 2% agarose gel (Sigma-Aldrich, Dorset, UK) of Tris-borate-
EDTA (TBE) solution containing ethidium bromide (5μL) (ICN Biomedicals Inc, OH, 
USA). Products were separated by applying a charge of 150V for 45 minutes to the 
loaded gel; using a 100bp ladder as reference (New England Biolabs, MA, USA). 
The negative charge of the phosphate backbone in DNA causes the product to 
migrate towards the anode, allowing separation by size. The DNA intercalates with 
the ethidium bromide, which fluoresces under UV light enabling sample detection 
(LePecq & Paoletti, 1967). Analysis was performed using the Image Lab on the Gel 
Doc XR+ System and the KODAK image station 4000MM (Carestream molecular 
imaging, CT, US).  
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Table 2.2: Semi-q PCR primer details 
mRNA semi-qPCR primers (Life Technologies) 
Primer Sequence (5’-3’) Amplicon size (bp) 
Gapdh Fwd GGACCAGGTTGTCTCCTGTG 322 
 Gapdh Rev GGCCCCTCCTGTTGTTATGG 
Albumin Fwd GCTGAGGCCAAGGATGTCTT 470 
 Albumin Rev CACTTGGTGACCTTCTCGCT 
Amylase 2a3 Fwd TGGTTCTCCCAAGGAAGCAG 834 
 Amylase 2a3 Rev CTCTTACAACTTTGAGTCGGCAT 
Nr1i3 Fwd AAAGCTGATGGGCCTGCTA 369 
 Nr1i3 Rev GAGGCTCCTGTCTTTCCCA 
 
Table 2.3: Semi-q PCR amplification conditions 
PCR Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7 
Gapdh  94oC 
2min 
94oC 
30sec 
59oC 
30sec 
72oC 
30sec 
Repeat 
2-4 x29 
72oC 
10min 
4oC ∞ 
Albumin  94oC 
2min 
94oC 
30sec 
60oC 
30sec 
72oC 
30sec 
Repeat 
2-4 x29 
72oC 
10min 
4oC ∞ 
Amylase 94oC 
2min 
94oC 
30sec 
59oC 
30sec 
72oC 
60sec 
Repeat 
2-4 x29 
72oC 
10min 
4oC ∞ 
Nr1i3 94oC 
2min 
94oC 
30sec 
58oC 
30sec 
72oC 
30sec 
Repeat 
2-4 x29 
72oC 
10min 
4oC ∞ 
 
2.2.8 Statistics 
All data are shown as mean + standard error of the mean (SEM) with sample size 
shown in figure legends. Student’s t tests were used to compare treatment with 
control, or one way analysis of variance (ANOVA) with Dunnett’s comparison for 
comparing multiple groups to a control. Graphs and analysis were 
produced/performed using Graph Pad 6 (La jolla, California). Statistical significance 
was defined as p<0.05 (*), p<0.01 (**), p<0.001 (***), p<0.001 (****). 
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2.3 Results and Discussion 
2.3.1 Aim 1: Characterising the differentiation of AR42J-B13 (B13) to 
hepatocyte-like AR42J-B13/H (B13/H) cells in response to dexamethasone. 
Upon treatment with 10nM dexamethasone for 2 weeks, B13 cells transdifferentiate 
into hepatocyte-like B13/H cells (Shen et al., 2000) and these cells can be 
maintained in culture for up to 30 days (Marek et al., 2003). To determine the most 
appropriate time-course of dexamethasone-induced differentiation, B13 cells were 
treated for 2, 3 or 4 weeks with 10nM dexamethasone as detailed in Figure 2.6. 
Ninety-six hours after the removal of the dexamethasone, the cells were assessed 
for expression of the hepatic phenotype. For comparison, untreated B13 cells were 
examined in parallel.  
 
Figure 2.6: B13 dexamethasone treatment plan 
Figure 2.6 represents the treatment scheme of 10nM dexamethasone- (dex) 
mediated differentiation of B13 cells to hepatocyte-like B13/H cells.  
 
Cyp2b activity Cyp2b activity (PROD) was used as a marker of the hepatocyte 
phenotype and functionality (Philip M E Probert et al., 2014). Figure 2.7 A shows that 
2 and 3 weeks dexamethasone treated B13 cells were able to metabolise 
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pentoxyresorufin at a rate significantly higher than that of untreated B13 cells, 
indicative of an increased hepatocyte-like phenotype. Although PROD activity was 
reduced at the 4 week time point, it was still higher than the undifferentiated B13 
cells.  
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Figure 2.7: Markers of the transdifferentiation phenotype of B13/H cells 
Figure 2.7.  A Cyp2b activity in B13/H cells by PROD compared to B13 cells. Y-axis 
is mean + SEM of Cyp activity determined by the rate of resorufin production of 3 
independent cultures. Student’s t test compared B13/H to B13 cells. ***p<0.001. B 
Representative semi-q PCR of B13 and B13/H cells differentiated for different times 
Amylase 
Albumin 
Car 
Gapdh 
B13 B13/H 
Week 2 
B13 B13/H 
Week 3 
B13 B13/H 
Week 4 
x10 x10 
x10 
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as indicated. This experiment was repeated with similar results for 3 independent 
cultures. Brightfield images are shown of: B13/H cells with undifferentiated B13 cells 
(C), 2 weeks differentiated B13/H cells (D) and undifferentiated B13 cells (E). Images 
are typical of cell morphology and were taken at x10 magnification. F Cyp2b activity 
in B13 cells treated with 2mM PB for 72 hours. Values were mean + SEM for 3 
independent cultures. 
 
Expression of B13/H marker genes Semi-q PCR analysis confirmed the 
expression of the liver marker, albumin, at all 3 time points in the B13/H cells, 
whereas there was no detectable albumin expression in the B13 cells (Figure 2.7 B). 
As expected, amylase expression was still present within the dexamethasone treated 
cells, probably as there are always sub-populations of undifferentiated cells (Al-
Adsani et al., 2010), which can clearly be identified as clusters of circular cells using 
brightfield microscopy (Figure 2.7 C, arrow head).  
 
I confirmed the expression of Car mRNA in the B13/H cells (Figure 2.7 B). 
Surprisingly I also detected Car mRNA in the B13 cells, in contrast to Probert et al., 
(Philip M E Probert et al., 2014) who were unable to detect Car mRNA in B13 cells. 
Assessing primer sets between both studies via Primer-BLAST (Ye et al., 2012) 
showed that the primers used by Probert et al., (Philip M E Probert et al., 2014) (Fwd 
5’-CTCTCCTGACAGGCCTGGGGT-3’: Rev 5’-CGAAGCTCAGCTAGCAGGCCC-3’) 
detected the Car splice variant (SV) 1 at 156 base pairs and SVs 2 and 3 at 174 
base pairs, while the primers used herein (Fwd 5’-AAAGCTGATGGGCCTGCTA-3’: 
Rev 5’-GAGGCTCCTGTCTTTCCCA-3’) additionally detected Car SV4, at 369 base 
pairs. My primer pair also detected the predicted gene, translocase of outer 
mitochondrial membrane 40 homolog (yeast)-like (Tomm40l), SV X1, which overlaps 
the Car gene. This suggests that either, Car SVs are expressed in B13 and B13/H 
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cells, or that the predicted gene, Tomm40l, is actually expressed in this cell model. 
To assess the functionality of Car expression in the non-differentiated B13 cells, I 
examined the induction of Cyp2b activity in B13 cells, which is a Car-mediated event 
(Sueyoshi et al., 1999; Wei, Zhang, Egan-Hafley, Liang, & Moore, 2000). Treating 
B13 cells with a single dose of 2mM PB for 72 hours produced a 50% increase in 
Cyp2b activity (p=0.0523) (Figure 2.7 F), consistent with a functional Car response.   
 
Cell morphology After treatment with dexamethasone there was a clear 
morphological change in the cell phenotype. B13/H cells exhibited the hepatocyte-
like flattened and elongated shape with finger-like projections (Figure 2.7 D), 
whereas B13 cells were smaller circular cells that proliferated in clusters (Figure 2.7 
E). These morphological traits were used as a checkpoint to determine successful 
differentiation. 
 
Summary – These results indicate that a 2 week dexamethasone treatment 
successfully transdifferentiated B13 cells to an hepatocyte-like phenotype, with a 
gain of albumin expression, increased Cyp2b expression and reduced (but not lost) 
amylase expression. Additionally, the morphology of the B13/H cells differed from 
the undifferentiated B13 cells. Furthermore, the transdifferentiated phenotype could 
be maintained for at least 4 weeks. 
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2.3.2 Aim 2: Assess the B13/H cell response to PB and PB-like compounds. 
2.3.2.1 Assess the B13/H cell response to PB 
Cyp2b activity Using markers from the literature (Philip M E Probert et al., 2014; 
Shen et al., 2000) I have shown that I am able to produce B13/H cells, which appear 
to behave as hepatocyte-like cells. I then went on to assess the response of B13/H 
cells to PB to determine appropriate dosing regimens, as well as confirm their 
hepatocyte-like functionality. B13/H cells were differentiated as described previously 
(Figure 2.6) for 2, 3 or 4 weeks, with subsequent PB treatment for 72 hours. 
Dexamethasone has been shown to augment PB-mediated affects in human primary 
hepatocytes (Pascussi, Gerbal-Chaloin, et al., 2000). However it has also been 
reported that dexamethasone decreases Cyp2b mRNA, but not protein, in Fao cells 
(de Waziers et al., 1992) and suppresses Cyp2b6 expression in HepG2 cells 
(Sueyoshi et al., 1999). To explore the effect of dexamethasone on PB’s induction of 
Cyp2b, B13/H cells were either treated with PB in media lacking, or supplemented 
with, dexamethasone (10nM). The former treatment group had 24 hours in 
dexamethasone-free media prior to PB treatment, as detailed in Figure 2.8 A. PB 
treatments were either: single doses of PB (2mM) for 72 hours (single dose), or 3 
doses of PB (2mM), one every 24 hours (daily dose), with respective vehicle 
controls.  
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A  
 
B       C          
D 
 
Figure 2.8: Effect of PB treatment on 
Cyp2b actvity in B13/H cells 
Figure 2.8 (A) depicts the treatment 
plan for measuring Cyp2b with various 
PB and dexamethasone treatments. 
Cyp2b activity in B13/H cells by PROD 
after 2mM PB and/or 10nM 
dexamethasone treatment at 2 (B), 3 
(C) and 4 (D) weeks dexamethasone-
induced differentiation. Results were 
representative of 3 independent 
cultures, and Y-axis is mean + SEM of 
Cyp activity determined by PROD. 
Student’s t test compared control with 10nM dex (dexamethasone), and one way 
ANOVA with Dunnett’s comparison compared control to PB, and dex to dex + PB. 
*p<0.05, **p<0.01.  
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Cyp2b activity (PB without dexamethasone) This data demonstrates that at 2 
weeks differentiation, B13/H cells had significantly increased Cyp2b activity with a 
single dose of 2mM PB compared to control (B13/H cells with no PB treatment), and 
that daily doses of PB did not significantly increase Cyp2b activity, in fact it 
attenuated the response (Figure 2.8 B).  
 
Cyp2b activity (PB with dexamethasone) Two week differentiated B13/H cells 
treated with 10nM dexamethasone also showed increased Cyp2b activity compared 
to B13/H cells treated with the dexamethasone vehicle (Figure 2.8 B). At the dose of 
dexamethasone used, this could be through canonical activation of the glucocorticoid 
receptor, which has been shown to activate both Pxr and Car in primary human 
hepatocytes (Pascussi et al., 2001). Furthermore, co-treatments with 
dexamethasone (10nM) and PB (2mM) showed an inhibition in Cyp2b activity, at 
both daily and single PB doses at 2 weeks transdifferentiation (Figure 2.8 B).  
 
Summary – This demonstrates that in B13/H cells co-treatments with 
dexamethasone and PB attenuated Cyp2b activity. Interestingly, B13/H cells 
transdifferentiated for 3 and 4 weeks showed reduced capacity for both PB- and 
dexamethasone-mediated induction of Cyp2b activity (Figure 2.8 C and D). This 
suggests that for maximal Cyp2b induction by PB, optimal differentiation of B13 to 
B13/H cells in our hands is after 2 weeks treatment with dexamethasone. This is 
consistent with the decline in basal Cyp2b activity from 2 weeks onwards as shown 
in Figure 2.7 A. 
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Subcellular localisation of Car Under basal conditions in primary cells, Car is 
sequestered in the cytosol. However in immortalised cells, Car appears to have 
escaped its regulatory control and is found primarily in the nucleus (reported in 
HepG2 cells) (Kawamoto et al., 1999). In this respect, B13/H cells appear to display 
this key characteristic of primary hepatocytes, I therefore attempted to confirm the 
subcellular localisation of Car. 
 
B13/H cells were differentiated for 2, 3 and 4 weeks and treated with PB, or vehicle 
control, for 72 hours in media devoid of dexamethasone (as shown in Figure 2.8 A - 
single PB dose without dexamethasone). I have shown that PB treatment for 72 
hours significantly induced Cyp2b activity at 2 weeks transdifferentiation of B13/H 
cells (Figure 2.8 B). Treated B13/H cells were harvested and nuclear and 
cytoplasmic fractions obtained for Car protein detection via immunoblot. To assess 
subcellular fractions and contamination, a cytoplasmic marker, β-actin, and a nuclear 
marker, Lamin B1, were used. In all cases there was minimal nuclear contamination 
in the cytoplasmic fractions, whereas there was evidence of cytoplasmic 
contamination in the nuclear fraction (Figure 2.9). Treatment with PB (2mM) 
suggests there was an increase in Car protein within the nuclear fraction compared 
to the nuclear fraction of control cells (Figure 2.9 A). However, it is difficult to 
unequivocally confirm this response due to the increase in the nuclear marker Lamin 
B1 with PB treatment. Koike et al., (Koike, Moore, & Negishi, 2005) previously 
assessed Lamin B1 as a marker for PB-mediated nuclear localisation for Car, which 
appeared to show a subtle (not quantified) increase with PB compared to control, 
suggesting a different nuclear marker may have been more appropriate. Interestingly 
at all 3 time points tested, Car was found to be in the nucleus of control samples and 
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not detected in the cytoplasm, indicating that B13/H cells are more similar to 
immortalised cells with regards to Car localisation. 
 
Summary – From these data I have shown that optimised transdifferentiation of B13 
cells was with 2 weeks of 10nM dexamethasone (from now on reference to B13/H 
cells indicates 2 weeks differentiation) and optimal Cyp2b activity was obtained by 
treating with single doses of PB. We have also established that while B13/H cells are 
responsive to PB, the location of Car in B13/H cells is primarily nuclear and therefore 
likely to be more similar to that of immortalised cells than compared with primary 
hepatocyte cells. 
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Figure 2.9: Car subcellular localisation 
Figure 2.9 depicts immunoblots of Car and loading controls, β-actin and Lamin B1, in 
2 (A), 3 (B) and 4 (C) weeks dexamethasone-differentiated B13/H cells with 72 
hours 2mM PB treatment. Each lane was derived from an independent culture.  
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Due to the constitutive activity of Car, if this nuclear receptor is present in the 
nucleus, why do we appear to demonstrate a PB response? It is possible that, due to 
the overlapping nature of Car and Pxr downstream targets, the response shown is 
due to Pxr activation? However, it has been reported that nuclear location of Car is 
not sufficient for gene expression alone, and may require further molecular changes 
(Pascussi, Gerbal-Chaloin, et al., 2000). In this respect, I argued in chapter 1 that 
Ampk activation may be part responsible for this (chapter 1.2.3). Activation of Ampk 
has been suggested to be due to decreased expression of miR-122 (Shizu et al., 
2012) as a result of Car-mediated Hnf-4α suppression (Kazantseva et al., 2015). 
Both Car (Miao, Fang, Bae, & Kemper, 2006) and Pxr (Bhalla, Ozalp, Fang, Xiang, & 
Kemper, 2004) have been reported to inhibit Hnf-4α-mediated gene expression. 
Therefore it is possible that basal Car activity or activation of Pxr, as a result of PB 
treatment, inhibits Hnf-4α, which results in decreased miR-122 and subsequent 
Ampk activation and nuclear activation of Car. In fact, Figure 2.10 shows that PB 
treatment (4mM) in 2 weeks dexamethasone-transdifferentiated B13/H cells 
significantly reduced miR-122 expression after 24 hours. It would be interesting to 
determine if PB-mediated inhibition of miR-122 may be involved in the activation of 
Car in B13/H cells. To explore this further would require additional treatment times to 
be examined in order to correlate miR-122 expression with Cyp mRNA expression 
and activity. To confirm the role of miR-122 and Car activation it would be interesting 
to over-express the miRNA and assess if the B13/H cells remain responsive to PB. 
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Figure 2.10: MiR-122 expression in PB treated B13/H cells 
Figure 2.10 depicts the expression of miR-122 in B13/H cells following 24 hours PB 
treatment. Results were representative of 3 independent cultures, and Y-axis is 
mean + SEM of miR-122 expression using 2-ΔCt to present fold change of target to 
time matched control. One way ANOVA with Dunnett’s comparison was used to 
compare PB (100µM, 2mM or 4mM) to control. ****p<0.0001 
 
Summary – This data shows that PB reduced miR-122 levels in B13/H cells, as 
seen in male C3H mice and human HepG2 cells (Shizu et al., 2012).  
 
2.3.2.2 Cyp2b activity and Cyp mRNA expression in 2 week dexamethasone 
transdifferentiated B13/H cells in response to PB 
Cyp2b activity Primary hepatocytes often require culturing in complex conditions in 
order to maintain their hepatic functions (K. Wallace, Fairhall, Charlton, & Wright, 
2010). Yusof et al., (Yusof & Edwards, 1990) demonstrated that by culturing primary 
rat hepatocytes in Williams’ medium E containing: Egf (10ng/mL), dexamethasone 
(30nM), insulin (300nM) and FBS (3% v/v) (referred to herein as hepatocyte media) 
at sub-confluency improved the transient hyperplasic response associated with PB 
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treatment in vivo. From this I hypothesised that culture of B13/H cells in an 
hepatocyte defined medium might improve the in vitro PB response. I first sought to 
test if differentiated B13/H cells cultured with this hepatocyte media would exhibit an 
improved response to PB-mediated induction of Cyp2b activity, when compared to 
standard culturing conditions. By comparing the effect of different cell media on 
Cyp2b activity I demonstrated that an hepatocyte defined medium produced a higher 
basal Cyp2b activity compared to standard B13 culture media and a serum stripped 
media (Figure 2.11 A). However, the standard B13 culture media appeared to be 
optimal for PB-mediated induction of Cyp2b (Figure 2.11 B, C and D). I included a 
serum stripped media as growth factors have been shown to inhibit PB signalling 
(Mutoh et al., 2013; Osabe & Negishi, 2011), and I wanted to explore the possibility 
that in a medium lacking hormones and certain growth factors, PB induction of 
Cyp2b would be improved. This did not appear to be the case. 
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Figure 2.11: Effect of media on Cyp2b activity in B13/H cells 
Figure 2.11 shows Cyp2b activity (PROD) in B13/H cells in different media types (A), 
and after PB treatment for 72 hours (B/C/D). Results were mean + SEM for 4 
independent cultures. Y-axis is of Cyp activity determined by the rate of resorufin 
production. Control treatment was compared to PB (100µM and 2mM) by one way 
ANOVA with Dunnett’s comparison. **p<0.01.  
 
Summary – The data confirmed that B13/H cells are capable of responding to PB 
treatment in a simple culture media without the requirement of many added 
supplements, and that the defined hepatocyte media tested here is unlikely to 
improve the B13/H cell response to PB. Therefore, culturing B13/H cells in B13 
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media (lacking dexamethasone) is optimal for eliciting a PB response, as measured 
by PROD. 
 
Expression of Cyp2b mRNA I confirm that Cyp2b1 mRNA was increased with PB 
(2mM) after 6 hours treatment (Figure 2.12 A), although expression was diminished 
after 24 hours (Figure 2.12 B) and undetectable after 72 hours (data not shown). 
Furthermore, I confirm that B13/H cells expressed the male specific Cyp2c11 (Philip 
M E Probert et al., 2014), which did not appear to be induced by PB (Figure 2.12 C 
and D).  
 
In agreement with my data, Probert et al., (Philip M E Probert et al., 2014) report that 
B13/H cells treated with PB exhibit similar responses as determined by qPCR and 
PROD, and demonstrate the reproducibility of this cell line.  
 
Summary – These data show that B13/H cells are capable of responding to PB and 
producing typical markers of PB exposure, in a manner comparable to independent 
laboratory groups. 
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Figure 2.12: Cyp mRNA expression in PB treated B13/H cells 
Figure 2.12 depicts mRNA expression by qRT-PCR of Cyp2b1 and Cyp2c11 after 6 
hours (A/C) or 24 hours (B/D) 2mM PB. Results were representative of 3 
independent cultures, and Y-axis is mean + SEM using 2-ΔCt to present fold change 
of target to control. Student’s t test compared control to PB. **p<0.01. 
 
2.3.2.3 Temporal- and dose-dependent response of Cyp2b activity in 2 week 
dexamethasone-differentiated B13/H cells in response to PB and PB-like compounds 
Data presented in Figure 2.13 and Figure 2.14 were obtained in collaboration with 
Myriam Haltalli (Department of Surgery and Cancer, Imperial). 
 
         2.  Characterising rat hepatocyte-like AR42J-B13/H cells as an in vitro model for phenobarbital treatment 
78 
 
I have established that treatment with PB (2mM) for 72 hours in 2 weeks 
dexamethasone-differentiated (10nM) B13/H cells provoked a reliable and 
reproducible induction of Cyp2b activity (by PROD). It has been suggested that 
B13/H cells are capable of being cultured for extended timeframes and so offer an 
advantage over the short-term chemical exposures required when working with 
primary hepatocytes. Here, by assessing Cyp2b activity at different times we hoped 
to identify an appropriate regime for in vitro PB exposure beyond 72 hours, and 
explore the effect of extended chemical treatments in these cells. Furthermore, we 
interrogated the response to PB and PB-like compounds to assess if the cells elicited 
reproducible responses to chemicals with similar phenotypic effects. The following 
data is from B13/H cells exposed to PB and PB-like compounds for the times 
indicated in Figure 2.13, with the media and compound refreshed every 72 hours. My 
previous data demonstrated that PB induces Cyp2b activity under this condition 
(Figure 2.8 B). 
 
Rat Car activators Two millimolar PB significantly induced Cyp2b activity at 3 and 9 
days (Figure 2.13 A), and we confirmed that doses of 2mM PB and above were able 
to significantly induce Cyp2b activity at 72 hours (Figure 2.14 A). The PB-like 
compound benzophenone (BP) was also tested. BP is used in agricultural chemical 
synthesis as well as a fragrance enhancer and flavour. BP was identified as a Cyp2b 
inducer, demonstrating similar adaptive responses in the liver as PB treated rats 
(Boobis et al., 2009; Chhabra, 2000), as well as similar molecular changes (Koufaris 
et al., 2012). We tested a dose response to BP at 72 hours where PB induced Cyp2b 
activity (PROD) (Figure 2.13 A and Figure 2.14 A) and found that doses of 750µM or 
1mM induced Cyp2b activity compared to control (p<0.05 by Student’s t test) (Figure 
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2.14 B). Clotrimazole has been identified as a direct activator of rat Car (Omiecinski 
et al., 2011). We showed that 10µM clotrimazole increased Cyp2b activity (PROD) at 
1, 3 and 9 days treatment compared to control (Figure 2.13 B). To support this 
finding we also examined the effect of clotrimazole dose on PROD after 72 hours 
treatment and found induction only occurred at 10µM (Figure 2.14 C).  
A      B 
C 
 
 
 
 
 
 
 
Figure 2.13: Time-response of Cyp2b 
activity in B13/H cells treated with PB 
and PB-like compounds 
Figure 2.13 illustrates Cyp2b activity in B13/H cells by PROD after 2mM PB (A), 
10µM clotrimazole (B), or 1.5µM TCPOBOP (C) treatments for the times indicated. 
Treatment and media were refreshed every 72 hours. Results were representative of 
3 independent cultures, and Y-axis is mean + SEM of Cyp activity determined by the 
rate of resorufin production. Student’s t test compared control to time matched 
treatment. *p<0.05, ****p<0.0001.  
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Mouse Car activator Car is known to respond to chemicals in a species-specific 
manner. For example, the rat Car activator clotrimazole is a human Car inverse 
agonist (Moore et al., 2000; Omiecinski et al., 2011), and the Car activator 
TCPOBOP has been reported to be mouse-specific (Omiecinski et al., 2011; Tzameli 
et al., 2000). To confirm that in the B13/H cells Car responded in a rat-specific 
manner, we treated B13/H cells with 1.5µM TCPOBOP (Philip M E Probert et al., 
2014). We found that there was no significant change in PROD compared to control 
at any time point tested (Figure 2.13 C). Although the response to TCPOBOP was 
variable, the data indicates that TCPOBOP was not a Car activator in the rat B13/H 
model. 
  
Summary – These data suggest that optimal treatment of B13/H cells, based on 
Cyp2b activity, requires single doses of PB or PB-like compounds for 72 hours, and 
that increases in Cyp2b activity can be maintained for up to 9 days exposure to 
compounds. Furthermore, B13/H cells responded to activation of Car in a rat-specific 
manner. 
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Figure 2.14: Dose-response of Cyp2b activity in B13/H cells treated with PB and PB-
like compounds  
Figure 2.14 describes the effect of chemical dose-response on Cyp2b activity in 
B13/H cells by PROD after PB (A), BP (B) or clotrimazole (C) exposure for 72 hours.  
Results were representative of 3 independent cultures, and Y-axis is mean + SEM of 
Cyp activity determined by the rate of resorufin production. One way ANOVA with 
Dunnett’s comparison was used to compare treatment to control. **p<0.01, 
***p<0.001, ****p<0.0001. 
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2.3.3 Aim 3: Explore the effect of PB and PB-like compounds on miRNA 
expression in B13/H cells. 
Data presented in Figure 2.15 were obtained in collaboration with Myriam Haltalli.  
 
Data from Koufaris et al., (Koufaris et al., 2012, 2013) reported that miRNA 
expression profiles can be used to predict mechanisms of action of different 
chemicals. The authors showed that PB induced miR-182/96 and miR-200a/b/429 in 
a time- and dose-dependent manner, and the PB-like compound BP also increased 
expression of these miRNAs. The regulation and function of these miRNAs will be 
discussed further in chapter 4 and 5. Importantly, the in vivo time-dependent 
induction of these miRNAs by PB is such that at 1, 3 and 7 days 1000ppm PB 
treatment, the miRNAs were not significantly changed from control. However from 14 
days onwards the miRNAs were significantly increased by 1000ppm PB 
(demonstrated with miR-200a, miR-200b and  miR-96) (Koufaris et al., 2013). We 
therefore wanted to further test the B13/H cell model with extended treatments. By 
treating with PB and BP, as well as the Car activator clotrimazole, we explored the 
reproducibility of the B13/H cells in responding to chemicals with similar mechanisms 
of action by analysing if the in vivo identified miRNAs were sensitive to these 
treatments. 
 
MiRNA expression after PB and PB-like treatments Treatment with PB (100µM 
and 2mM) did not significantly alter the expression of miR-182 or miR-96 at 3 days 
treatment compared to control (Figure 2.15 A and B), despite induction of Cyp2b 
         2.  Characterising rat hepatocyte-like AR42J-B13/H cells as an in vitro model for phenobarbital treatment 
83 
 
under these conditions (2mM PB) (Figure 2.13 A). However at 9 days, where we 
showed Cyp2b induction (Figure 2.13 A), PB (2mM) significantly induced both 
miRNAs compared to control (Figure 2.15 A and B). This suggests that PB was able 
to time-dependently induce miR-182 and miR-96 in the B13/H cells in a similar 
fashion as shown in vivo. Furthermore, we show that miR-96 was induced by BP 
(500µM) in the same manner (Figure 2.15 C). Our data demonstrates that two 
compounds, PB and BP, which display similar hepatic responses in vivo, both 
induced the expression of associated miRNA markers in vitro. Interestingly, the 
induction of miR-96 expression by clotrimazole (10µM) at 3 days treatment (Figure 
2.15 D) was consistent with clotrimazole’s rapid induction of Cyp2b (Figure 2.13 B). 
Finally, we confirmed that the mouse-specific Car agonist TCPOBOP (1.5µM) did not 
induce either miR-182 or miR-96 under the conditions used here (Figure 2.15 E and 
F). 
 
We also determined the expression of miR-200b in B13/H cells but in these samples 
the Ct values were such that the target was considered not to be expressed (Ct >35) 
(data not shown). 
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A      B 
 
C      D 
 
 
E      F 
 
 
 
Figure 2.15: miRNA expression in B13/H cells treated with PB and PB-like 
compounds 
Figure 2.15 shows miRNA expression by qRT-PCR of miR-182 (A) and miR-96 (B) 
after treatment with PB, miR-96 in response to BP (C) or clotrimazole (D) and miR-
182 (E) and miR-96 (F) after TCPOBOP treatment. Results were representative of 3 
independent cultures, and values were mean + SEM using 2-ΔCt to present fold 
change of target to time matched control. One way ANOVA with Dunnett’s 
comparison was used to compare PB (100µM or 2mM) to control, and Student’s t 
test compared control to PB. *p<0.05. **p<0.01. 
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MiRNA expression in B13 and B13/H cells Transdifferentiation of B13 to B13/H 
cells results in an increase in expression of miR-182 (data not shown) and PB has 
also been used to maintain primary hepatocytes in a differentiated state (Miyazaki et 
al., 1998). It is therefore possible that removal of dexamethasone and PB might 
result in dedifferentiation of B13/H cells and the levels of the miRNAs might be 
expected to reduce in the control cells over time. To explore this, I have assessed 
the change in miR-182 cluster partner, miR-96, over the treatment course. Figure 
2.16 compares the expression of miR-96 between control samples at day 3 and 
control samples at day 9. The data shows that miR-96 expression, although variable, 
at 3 days did not significantly decrease over time in the control treatment groups 
(Figure 2.16 A and B). This suggests that PB was not required to maintain the 
hepatocyte-like phenotype in B13/H cells. Furthermore, Figure 2.15 D indicates that 
3 days treatment with clotrimazole (10µM) was sufficient to induce miR-96, 
suggesting that the B13/H cells are responsive to PB and PB-like compounds. 
 
Summary – Collectively these data suggest that B13/H cells produced a miRNA 
response similar to that seen in vivo in rats with PB and PB-like compounds. 
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Figure 2.16: Comparing miRNA expression in B13/H cells between 3 and 9 days 
Figure 2.16 shows mRNA expression by qRT-PCR of miR-96 expression in control 
and PB (A) or BP (B) treated B13/H cells respectively. Results were representative 
of 3 independent cultures, and values were mean + SEM using 2-ΔCt to present fold 
change of target to day 3 control. Student’s t test compared day 3 to day 9 control or 
day 9 control to day 9 PB. *p<0.05.  
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2.4 Conclusions  
B13/H cells provide Toxicologists with a reproducible, cost-effective and simple 
model for interrogating hepatocyte-like responses in vitro (Philip M. E. Probert et al., 
2015). Here we demonstrated that 2 weeks dexamethasone-induced (10nM) 
transdifferentiated B13/H cells can respond to PB and PB-like compounds with 
increased Cyp2b activity as well as associated changes in miRNAs in a manner 
similar to the rat in vivo (Koufaris et al., 2012, 2013; Waterman et al., 2010).  
 
Probert et al., (Philip M E Probert et al., 2014) could not detect Cyp2b1 protein but 
did detect 2b1 mRNA and activity by PROD assay after PB treatment, in agreement 
with the data presented here. This could suggest that perhaps the induction of 
PROD activity is independent of Cyp2b1 protein and could involve Cyp2c11 and/or 
Cyp3a2 (Langouët et al., 1997). Our data suggested that although Cyp2c11 was 
expressed in B13/H cells, it was not induced after 6 or 24 hours PB treatment (2mM) 
(Figure 2.12 C and D), which is in agreement with the rat in vivo (Kot & Daniel, 
2007). PB has been shown to induce Cyp3a2 in Sprague-Dawley and Wistar rats 
(Kishida et al., 2008), and CYP3A has been shown to be induced by PXR in human 
primary hepatocytes (Pascussi, Drocourt, Fabre, Maurel, & Vilarem, 2000); this could 
suggest that the Cyp450 activity measured by the PROD assay here may be through 
PB-mediated activation of Pxr. This could also have implications on Car expression 
in B13 cells discussed earlier (Figure 2.7 B and F). However, the increase in Cyp2b1 
mRNA with PB treatment (Figure 2.12 A) is indicative of Car activation, which is 
corroborated by Marek et al., (Marek et al., 2003) who show that testosterone is 
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metabolised in B13/H cells and that in the presence of PB generates a testosterone 
metabolite indicative of Cyp2b1/2 activation.  
 
Interestingly, Probert et al., (Philip M E Probert et al., 2014) show that TCPOBOP at 
the same dose used in our work did induce Cyp2b1 and Cyp3a1 mRNA in B13/H 
cells, although the reason for this was not discussed. To fully explore the possibility 
that B13/H cells respond to TCPOBOP a dose response should be performed. 
Tzameli et al., (Tzameli et al., 2000) show that peak activation of a Car expression 
vector in HepG2 cells was at approximately 300nM TCPOBOP with an half maximal 
effective concentration (EC50) of 20nM. TCPOBOP is a mouse Car activator, and a 
human Pxr activator (Moore et al., 2000), it is therefore possible that at the high 
concentrations used here in my study that TCPOBOP may induce Cyp450 mRNA. 
Nonetheless, our data demonstrates that under the conditions used herein Car 
activation in the B13/H cells was rat specific. However, subcellular fractionation of 
PB treated B13/H cells and immunoblot analysis showed that Car protein was 
undetectable in the cytoplasm of control or PB treated B13/H cells. This suggests 
that despite the B13/H cell’s metabolic capacity and PB responsiveness, subcellular 
localisation of Car in B13/H cells was more similar to immortalised cells than to 
primary cells. 
 
Chapter 2 Conclusions – Overall our data suggest that the B13/H cells are a useful 
model for exploring the molecular effects induced by PB and PB-like compounds, 
and that B13/H cells produce similar responses to PB and PB-like compounds as 
has been reported in vivo (Koufaris et al., 2012, 2013). However, future research into 
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characterising this model should focus on the extent of PB-mediated induction of Car 
and Pxr and the potential effects of TCPOBOP in this cell line. In this respect, the 
next chapter will focus on the interaction of PB with growth factors to begin to 
interrogate the role of growth factor responses in PB signalling. 
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3. Cross-talk between growth factor signalling and phenobarbital 
signalling pathways 
 
3.1 Introduction  
Chapter 2 focussed on characterising the B13/H cells and their response to PB. In 
this chapter I interrogate the effect of PB on epidermal growth factor (Egf) and 
hepatocyte growth factor (Hgf) signalling pathways to explore potential regulatory 
interactions with PB signalling. 
 
3.1.1 PB antagonises Egfr in the mouse to activate Car  
As discussed in chapter 1.2.3, PB indirectly activates Car through a signalling 
pathway, which dephosphorylates Car. This causes Car to dissociate from 
cytoplasmic chaperones and subsequently to translocate into the nucleus 
(Kawamoto et al., 1999; Kobayashi et al., 2003; Yoshinari et al., 2003). In the 
mouse, PB is thought to initiate these events through antagonising the Egf receptor 
pathway (Egfr) (Mutoh et al., 2013).  
 
Phosphorylated & cytoplasmic Car Under growth factor stimulation the adapter 
protein, Shc, is phosphorylated by an activated receptor, and bound by another 
adapter protein, Grb2, via its phospho-tyrosine (Src homology 2 domain: SH2) 
binding domain. The guanine nucleotide exchange factor, Sos, is then recruited, 
which facilitates activation of ras through the transfer of GTP to ras (Ravichandran, 
2001). Raf can then bind to ras via its ras-binding domain, resulting in a number of 
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de-phosphorylation and phosphorylation steps to activate raf. Raf then binds, 
phosphorylates and activates Mek1/2, which binds, phosphorylates and activates 
extracellular signal regulated mitogen-activated kinase (Erk)1/2 (Matallanas et al., 
2011). Osabe and Negishi (Osabe & Negishi, 2011) reported that 2mM PB was able 
to inhibit Erk signalling in mouse primary hepatocytes, which is believed to be 
associated with decreased phosphorylation of Car (Figure 3.1). Furthermore, both 
Egf (10µg/mL) and Hgf (10µg/mL) were able to inhibit 1.5mM PB induced expression 
of Cyp2b10 mRNA in mouse primary hepatocytes, which the authors attributed to 
Erk activation (Koike et al., 2007). Activated Erk was suggested as the intrinsic cell 
signal for Car phosphorylation, which maintains Car in the cytoplasm; thereby 
inhibiting Car-mediated gene transcription (Koike et al., 2007; Osabe & Negishi, 
2011).  
 
Figure 3.1: Activation of Car by PB in the mouse 
Figure 3.1 PB is reported to antagonise growth factor signalling in the mouse to 
induce Car translocation to the nucleus. Growth factor-mediated cytoplasmic 
sequestration of Car is shown in green, while the antagonistic PB-induced response 
is shown in blue. Adapted from (Matallanas et al., 2011; Mutoh et al., 2013). 
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Dephosphorylated & nuclear Car Shc can also interact with Src via their proline 
rich domains (Src homology 3 domain: SH3) (Ravichandran, 2001). Active Src has 
been reported to phosphorylate receptor for activated C kinase (Rack)1 and abolish 
Rack1 association with protein phosphatase 2a (Pp2ac) (Mutoh et al., 2013). Mutoh 
et al., (Mutoh et al., 2013) reported that PB-mediated antagonism of the Egfr enabled 
de-phosphorylation of Car by co-recruitment of de-phosphorylated Rack1 to Pp2ac 
(Figure 3.1), which is known to be the signal for Car nuclear translocation (Mutoh et 
al., 2013). Rack1 is a scaffold protein involved in stabilising, anchoring and shuttling 
proteins within the cell (Adams, Ron, & Kiely, 2011). 
 
Therefore, it is thought that in the mouse PB indirectly activates Car through 
antagonism of the Egfr and through inhibition of the downstream kinase, Erk. 
 
3.1.2 Effects of Egf on PB-mediated gene transcription in the rat 
Cyp2b1/2 mRNA were significantly induced by 2mM PB in Male Wistar rat primary 
hepatocytes. This induction was shown to be inhibited by simultaneous treatment 
with Egf (20ng/mL), which was also able to suppress PB-mediated induction of Ugt2. 
Treatment with Hgf (20ng/mL) was unable to inhibit the expression of either 
Cyp2b1/2 or Ugt2 by PB (Kawamura et al., 1999). The ability of Egf (10ng/mL) to 
inhibit PB-mediated (1.5mM) expression of Cyp2b mRNA and activity were also 
demonstrated by Aubrecht et al., (Aubrecht et al., 1995) in male Wistar rats. 
Furthermore, indirectly inhibiting Erk1/2 through inhibition of its upstream kinase, 
Mek1/2, augmented PB-mediated induction of Cyp2b1/2 and Cyp3a1/2 (F Joannard 
et al., 2000; Florence Joannard et al., 2006). These data here suggest that Erk 
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inhibits expression of PB-regulated genes in the mouse and rat. Interestingly, 
Joannard et al., (Florence Joannard et al., 2006) reported that 15 minute treatment 
with 5mM PB increased Erk activity in male Sprague-Dawley rat primary 
hepatocytes. However, it is not clear to what extent PB interacts with the Egfr 
pathway in rat B13/H cells, compared to primary rat hepatocytes. 
 
To begin to explore the association with PB and the Egfr pathway in the rat I have 
utilised the B13/H cells described in chapter 2 in combination treatments with PB 
plus Egf or Hgf. Hgf was included to determine if the PB interaction was specific to 
the Egfr pathway, as indicated above. In order to begin interrogating these pathways, 
2 common downstream kinases (Berasain et al., 2009) were chosen to assess 
changes in activity with the combination treatments: (1) Erk was selected as it was 
reported that PB modulated Erk activity in mouse primary hepatocytes (Osabe & 
Negishi, 2011), and rat primary hepatocytes (Florence Joannard et al., 2006); (2) Akt 
was chosen as it has previously been reported that the Akt activator, Pi3k, had 
minimal effect on PB-mediated Cyp expression (F Joannard et al., 2000).  
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3.1.3 Hypothesis 
If B13/H cells resemble primary rat hepatocytes, then PB will augment Egf-induced 
Erk activity but not Akt activity. Furthermore, neither Hgf-induced Erk, nor Akt activity 
will be affected by PB treatment. 
  
3.1.4 Aims 
4. Optimise growth factor treatment dose and time for Erk and Akt activation in 
B13/H cells. 
5. Assess the B13/H cell response to PB in combination with either growth factor 
to determine potential roles of these signalling pathways in the rat. 
6. Assess the activation of these pathways in the rat in vivo. 
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3.2 Methods 
3.2.1 Tissue Samples 
Ethics approval and in vivo experimentation were conducted by Syngenta. This study 
has been previously described (Waterman et al., 2010). Briefly, male Fischer rats 
were fed a diet containing 1000ppm PB or control diet ad libitum for 90 days with 
liver collections at 1, 3, 7, 14 and 90 days. These samples were snap frozen and 
stored at -80oC, until thawed for protein extraction. All studies were performed on left 
lobe liver samples. 
 
3.2.2 Cell culture 
As detailed in chapter 2.2.1. 
Culture conditions were as previously described with 13 days differentiation with 
10nM dexamethasone. Cell media was then replaced with dexamethasone-free, 5% 
heat inactivated dextran coated charcoal (HI-DCC) stripped FBS supplemented 
media for 24 hours before PB treatment for 72 hours to assess changes in Cyp2b 
activity by PROD, or for 72 hours prior to growth factor treatments.  
 
3.2.3 Cell counts & alamarBlue® 
Cell counts were performed using the Moxi Z (ORFLO, Ketchum, ID). Cells were 
passed through a passage with a voltage applied, as the cells move through, the 
Moxi measures the number of cells and their volume relative to the impedance of the 
voltage (http://orflo.com/howitworks.html).   
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AlamarBlue® can be used to measure cell viability. Viable cells incorporate the 
assay’s non-fluorescent compound, resazurin, which is reduced in the cytosol to the 
fluorescent product, resorufin. The production of resorufin is dependent on cytosolic 
reducing enzymes and is proportional to the number of cells, and so this assay is 
often used to determine viability/proliferation, and has been shown to be comparable 
with, and a quicker assay than, [3H]thymidine incorporation (Ahmed, Gogal, & Walsh, 
1994). Data obtained in collaboration with Mariana Flores-Torres (Figure 3.2) 
demonstrates the change in alamarBlue® reduction is proportional to B13/H cell 
density. 
0 2 4 6 8 1 0
0
5 0 0
1 0 0 0
1 5 0 0
A la m a rB lu e  c o m p a r is o n  to  c e ll d e n s ity
B 1 3 /H  c e ll d e n s ity  (x 1 0
4
c e lls )
R
F
U
 
Figure 3.2: Alamar blue reduction 
Figure 3.2 shows the relative fluorescence units (RFU) from alamarBlue® reduction 
at different cell densities, from 3 independent cultures. 
 
3.2.4 Cyp450 enzyme activity - PROD  
Pentoxyresorufin-O-dealkylase (PROD) assay was used to determine Cyp2b activity, 
as described in chapter 2.2.2. 
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3.2.5 Chemical treatments – cell signalling 
To explore the roles of growth factors and phenobarbital signalling, B13/H cells were 
treated with rat epidermal growth factor (Egf) (Sigma-Aldrich, Dorset, UK) (solvated 
in 0.1% bovine serum albumin [BSA]) or human hepatocyte growth factor (Hgf) 
(PeproTech EC Ltd, London, UK) (solvated in 0.1% BSA), with specific inhibitors to 
the Egf receptor, Erlotinib (Cayman Chemical, MI, USA) (made to concentration in 
DMSO), or to the Hgf receptor, SU11274 (VWR International Ltd, Leicestershire, UK) 
(solvated in DMSO), in combination with phenobarbital (made up in 5% stripped 
media). Treatment combinations are described in figure legends. B13 cells were 
seeded at 4x104 cells per well in 24-well plates and differentiated as described 
previously. At 13 days differentiation the cell culture media was substituted for media 
containing 5% HI-DCC-stripped FBS for 72 hours prior to any treatments with growth 
factors to reduce background signalling 
(http://www.lifetechnologies.com/uk/en/home/life-science/cell-culture/mammalian-
cell-culture/fbs/specialty-serum/charcoal-stripped-fbs.html; date accessed 
14/06/2015). Protein was harvested from samples and subsequently analysed by 
immunoblotting as described below. 
 
3.2.6 Immunoblots 
Unless stated otherwise chemicals were obtained from Sigma-Aldrich (Dorset, UK). 
 
Cell lysis Cell samples were lysed directly from the culture plate on ice after 
washing with ice cold PBS. Lysis was performed with RIPA buffer containing Halt 
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Protease Inhibitor and phosphatase inhibitor cocktail 2 and 3 (at final dilutions of 
1:100) for at least 10 minutes. In order to assess phospho-proteins by immunoblot it 
was important to use phosphatase inhibitor cocktails 2 and 3, to inhibit tyrosine and 
serine/threonine phosphatases respectively. The cell lysate was centrifuged at 
10,000g to collect the soluble protein supernatant. 
 
Tissue lysis Frozen rat liver tissue samples of 50-100mg were homogenised in lysis 
buffer prepared in dmH2O with constituents: Igepal (0.1%), sodium chloride (NaCl) 
(150mM), tris (1mM) (Fisher Scientific, PA, USA), edetic acid (EDTA) (1mM) and 
Halt Protease Inhibitor and phosphatase inhibitor cocktail 2 and 3 (at final 
concentrations of 1:100), using a T25 basic IKA Labortechnik tissue homogeniser. 
Samples were incubated on ice for 10 minutes then centrifuged at 10,000g to pellet 
insoluble material. Supernatant was collected for protein quantification. 
 
Protein concentration was quantified using the BCA assay, as described in chapter 
2.2.3. 
 
SDS-PAGE gel preparation An acrylamide resolving gel (10% acrylamide/bis-
acrylamide) under reduced (i.e. β-mercaptoethanol in the loading buffer) and 
denaturing conditions (i.e. SDS, and sample heating) was prepared with 
constituents: Tris (500mM), sodium dodecyl sulphate (SDS) (3.4mM), ammonium 
persulphate (APS) (2.7mM) and tetramethylethylenediamine (TEMED) (10.3mM). A 
bis-acrylamide (5%) stacking gel was set on top of the resolving gel, containing Tris 
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(284mM), SDS (7.9mM), APS (8.7mM) and TEMED (6.6mM), and a 15 well 1.5mm 
well-forming comb was set in place.  
 
Sample preparation Protein samples were lysed and then quantified by the BCA 
assay as mentioned above. Samples were diluted to 1µg/µL. Twenty micrograms of 
protein per sample were loaded with 5µL SDS loading buffer, containing SDS 
(350mM), Tris-HCl (200mM), glycerol (2.7M), bromophenol blue (1.6mM) and 
supplemented with β-mercaptoethanol (1:20). Samples and biotinylated protein 
ladder (Cell Signalling, MA, USA) were heated to 95oC for 5 or 2 minutes, 
respectively, and then centrifuged at 4,000g for 5 minutes. Samples, biotinylated 
protein ladder and Novex Sharp pre-stained protein standard (Life Technologies, 
Paisley, UK) were then loaded into the prepared gel. 
 
Gel electrophoresis Upon addition of a current, proteins migrate down an agarose 
gel relative to their mass and charge. Samples were run at 60V through the 5% gel 
until they were stacked along the junction with the 10% gel. Samples were then run 
at 100V to separate proteins in order of size. Electrophoresis was performed using 
Biorad tanks, containing a running buffer of tris (2.5mM), glycine (25mM), and SDS 
(3.5mM).  
 
Protein transfer Protein was transferred onto a protran nitrocellulose membrane 
(0.45μm pore) (Bio-Rad, Hertfordshire, UK) pre-soaked in a Tris-glycine-methanol 
transfer buffer (25mM-186mM-20%v/v). The protein was transferred from gel to 
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membrane through semi-dry or wet transfer. For semi-dry transfer a BioRad Trans-
Blot SD semi-dry electrophoretic transfer cell was used running at 20V for 40 
minutes. For wet transfers Biorad tanks were used with samples transferred at 150V 
for 1 hour 20 minutes. Successful transfer was checked using the protein dye 
Ponceau S solution. 
  
Immunoblotting Membranes were blocked for one hour in a blocking buffer 
containing skimmed milk (5%) made up in PBS-Tween20 (0.1% Tween20). Blocking 
limits nonspecific binding of subsequent antibodies. Between blocking and antibody 
incubations, membranes were washed 3x 5 minutes with PBS-Tween20 to remove 
contaminants. Target proteins were visualised using antibodies diluted in a blocking 
buffer. Protein-fixed nitrocellulose membranes were incubated with primary 
antibodies overnight at 4oC or at room temperature for 2 hours, and incubations with 
secondary antibodies were at room temperature for 2 hours.  In cases where 
phospho-antibody and total antibody were used, the blot was stripped using reblot 
solution (Millipore, MA, USA) for 20 minutes, after first visualising the phospho-target 
protein. Secondary antibodies were linked to horseradish peroxidase (HRP), which 
oxidises luminol in a chemiluminescence reaction and this was detected on a Gel 
Doc XR+ System (Kodac). Luminata Forte (Millipore, MA, USA) was used as the 
substrate for the chemiluminescence.  
 
Primary antibodies mouse α-Gapdh (1:1,000 dilution, Abcam ab8245), rabbit α-β-
tubulin (1:500, Abcam ab6046), rabbit α-Akt (1:200, Santa Cruz sc-8312), rabbit α-
pAkt (Ser 473) (1:350, Santa Cruz sc-7985-R), rabbit α-Erk (1:200, Santa Cruz sc-
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94), mouse α-pErk (human tyr 204) (1:200, Santa Cruz sc-7383), rabbit α-Elk1 
(1:200, Santa Cruz sc-355), mouse α-pElk1 (Ser 383) (1:200, Santa Cruz sc-8406), 
rabbit anti-FoxO1A (1:1000, Abcam ab133893) and rabbit anti-pFoxO1A (Ser 256) 
(1:500, Abcam ab131339).  
 
Secondary antibodies α-biotin-HRP (1:1,000, Cell signalling #7075P5), goat α-
mouse-HRP (1:10,000, Abcam ab6789), goat α-rabbit-HRP (1:5,000, Abcam 
ab97051). 
 
3.2.7 Meso Scale Discovery (MSD) multi-spot assay system 
The MAP Kinase Phosphoprotein Assay Whole Cell Lysate Kit (MSD, MD, USA) was 
used to quantify the levels of phospho-p38 at Thr180/Tyr182, phospho-Erk1/2 at 
Thr202/Tyr204 and Thr185/Tyr187 and phospho-Jnk at Thr183/Tyr185 in the rat liver 
samples following the manufacturer’s protocol. Briefly, the assay plate was blocked 
with a kit derived blocking solution to prevent non-specific binding of proteins, and 
then washed to remove excess solution. Samples were loaded at 20µg of tissue 
lysate per well. Each well was pre-coated with three different antibodies, one 
antibody for phospho-p38, one for phospho-Erk1/2 and one for phospho-Jnk, with 
each antibody located in its own spot within the well. The analytes of interest bind to 
the capture antibodies by incubating the plate and samples at room temperature for 
3 hours on a plate shaker (500 rpm). The plate was washed again to remove 
unbound sample and the detection antibodies were added. The detection antibodies 
were diluted to a final concentration of 1:50 and bind to the sequestered analyte, 
recognising total p38, total Erk1/2 or phospho-Jnk. The detection antibodies were 
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conjugated with an electrochemiluminescent tag that emits light when a voltage is 
applied during measuring of the assay plate on a SECTOR Imager 2400A, allowing 
the relative levels of each analyte to be quantified.  
 
3.2.8 Statistics 
In vitro as described in chapter 2.2.8.  
 
In vivo statistics were also performed using Graph Pad 6 as above, except showing 
standard deviation (SD) and comparing treatment groups with control using Mann-
Whitney. 
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3.3 Results and Discussion 
3.3.1 Aim 1: Optimise growth factor treatment dose and time for Erk and Akt 
activation in B13/H cells. 
3.3.1.1 Optimising treatment doses 
B13/H cells were differentiated for 2 weeks with 10nM dexamethasone as detailed in 
chapter 2. Upon differentiation, dexamethasone was removed and cells were 
cultured in 5% HI-DCC stripped FBS supplemented media for 72 hours prior to 
growth factor treatments. HI-DCC stripped FBS was used in order to reduce the 
background signal of growth factor signalling pathways. As a quick and effective 
method to test Hgf and Egf dose responses in the B13/H cells, the alamarBlue® 
assay was used.  
 
Growth factors B13/H cells were treated with a dose range of Hgf (1-50ng/mL) 
(Figure 3.3 A) or Egf (0.1-10ng/mL) (Figure 3.3 B) for 24 hours. The dose range for 
Hgf was selected based on Kawamura et al., (Kawamura et al., 1999) who reported 
that Hgf (20ng/mL) did not inhibit Cyp2b expression induced by PB (2mM). The dose 
range for Egf was based on the report by Aubrecht et al., (Aubrecht et al., 1995) who 
demonstrated that Egf (10ng/mL) could inhibit the induction of Cyp2b by PB 
(1.5mM).  
 
Hgf produced a significant dose-dependent increase in resorufin production up to 
20ng/mL (Figure 3.3 A). Egf also significantly increased resorufin production in a 
dose-dependent manner up to 10ng/mL (Figure 3.3 B). This response was lost after 
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48 hours for Hgf and Egf (data not shown). It has been previously reported that 
B13/H cells do not proliferate in the presence of Egf (100ng/mL) (Philip M E Probert 
et al., 2014) for 4 days, as measured by bromodeoxyuridine (BrdU) incorporation 
during S phase of the cell cycle. The disparity between the data presented here and 
that of Probert et al., (Philip M E Probert et al., 2014) could be due to the different 
treatment times used, as the data shown here indicated a minimal and transient 
effect of mitogens only at 24 hours treatment. However, as B13/H cells cultured in 
normal media are quiescent, and the Hgf- and Egf-mediated increase in resorufin 
production shown here are transient, it would suggest that Hgf and Egf may be 
inducing signalling activities that resulted in resorufin production, but not stimulating 
proliferation within the cells. This was confirmed using a cell count assessment (data 
not shown). 
 
Summary – Twenty ng/mL Hgf and 5ng/mL Egf were selected as optimal treatment 
doses for B13/H cells. 
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Figure 3.3: Growth factor and PB dose response 
Figure 3.3 shows alamarBlue® reduction of B13/H cells treated with a dose range of 
Hgf (n=3) (A), Egf (n=4) (B), or PB (n=4) (C) for 24 hours, or in combination (E/F) 
(n=3/4). Cyp2b activity in B13/H cells after 72 hours PB treatment in 5% stripped 
media (5% HI-DCC stripped FBS supplemented media) was shown (n=4) (D). Data 
were mean + SEM, with y-axis as fold change to vehicle control. Significance was 
tested by one way ANOVA with Dunnett’s comparison to respective control, or 
Student’s t test comparing control with growth factor alone. 
 
 
PB The effect of PB on alamarBlue® reduction was then assessed. PB alone (10µM-
5mM) for 24 hours was shown not to be mitogenic, and at the highest concentration 
(5mM) showed a decrease in resorufin production (Figure 3.3 C). Furthermore, 5mM 
PB was able to significantly induce Cyp2b activity as determined by PROD, after 72 
hours treatment in 5% HI-DCC stripped FBS supplemented media (Figure 3.3 D).  
 
PB plus growth factors Previous work has suggested that PB <1.5mM in 
combination with Egf was mitogenic, yet higher doses suppressed proliferation in 
primary rat hepatocytes (Jirtle & Meyer, 1991). Treating B13/H cells with Hgf 
(20ng/mL) or Egf (5ng/mL) in the presence of PB (10µM-5mM) for 24 hours, we 
failed to reproduce the biphasic effect of PB as reported by others (Figure 3.3 E and 
F). However, 5mM PB was suppressive in these co-treatments, reducing resorufin 
production to a level comparable to control cells.  
 
Summary – Five mM PB was selected as the optimal treatment dose for 
combination treatments with growth factors. 
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3.3.1.2 Optimising growth factor treatment time for Erk and Akt activity 
To confirm a functional growth factor signalling response and optimal treatment 
duration, B13/H cells were treated with 20ng/mL Hgf for 30, 60, 90 and 120 minutes 
and Erk and Akt activity were assessed by immunoblots (Figure 3.4). Treatment for 
up to 90 minutes with Hgf significantly increased Erk (Figure 3.4 A) and Akt (Figure 
3.4 B) activation (as measured by a ratio of phospho-protein to total protein) 
compared to time-matched control. The immunoblots shown (Figure 3.4 C and D) 
demonstrated clear changes in phospho-protein compared to control.  
 
Summary – Hgf treatment induced significant activation in Erk and Akt up to 90 
minutes, therefore 60 minutes and 90 minutes growth factor treatments were 
selected as optimal for treatment combinations. 
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Figure 3.4: Twenty ng/mL Hgf time response - Erk/Akt activity 
Figure 3.4 details Hgf activation on Erk (A) and Akt (B) signalling pathways after 30-
120 minutes treatment, with immunoblots shown for 30-60 mintes (C) and 90-120 
minutes (D). Data were representative of 3 independent cultures, showing mean + 
SEM and with y-axis as Erk and Akt activity measured as a ratio of phospho-protein 
to total protein normalised to Gapdh. Significance was tested by Student’s t test 
comparing time matched vehicle with Hgf.  
Erk1/2 
30 minutes 
p-Erk1/2 
Akt 
p-Akt 
20ng/mL Hgf 20ng/mL Hgf 
Gapdh 
60 minutes 
BSA BSA 
Erk1/
2 
p-Erk1/2 
Akt 
p-
Akt 
Gapdh 
90 minutes 
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3.3.1.3 Effect of phenobarbital alone on Erk or Akt pathway activity in B13/H cells 
PB (2mM) treatment for 1 hour has been shown to reduce Erk activity in male C3H 
mouse primary hepatocytes (Osabe & Negishi, 2011). This was not reproduced by 
us in rat B13/H cells when treated with PB alone (Figure 3.5 A). This is in 
concordance with the alamarBlue® data showing that PB alone was not mitogenic 
(Figure 3.3 C). However, the inhibition of Erk (and Akt) activity with erlotinib (Figure 
3.5 A (and B)) was found to not be significant and the data reported here was 
interpreted with caution. Therefore, through stimulating pathway activation with 
growth factors I aim to increase Erk and Akt pathway signalling to interrogate the 
effect of PB on these pathways.  
 
A lower dose of PB (1µM) was chosen after preliminary alamarBlue® data 
suggested resorufin production at this dose (data not shown). In this experiment and 
subsequent experiments using Egf, the Egfr inhibitor, erlotinib was included as a 
negative control. Erlotinib inhibits the Egfr by competing with ATP for its receptor 
binding site (Schettino, Bareschino, Ricci, & Ciardiello, 2008); the dose chosen 
demonstrated effective inhibition of EGF-induced (10ng/mL) EGFR phosphorylation 
with 10µM erlotinib (Buck et al., 2006). The Erk phospho-residue measured here, is 
the same as that assessed by Osabe and Negishi (tyrosine-204) in the mouse 
(Osabe & Negishi, 2011), although the antibody used by Osabe and Negishi also 
recognised threonine-202. These 2 residues are both phosphorylated by mitogen-
activated protein kinase kinase (Mek) and both require phosphorylation for full 
activation of Erk (Butch & Guan, 1996).
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A      B 
  
C 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Sixty minute PB treatment - Erk/Akt activity 
Figure 3.5 details the effect of 60 minutes PB on Erk (A) and Akt (B) activity. 
Representative blots shown (C). Data were representative of 3 independent cultures, 
showing mean + SEM and with y-axis as fold change to vehicle control. Erk and Akt 
activity were measured as a ratio of phospho-protein to total protein normalised to 
Gapdh from 3 separate immunoblots. Significance was tested by one way ANOVA 
with Dunnett’s comparison to control.  
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3.3.2 Aim 2: Assess the B13/H cell response to PB in combination with either 
growth factor to determine potential roles of these signalling pathways in the 
rat. 
3.3.2.1 Phenobarbital potentiates Egf-mediated Erk and Akt phosphorylation in 
B13/H cells 
As described previously, Mutoh et al., (Mutoh et al., 2013) reported that the Egfr 
acted as the PB receptor, in which PB antagonised Egfr phosphorylation to allow the 
nuclear translocation of Car and gene transcription. The authors demonstrated that 
in mouse primary hepatocytes, Egfr phosphorylation induced by 30 minutes pre-
treatment with Egf (100µg/mL) could be antagonised by the addition of PB (2.5mM), 
and that pre-treating with PB for 30 minutes could retard the effects of Egf. However, 
using optimized treatment conditions, treating B13/H cells with PB (5mM) for 30 
minutes followed by Egf (5ng/mL) for 60 minutes resulted in a significant increase in 
both Erk and Akt phosphorylation compared to Egf alone (Figure 3.6 A and B 
respectively). PB with growth factor vehicle did not significantly alter pathway 
activation (Figure 3.6 A and B).  
 
If the treatment of the B13/H cells with PB responded similarly to the mouse it would 
be expected that PB would suppress Erk phosphorylation while have no effect on 
Akt, yet surprisingly, PB increased Egf-mediated phosphorylation of both Erk and 
Akt. This is in agreement with the data from Joannard et al., (Florence Joannard et 
al., 2006) who reported that PB increased Erk activity in primary rat hepatocytes. 
This suggests that in B13/H cells, unlike in the mouse, Erk is activated by PB. The 
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function of increased Erk may be as a negative regulator of PB-mediated activation 
of Car genes. This was indicated by Mek inhibition, which has been shown to 
potentiate PB induction of Cyp2b1/2 and Cyp3a1/2 mRNA expression in male 
Sprague-Dawley rat primary hepatocytes (F Joannard et al., 2000; Florence 
Joannard et al., 2006). Assessing Cyp gene expression in B13/H cells under these 
treatment conditions would confirm the negative feedback of Erk activity.
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Figure 3.6: Thirty minutes treatment with PB followed by 60 minutes with 5ng/mL Egf 
- Erk/Akt activity 
Figure 3.6 shows the effect of pre-treating PB or inhibitor for 30 minutes followed by 
BSA vehicle or Egf (5ng/mL) for 60 minutes on Erk (A) and Akt (B) activity. 
Representative blots shown (C). Data were representative of 3 independent cultures, 
showing mean + SEM and with y-axis as fold change to Egf alone. Erk and Akt 
activity were measured as a ratio of phospho-protein to total protein normalised to 
Gapdh from 3 separate immunoblots. Significance was tested by one way ANOVA 
with Dunnett’s comparison to control or Egf alone, and Student’s t test to compare 
control with Egf alone.  
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Summary – PB has the ability to potentiate Erk and Akt phosphorylation in the 
presence of Egf in rat B13/H cells. These data suggest Egf-Erk could be involved in 
PB-mediated gene expression, and that gene expression in B13/H cells in response 
to PB is likely to be similar to that of rat primary hepatocytes. The function of Akt is 
discussed below.  
 
3.3.2.2 Phenobarbital potentiates Hgf-mediated Akt phosphorylation in B13/H cells 
Regulation of PB-induced genes in the rat has been reported to be controlled by Egf 
but not Hgf (Kawamura et al., 1999). Therefore rat B13/H cells were treated with Hgf 
(20ng/mL) for 60 minutes, after pre-treatment with PB (5mM) for 30 minutes. This 
potentiated Hgf-induced Akt activity, but was not as obvious for Erk activation (Figure 
3.7 A and B). Interestingly, PB treatment (5mM) in the absence of Hgf (90 minutes 
total treatment time) resulted in increased Akt activity (although not significant) 
(Figure 3.7 B and C). This suggests that PB may influence Akt activation 
independently of growth factor treatments. A trend for increased Akt activation was 
also noted in Figure 3.5 B and Figure 3.6 B without growth factors, albeit at lower 
levels than seen in Figure 3.7 B. The Hgf receptor inhibitor, SU11274 (100nM), was 
included as a negative control (Berthou et al., 2004). Unfortunately, at 100nM 
SU11274 there was no effect on pathway activity (data not shown). These data 
suggest this inhibitor may not be effective in these cells, or require a higher dose.  
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Figure 3.7: Thirty minutes treatment with PB followed by 60 minutes with 20ng/mL 
Hgf - Erk/Akt activity 
Figure 3.7 shows the effect of pre-treating PB or inhibitor for 30 minutes followed by 
BSA vehicle or Hgf (20ng/mL) for 60 minutes on Erk (A) and Akt (B) activity. 
Representative blots shown (C). Data were representative of 3 independent cultures, 
showing mean + SEM and with y-axis as fold change to Hgf alone. Erk and Akt 
activity were measured as a ratio of phospho-protein to total protein normalised to 
Gapdh from 3 separate immunoblots. Significance was tested by one way ANOVA 
with Dunnett’s comparison to control or Hgf alone, and Student’s t test to compare 
control with Hgf alone. 
 
 
 
 
 
 
 
 
 
        3.  Cross-talk between growth factor signalling and phenobarbital signalling pathways 
 
116 
 
Summary – PB increased Hgf-mediated phosphorylation of Akt, and not Erk, 
suggesting Hgf-Erk signalling is not involved in regulating the PB response, and that 
PB-mediated potentiation of Erk activation is specific to Egf signalling. Furthermore, 
Akt activity was increased by PB (5mM) in the absence of growth factors, suggesting 
growth factor-independent activation. The function of Akt signalling is discussed 
below.  
 
3.3.2.3 The role of Akt activation in PB plus Egf/Hgf treatments 
Due to increased Akt phosphorylation demonstrated in Hgf/PB treatments some of 
these samples were examined for changes in the downstream Akt target, FoxO1. 
FoxO1 is a transcription factor that controls expression of gluconeogenic, anti-
proliferative and pro-apoptotic genes (Puigserver et al., 2003; X. Zhang, Tang, 
Hadden, & Rishi, 2011). Pre-treating with PB (5mM) for 30 minutes significantly 
increased Hgf-mediated (20ng/mL) Akt activation (Figure 3.7 B), as did the reverse 
experiment; pre-treating with Hgf (20ng/mL) for 30 minutes followed by PB (5mM) for 
60 minutes (Figure 3.8 A). In the same samples that showed increased Akt 
phosphorylation with Hgf plus PB compared to Hgf alone (Figure 3.8 A), FoxO1 
activity appeared to be increased with Hgf (20ng/mL) treatment, as well as in pre-
treated PB (5mM) samples, compared to control (Figure 3.8 B). However, the lack of 
a significant increase in FoxO1 activity in both treatment groups could reflect the 
time-dependent process of phosphorylation after Hgf/PB treatment and would 
require optimising as performed for Erk and Akt (Figure 3.4) to confirm pathway 
changes.  
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Figure 3.8: Thirty minutes treatment with 20ng/mL Hgf followed by 60 minutes with 
PB - FoxO1 activity 
Figure 3.8 shows the effect of pre-treating with 20ng/mL Hgf for 30 minutes followed 
by PB for 60 minutes on Akt activity (A) and FoxO1 activity (B). FoxO1 immunoblots 
shown (C). Data were representative of 4 independent cultures, showing mean + 
SEM and with y-axis as fold change to control. FoxO1 activity was measured as a 
ratio of phospho-protein to total protein normalised to Gapdh from 1 immunoblot. 
Significance was tested by one way ANOVA with Dunnett’s comparison to Hgf alone. 
FoxO1/p-FoxO1 were the top bands of the pairs (as indicated by the arrow head).  
 
B13/H cells were also treated with Hgf (20ng/mL) for 30 minutes followed by PB 
(5mM) for 48 hours to assess if under conditions where short term PB increased Akt 
phosphorylation, whether this influenced Akt-mediated cell survival or hypertrophy 
(Matsui, Nagoshi, & Rosenzweig, 2003). The data in Figure 3.9 demonstrates that 
p-FoxO1 
FoxO1 
Gapdh 
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PB (5mM) in the presence of Hgf (20ng/mL) induced subtle changes in cell count 
(Figure 3.9 A) and cellular hypertrophy (Figure 3.9 B) (as determined by the ratio of 
cell count to total protein (Das et al., 2014)); the magnitude of these responses 
suggest the effects of Akt on cellular hypertrophy and cell count were not dramatic.  
A      B    
C e ll c o u n t fo ld  c h a n g e  a f te r  3 0  m in u te s
2 0 n g /m L  H g f  fo llo w e d  b y  4 8  h o u rs  5 m M  P B
C
o
n
tr
o
l
5
m
M
 P
B
2
0
n
g
/m
L
 H
g
f
5
m
M
 P
B
0 .0
0 .5
1 .0
1 .5
*
C
e
ll
 c
o
u
n
t 
(f
o
ld
 c
h
a
n
g
e
to
 m
a
tc
h
e
d
 c
o
n
tr
o
l)
+ 2 0 n g /m L  H g f
C e ll h y p e r tro p h y  a f te r  3 0  m in u te s
2 0 n g /m L  H g f  fo llo w e d  b y  4 8  h o u rs  5 m M  P B
C
o
n
tr
o
l
5
m
M
 P
B
2
0
n
g
/m
L
 H
g
f
5
m
M
 P
B
0 .0 0
0 .0 5
0 .1 0
0 .1 5
R
a
ti
o
 o
f 
c
e
ll
 c
o
u
n
t 
(x
1
0
6
)
to
 t
o
ta
l 
p
r
o
te
in
 (
u
g
)
+ 2 0 n g /m L  H g f
 
Figure 3.9: Thirty minutes 20ng/mL Hgf followed by 48 hours PB 
Figure 3.9 shows B13/H cells treated with 20ng/mL Hgf for 30 minutes followed by 
PB for 48 hours. Cell counts between control and Hgf samples treated with PB 
(5mM) are shown (A) and the effect of cellular hypertrophy (B). Hypertrophy was 
measured as the ratio of cell count to total protein. Results were mean + SEM. 
Significance was determined by Student’s t test to compare control to PB, and Hgf to 
Hgf + PB. *p<0.05. 
 
Summary – Although PB appeared to increase Hgf-mediated Akt phosphorylation 
the functional output of this is uncertain at the moment, as cell counts, hypertrophy 
and activity of a downstream Akt target, FoxO1, are unchanged with PB plus Hgf 
compared to Hgf alone.  
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To understand the changes seen with Erk and Akt phosphorylation further, rat liver 
tissues were also assessed for changes in pathway activation following PB 
treatment. 
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3.3.3 Aim 3: Assess the activation of these pathways in the rat in vivo. 
3.3.3.1 Growth factor pathways are unchanged in the rat in vivo 
Joannard et al., (Florence Joannard et al., 2006) showed that 15 minutes 5mM PB 
treatment increased activation of Erk, Jnk and p38 in male Sprague-Dawley rat 
primary hepatocytes. Erk was reported to act as a negative regulator of Cyp2b 
induction, while p38 was a positive regulator. Furthermore, 3 days PB treatment in 
the rat in vivo has been shown to induce a transient state of hyperplasia (Waterman 
et al., 2010) and this has previously been associated with increased plasma Hgf 
(Lindroos et al., 1992). Akt activation is known to effect cell proliferation (Manning & 
Cantley, 2007) and as B13/H cells demonstrated changes in Akt phosphorylation 
with PB plus growth factors (described above), I interrogated these pathways in vivo.  
 
The first 14 days of PB exposure were analysed (days 1, 3, 7 and 14) from an acute 
in vivo PB treatment study (previously described by Waterman et al., (Waterman et 
al., 2010)) as this covers the phase of PB-induced adaptive hepatomegaly 
concluding with mitoinhibition. Ninety days treatment were also included to 
determine if prolonged PB exposure effected these pathways.  
 
Erk pathway activity Comparing 1000ppm PB to control, Erk activity (Figure 3.10 A) 
and its downstream target, Elk (Figure 3.10 B), were not significantly changed with 
PB treatment. Although showing non-significant decreased activity at 7 (Figure 3.10 
A) and 1 days (Figure 3.10 B) with PB treatment (1000ppm), respectively, the lack of 
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consistent changes over time suggest long-term Erk activity was not affected by PB 
treatment in vivo. 
A                                                                                         B 
 
C 
 
 
 
 
 
 
 
Figure 3.10: Erk and Elk activity in PB treated rat liver 
Figure 3.10 shows Erk activity in the livers of 1, 3, 7, 14 and 90 days 1000ppm PB 
treated rats using the MSD platform (A). Pathway activity was measured as change 
in phospho-protein normalised to total protein loaded. Elk activity was also assessed 
in the livers of 1, 7 and 14 days 1000ppm PB treated rats (B) via immunoblots (C). 
Elk activity was measured as a ratio of phospho-protein to total protein normalised to 
Gapdh from 1 immunoblot. Data were representative of 3 samples, showing mean + 
SD and with y-axis as fold change to time matched vehicle control. Significance was 
tested by Mann-Whitney between time matched control and treatment.  
 
Jnk and p38 activity Erk is part of a signalling hub known as the mitogen-activated 
protein kinase (MAPK) pathway. The MAPK pathway consists of 2 other signalling 
kinases, p38 MAPK (p38) and Jun N-terminal kinase (Jnk). These 2 other kinases 
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are also activated through growth factor pathways (as well as through environmental 
stress and inflammatory signals) and are involved in the regulation of cell survival 
(Wagner & Nebreda, 2009) and have been implicated in the PB signalling response 
(Florence Joannard et al., 2006). Figure 3.11 shows that at the time points tested 
and dose of PB used (1000ppm), there were no significant changes in MAPK activity 
compared to control.  
A       B 
 
Figure 3.11: MAPK pathway activity in PB treated rat liver 
Figure 3.11 shows MAPK pathway activity in the livers of 1, 3, 7, 14 and 90 days 
1000ppm PB treated rats using the MSD platform. Jnk (A) and p38 (B) pathways 
were analysed. Data were representative of 3 independent samples, showing mean 
+ SD and with y-axis as fold change to time matched control. Pathway activity was 
measured as change in phospho-protein normalised to total protein loaded. 
Significance was tested by Mann-Whitney between time matched control and 
treatment.  
 
Akt pathway activity The activity of Akt and its downstream target, FoxO1, were 
also assessed, due to increased Akt activation with PB treatment in vitro. I found that 
both Akt and FoxO1 showed a non-significant increased activity at 3 days PB 
(1000ppm) compared to control, while there were no changes between treatment 
and control at 14 days with either Akt or FoxO1 (Figure 3.12). The suggestive 
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increase in pathway activity could reflect PB-induced hyperplasia at this time 
(Waterman et al., 2010).  
A      B 
 
C 
 
 
 
 
 
 
D 
 
 
 
 
 
 
Figure 3.12: Akt and FoxO1 activity in PB treated rat liver 
Figure 3.12 shows Akt (A) and FoxO1 (B) activity in the livers of 3 and 14 days 
1000ppm PB treated rats. Akt and FoxO1 immunoblots shown (C/D). Data were 
representative of 3 samples, showing mean + SD and with y-axis as fold change to 
time matched vehicle control. Akt and FoxO1 activity were measured as a ratio of 
phospho-protein to total protein normalised to β-tubulin from 1 immunoblot. 
Significance was tested by Mann-Whitney between time matched control and 
treatment.  
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Discussion – These data suggest that changes in MAPK pathway activity with PB 
treatment reported in the literature are likely to be early transient effects, as they are 
not maintained beyond 24 hours PB in vivo. It is known that responses to MAPK 
activation are dependent on duration and strength of kinase signalling. For example, 
as demonstrated with Jnk, whereby transient activation stimulates cell survival but 
prolonged activation induces apoptosis (Wagner & Nebreda, 2009). Furthermore, 
due to the trend for increased Akt activity in vivo, these data suggest that the 
increase in Akt activity with PB in vitro may reflect cell signalling changes indicative 
of PB-mediated transient hyperplasia. 
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3.4 Conclusions 
In mouse primary hepatocytes, PB-mediated activation of Car has been reported to 
be via inhibition of the Egfr, allowing subsequent translocation of Car to the nucleus 
(Mutoh et al., 2013). Inactivation of the Egfr downstream target, Erk, has also been 
implicated in the nuclear translocation of Car (Koike et al., 2007; Osabe & Negishi, 
2011). In the rat, Egf has been shown to suppress PB-mediated induction of Car-
regulated genes, while Hgf has no effect (Kawamura et al., 1999).  
 
PB + Egf: Erk Through treatments with Egf plus PB it was shown that compared to 
Egf alone, PB plus Egf potentiated Erk activity (Figure 3.6). It is unlikely that the dose 
of Egf used here was a saturating dose as Mutoh et al., (Mutoh et al., 2013) used a 
much higher dose of Egf (100µg/mL and 5ng/mL respectively). This suggests that 
PB does not inhibit Erk activation as seen in the mouse. Further, Egf is reported to 
inhibit PB-mediated gene expression in the rat (Kawamura et al., 1999). Therefore, 
Erk activation could be part of a negative feedback loop specific to the rat, which this 
data suggests may be reproducible between rat primary hepatocytes (Florence 
Joannard et al., 2006) and the B13/H cell model. This indicates that in the rat, Car is 
likely activated through a disparate mechanism to the mouse (Figure 3.13). 
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Figure 3.13: Car activation in the mouse and rat 
Figure 3.13 shows the proposed model of PB-mediated Car activation comparing the 
mouse and rat. 
 
PB + Egf/Hgf: Akt (FoxO1) Interestingly, PB potentiated Akt activity in combination 
with either Egf or Hgf compared to growth factor alone (Figure 3.6 and Figure 3.7). 
This could be expected given that activation of Car inhibits FoxO1 mediated gene 
transcription (Kodama et al., 2004), and Akt activation results in FoxO1 inactivation 
via phosphorylation and exclusion from the nucleus (X. Zhang et al., 2011). FoxO1 
activity, as measured by changes in phosphorylated protein, was potentially elevated 
in vivo but not significantly (Figure 3.12 B), as was Akt activity (Figure 3.12 A). I was 
not able to demonstrate this for FoxO1 in vitro (Figure 3.8 B). To determine if PB-
mediated activation of Akt does increase FoxO1 phosphorylation in this context, it 
would be necessary to complete a time-course of FoxO1 activity to ascertain the 
optimal time required to assess changes in FoxO1 phosphorylation.  
 
PB + Egf/Hgf: Akt (hyperplasia) Akt activity is also associated with proliferation 
(Manning & Cantley, 2007), and the trend for increased activity seen in vivo (Figure 
3.12 A) is suggestive of PB-induced hyperplasia. I showed increased Akt activity in 
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vitro in the presence of either Egf or Hgf, and even trends for increased Akt activity 
without growth factor treatment (Figure 3.5 B, Figure 3.6 B and Figure 3.7 B). This 
suggests that in vitro, PB may influence the Akt pathway independently of growth 
factor treatment, which could contribute to the molecular mechanisms underlying PB-
induced hyperplasia (Figure 3.14). 
 
Figure 3.14: The effect of PB on Erk and Akt activity in the rat 
Figure 3.14 shows the proposed model of PB-mediated growth factor-dependent 
effect on Erk activity, and growth factor-independent effect on Akt activity. 
 
Akt activation is also known to induce cell survival and hypertrophy (Matsui et al., 
2003), both of which showed minimal changes with PB plus Hgf compared to growth 
factor alone suggesting they are not greatly influenced by Akt activation in this 
context. 
  
Chapter 3 Conclusions – Erk is reported to be a negative regulator of PB-induced 
genes in the mouse and rat, and that Erk is inhibited by PB treatment in the mouse. 
However, Erk is activated by PB in the rat suggesting a negative feedback loop to 
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modulate the PB response. This appears to be common between rat primary 
hepatocytes and the B13/H cell system. Furthermore, PB-mediated increased Erk 
activity was specific to Egf signalling and not seen with Hgf. The function of 
increased Akt activity in this context requires further research, but as indicated from 
in vivo data, could be contributing to PB-induced transient hyperplasia.  
 
I conclude that although Car is found in the nucleus of untreated B13/H cells, Car is 
still PB-inducible and this work demonstrates that the B13/H cells are similar to rat 
primary hepatocytes in response to PB and its effect on growth factor signalling, 
which is different to that of the mouse. 
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4. Regulation of phenobarbital-induced miRNAs 
4.1 Introduction 
In this chapter I explore the molecular mechanisms of PB-mediated miRNA 
induction, with a focus on the miRNA cluster, miR-182/96.  
 
4.1.1 Regulation of miR-182/96 
Koufaris et al., (Koufaris et al., 2012, 2013) have reported that 2 clusters of miRNAs, 
miR-182/96 and miR-200a/b/429, are time- and dose-dependently induced by PB 
treatment in the rat. This has subsequently also been demonstrated in vitro (chapter 
2), yet the mechanisms underlying this PB-mediated response are unknown. With a 
focus on pathways that are related to the PB phenotype, I discuss potential 
regulators of the miR-182/96 cluster below, in alphabetical order. I also consider the 
role of Car in regulation of both clusters of miRNAs to explore function. 
 
Car – Car is activated by PB (Honkakoski et al., 1998; Sueyoshi et al., 1999), but 
has not been reported as being a direct regulator of miR-182/96 or miR-200a/b/429. 
However, it has been suggested that these miRNAs are involved in maintaining 
homeostasis during PB exposure, and as Car is required for PB-induced tumours, it 
might be expected that these miRNAs are regulated independently of Car. It has 
been reported that PB can regulate genes independently of Car (Ueda et al., 2002), 
therefore understanding the role of Car activation on these miRNAs would prove 
important in exploring their homeostatic function and in identifying their upstream 
regulator.  
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Hnf-4α –PB treatment induces nuclear translocation of Hnf-4α (Bell & 
Michalopoulos, 2006), yet nuclear Car inhibits Hnf-4α-mediated gene transcription by 
competing for DR1 binding sites in gene promoter regions as well as for nuclear co-
factors, glucocorticoid receptor interacting protein- (GRIP-)1 and peroxisome 
proliferator-activated receptor γ coactivator- (PGC-)1α (Miao et al., 2006). 
Furthermore, an acute PB treatment (500ppm) study in male Fisher (F344) rats 
predicted that Hnf-4α is induced after 2 weeks PB treatment; using the pathway 
prediction program, Ingenuity® Pathway Analysis (Kakehashi et al., 2013), which is 
in agreement with the time-dependent induction of the miRNAs. Additionally, 
Koufaris et al., (Koufaris, 2011) identified Hnf-4α binding sites up-stream of both 
miR-200b and miR-96, suggesting potential regulation.  
 
Methylation – PB has been shown to induce global hypermethylation after 14 days 
PB treatment (1000ppm) in male Fisher rats (Koufaris et al., 2013). There is also 
substantial evidence of altered methylation in PB treated mice; around the promoter 
proximal region of strongly induced genes there is an initial gain in the methyl-
intermediate, 5-hydroxymethylcytosine (5hmc), indicating demethylation, and 
eventual loss of this marker and 5-methylcytosine (5mc) (Thomson, Moggs, et al., 
2013; Thomson et al., 2012; Thomson, Hunter, et al., 2013). MiR-182 was found to 
have decreased expression in human renal cell carcinoma tissue compared to non-
tumour renal tissue, and this was associated with high methylation levels up-stream 
of the miRNA (Xin Xu et al., 2014). Furthermore, treatment with a methyltransferase 
inhibitor 5-azacytidine, reduced methylation levels and increased expression of miR-
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182 in renal cell carcinoma cell lines, suggesting a role of epigenetic regulation in 
miR-182 expression (Xin Xu et al., 2014).  
 
P53 – The effect of PB on p53 inducibility has been explored in Female Sprague-
Dawley rats treated with an initiating dose of DEN (single intraperitoneal injection at 
0.3mmol/kg body weight) followed by a subsequent regime of PB (500ppm) for up to 
14 months, or DEN administration (weekly intraperitoneal injection at 0.3mmol/kg 
body weight) for up to 3 months (Finnberg, Stenius, & Högberg, 2000). Twenty-four 
hours prior to sacrifice, the animals were again treated with DEN to assess the p53 
induction response. The authors showed that in enzyme altered foci (characterised 
by glutathione-S-transferase pi positive staining) PB treated rats had increased p53 
levels compared to DEN treated rats.  
 
Primary hepatocytes from B6C3F1 mice treated with PB (2mM) for 23 hours have 
been shown to exhibit delayed p53 induction in response to the DNA damaging 
compound, bleomycin (16µg/mL), compared to non-PB treated cells (Gonzales et al., 
1998).  
 
Comparing in vivo rat with in vitro mouse responses is difficult, but this could suggest 
that PB may effect p53 induction discordantly between rats and mice; whereby rats 
remain sensitive to p53 induction, while mice develop retarded p53 induction in 
response to PB. MiR-182 has been shown to be dependent on p53 expression in 
human uveal melanoma cell lines, M23 and SP6.5 (Yan et al., 2012), and PB-
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induced miR-182 expression is specific to the rat (Koufaris et al., 2012, 2013; 
Lempiäinen et al., 2013) thereby implicating p53 as a potential regulator of miR-182 
in the rat. 
  
ROS – Oxidative stress has been suggested as a mediator of PB-induced non-
genotoxic carcinogenesis in rats due to increased expression of genes implicated in 
increased oxidative stress, such as Cyp450s and glutathione-S-transferases (GSTs) 
(Dail, Shack, Chambers, & Burgess, 2008; Elrick et al., 2005; Klepeisz et al., 2013), 
and an increase in the oxidative marker 8-hydroxy-2'-deoxyguanosine (8-OHdG) 
(Imaoka et al., 2004). However, a recent study in male C57BL/6J mice reported 
minimal effects of PB (0.05% w/v) on heme oxygenase 1 induction, a gene involved 
in oxidative stress pathway (Henderson, Cameron, Chatham, & Stanley, 2015), 
despite this dose of PB previously being reported as inducing tumours in this strain 
of mice, albeit with an initiating dose of the genotoxin DEN (Braeuning et al., 2014). 
MiR-182 and miR-200a have been reported to be induced in the human uterine 
leiomyoma cell line, DD-HLM, when treated with hydrogen peroxide (100µM) for a 
total of 48 hours after an initial treatment regime of once an hour for 5 hours (Xiaofei 
Xu et al., 2014). Although rat Fao cells treated with hydrogen peroxide (500µM) for 
24 hours show no significant change in miR-200b compared to control (Koufaris et 
al., 2012). Taken together this suggests that increased ROS may be a contributing 
factor to miRNA induction. 
 
Tgf-β – In rats, putative preneoplastic cells are reported to express reduced levels of 
the epithelial cell growth inhibitor, transforming growth factor- (Tgf-)β1, in response 
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to 2 months DEN (50ppm) and 3 months PB (0.1% w/v) than do surrounding normal 
periportal hepatocytes, which show a marked increase in Tgf-β1 levels (Jirtle & 
Meyer, 1991). Male Fisher rats treated with DEN (50ppm) for 1 month, then 4 
months PB (0.1% w/v) also show reduced Tgf-β receptor levels in tumours compared 
to surrounding cells (Mansbach et al., 1996). This suggests that normal hepatocytes 
have increased activity of Tgf-β in response to PB, which maintains mitoinhibition 
compared with preneoplastic cells. Tgf-β (0.5 ng/ml) has also been shown to induce 
miR-182 after 12 hours treatment in human gall bladder cancer cells, GBC-SD (Qiu 
et al., 2014), suggesting a link between miRNA expression and Tgf-β.  
 
These above components of the PB phenotype will be assessed as regulators of the 
miR-182/96 cluster (Figure 4.1) to determine the molecular mechanism underlying 
miRNA perturbation, in order to further understand the function of these miRNAs. 
 
 
 
 
 
 
Figure 4.1: Potential miR-182/96 regulators 
Figure 4.1 is an arbitrary depiction of potential positive regulators of miR-182/96 
involved in the PB response, identified from the literature and discussed in text.  Β-
Catenin is discussed later.
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4.1.2 Hypothesis 
The PB-induced miRNAs, miR-182/96, are regulated independently of Car in vivo. 
 
4.1.3 Aims 
1. Explore miRNA expression in PB treated wild type (WT) and Car knockout 
(KO) rats to determine underlying molecular stimulus for perturbed 
expression. 
2. Interrogate the expression of potential miRNA regulators in PB treated rat liver 
tissue. 
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4.2 Methods 
4.2.1 Tissue samples 
Ethics approval and in vivo experimentation were performed by CXR Biosciences 
and Syngenta.  
 
Car KO study Liver tissue samples from male Sprague-Dawley WT Car and KO rats 
were provided by CXR Biosciences (Chamberlain, Haines, & Elcombe, 2014). Rats 
were treated with either a control or PB (500ppm) diet for 7 days, with subsequent 
liver collections used herein for RNA analysis.  
 
Methylation analysis Liver tissue samples from male Fisher rats were provided by 
Syngenta. Rats were treated with control or PB (1000ppm) diet for 7, 14 and 28 
days, with subsequent liver collections, used herein for methylation analysis via 
pyrosequencing.   
 
Transcriptomic analysis Liver samples used are described in chapter 3.2.1. 
Twenty-eight day PB (50ppm and 1000ppm) treated rat samples detailed in 
“Methylation analysis” (4.2.1) were also used for gene expression analysis.  
 
4.2.2 Cell culture and chemical treatments  
Cell culture was performed as detailed in chapter 2.2.1. 
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To explore the functional response of the B13/H cells to phenobarbital, B13/H cells 
were treated in combination with phenobarbital and with the Car inhibitor 5α-androst-
16-en-3α-ol (androstenol) (solvated in 95% ethanol) (Sigma-Aldrich, Dorset, UK) or 
okadaic acid sodium salt (OAA) (solvated in DMSO) (Millipore, MA, USA). B13 cells 
were seeded at 2x105 cells per well in 6-well plates and differentiated as in chapter 
2.2.1. Samples were harvested for RNA and subsequent qRT-PCR. 
 
4.2.3 RNA extraction 
MirVana PARIS RNA extraction kits were used as detailed in chapter 2.2.5, with 
modification to sample lysis for tissue samples as described below. Samples were 
stored at -80oC, and moved onto dry ice for RNA extraction. Homogenisation was 
performed as quickly as possible to avoid RNA degradation. Approximately 50-
100mg of tissue was disrupted in ice cold MirVana kit cell disruption buffer (625µL) 
using a tissue homogeniser. Samples were processed one at a time, incubating on 
ice with denaturing solution, which contains RNase inactivating guanidinium 
thiocyanate and ensures integrity of the sample. 
 
4.2.4 qRT-PCR 
As detailed in chapter 2.2.6. 
 
4.2.5 DNA extraction 
The Qiagen QIAamp DNA mini kit 50 (Qiagen, Manchester, UK) was used to extract 
DNA from <25mg flash frozen rat liver tissue samples. Extractions were performed 
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following manufacturers protocols. Briefly, samples were homogenised in PBS 
(80µL) using a T25 basic labortechnik homogeniser. Homogenate was lysed in kit 
ATL buffer containing proteinase K by occasional vortexing and incubated for 3 
hours at 56oC. Lysis was completed with the addition of kit Buffer AL and incubation 
for 10 minutes at 70oC. As with RNA extractions, 100% ethanol was added to the 
samples to aid binding to the silica mini columns, which were subjected to a series of 
kit buffer washes to remove salts and proteins. Samples were eluted in kit Buffer AE. 
DNA quality was determined as with RNA (chapter 2.2.5).  
 
4.2.6 Bisulphite conversion  
DNA methylation can be quantified by the conversion of unmethylated cytosines to 
uracil, which are amplified as a thymine after PCR. Methylated cytosines (within a 
cytosine-guanine pair [CpG]) are protected and remain unchanged following 
bisulphite conversion (Figure 4.2) (Frommer et al., 
1992). The changes in these nucleotides can be 
compared across samples after PCR amplification by 
pyro-sequencing. 
 
Figure 4.2: Pyro-sequencing methodology 
Figure 4.2 depicts the steps involved in determining site-
specific methylation status using pyro-sequencing. 
Adapted from Frommer et al., (Frommer et al., 1992) 
 
The EZ DNA methylation kit (Zymo research, CA, USA) was used for bisulphite 
conversion. DNA (500ng) in nuclease free water (50µL) containing M-Dilution buffer 
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(diluted to 1:10) was heated for 15 minutes at 37oC followed by the addition of 2x 
volume of Ct conversion reagent and incubated for 16 hours at 50oC in the dark. The 
conversion reagent chemically deaminates unmethylated cytosines to uracil 
(Frommer et al., 1992). Samples were chilled on ice for 10 minutes and bound to a 
spin column with kit M-Binding buffer. Column-bound samples were washed with a 
series of kit buffers to remove precipitates and finally eluted with kit M-Elution buffer. 
Quality control standards were also included during the bisulphite conversion for 
pyro-sequencing to act as references to 100% methylated rat gDNA and 0% 
methylated rat gDNA (Millipore, MA, USA) as well as standard rat gDNA (Affymetrix, 
CA, USA) (Figure 4.3).  
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Figure 4.3: Methylation assessment optimisation 
Figure 4.3 shows the mean percentage level of methylation at the 5 CpG sites 
measured in the three assay standards used across 2 technical replicates. 
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4.2.7 Bisulphite PCR 
FastStart TaqDNA Polymerase, dNTPack (Roche, Hertfordshire, UK) was used for 
PCR amplification. PCR master mix was made per sample, which consisted of PCR 
buffer (diluted 1:10), dNTPs (50µM), forward primer (400nM), biotinylated reverse 
primer (400nM) (to allow capture of single stranded PCR product to streptavidin-
coated Sepharose beads (Figure 4.2) (Royo, Hidalgo, & Ruiz, 2007)), Taq DNA 
polymerase (1 unit) and bisulphite DNA (10ng) made up with nuclease free water 
(final volume of 25µL). PCR amplification was run on a PTC-200 Peltier Thermal 
Cycler: 95oC for 6 minutes, then 40 cycles of 95oC, 59oC and 72oC for 30 seconds 
each, followed by 72oC for 5 minutes and finally 4oC. PCR primers used were: 
forward 5’-GGGTTTTTTAGTTTGGTGGGAATAT-3’, reverse 5’-
CTCTTCTTTCTTCCCCAACATC-3’ (5’ biotinylated). PCR products were run on 2% 
agarose gel as described in chapter 2.2.7. Temperature gradient PCR (53-60oC) 
showed that optimal conditions were 59oC for primer annealing (data not shown). 
Template controls were included to check for DNA contamination in the PCR mix 
prior to pyro-sequencing.  
 
4.2.8 Pyro-sequencing 
A Pyromark Q24 (Qiagen, Manchester, UK) was used for the pyro-sequencing. 
Component binding mixture was made for each PCR product, consisting of binding 
buffer (diluted to 1:2), sepharose beads (diluted to 1:80) and PCR product (diluted to 
1:8) made to a final volume in nuclease free water (up to 80µL). The component 
buffer with samples were subjected to a series of washes with ethanol, denaturing 
buffer and wash buffer by the Pyromark vacuum pump before being transferred to a 
        4.  Regulation of phenobarbital-induced miRNAs 
 
140 
 
sequencing plate containing aliquots of the sequencing primer (300nM) in annealing 
buffer (25µL). The sequencing plate was then heated for 2 minutes at 80oC, followed 
by 5 minutes at room temperature to allow denaturation of sample and annealing of 
primers. The sequencing plate was then run on the Pyromark. 
  
The captured template sequence was read by elongation from the sequencing 
primer with sequential incorporation of single nucleotides. Incorporation of a 
nucleotide into the sequence releases a phosphate group, which is converted to ATP 
by ATP-sulphurylase and reacts with luciferase to produce a light signal read by the 
Pyromark. The sequencing primer used was 5’- ATTTGGTTTTGAATTGTGT-3’. 
Negative controls were included to check for primer dimers, which cause misreading 
by the pyro-sequencer. 
 
4.2.9 Statistics 
In vitro analysis was performed as described in chapter 1.2.8. In vivo data is shown 
as mean + standard deviation (SD) with sample size shown in figure legends. 
Kruskal-Wallis and Dunn’s multiple comparison were used to compare treatment with 
control, as well as Spearman’s correlation. Graphs and analysis were 
produced/performed using Graph Pad 6 (La jolla, California). Statistical significance 
was defined as p<0.05 (*), p<0.01 (**), p<0.001 (***), p<0.001 (****). 
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4.3 Results and Discussion 
4.3.1 Aim 1: Explore miRNA expression in PB treated WT and Car KO rats to 
determine underlying molecular stimulus for perturbed expression.  
4.3.1.1 MiR-182 is time-dependently expressed in PB treated rats  
Phenobarbital treatment in the rat has been shown to significantly induce two 
clusters of miRNAs, the miR-200a/b/429 cluster and miR-182/96 (Koufaris et al., 
2012, 2013) (Figure 4.4). This work has taken a focus on miR-182/96 to explore their 
regulation and function as a result of PB treatment, as little is known about their role 
in the context of PB exposure in the rat. MiR-183 is the third member of the miR-
182/96 cluster but is not discussed herein as miR-183 expression levels were too 
low to be reliably quantified (Koufaris, 2011), although correlation analysis of 
microarray data obtained from Koufaris, (Koufaris, 2011) demonstrated miR-182 and 
miR-96 exhibit significant positive expression, suggesting expression of the miRNA 
cluster (Figure 4.4 B).  
 
I discuss both clusters in the context of Car activation. Mounting evidence suggests 
that miR-200a/b/429 are involved in maintaining liver homeostasis through inhibiting 
epithelial to mesenchymal transition (EMT); a feature of cancer progression. In PB 
treated rats these miRNAs are reported to inhibit the expression of zinc-finger E-box 
binding homeobox (Zeb)1/2 (Koufaris et al., 2012, 2013), which are 2 transcription 
factors involved in the progression of EMT via increasing expression of 
mesenchymal markers and decreasing expression of epithelial markers, such as E-
cadherin (Aigner et al., 2007).  
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Figure 4.4: MiR-182 expression in subchronic PB treatment study 
Figure 4.4 (A) details miR-182 expression by qPCR after PB treatment for up to 90 
days. Data were mean + SD of 3 samples, comparing treatment to control with 
Kruskal-Wallis and Dunn’s multiple comparison. Change over time was measured by 
a one way ANOVA linear trend analysis of 1000ppm PB. Data were published in 
(Koufaris et al., 2013) (B) Spearman correlation of miR-182/96 fold change in 90 
days 1000ppm PB and control treated rats. Adapted from miRNA microarray data 
(Koufaris, 2011). 
 
Summary – MiR-182 expression was time-dependently increased with PB treatment 
(1000ppm) in the rat. 
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4.3.1.2 Car as a regulator of miR-182/96 expression in PB treated Car wild type and 
knockout rats  
Car wild type and knockout rat samples were obtained from CXR biosciences. Car 
wild type samples showed increased Cyp2b1/2 mRNA expression and activity with 
PB (500ppm) treatment compared to control, which was abolished in the PB 
treatment group of Car knockout samples, indicating effective loss of Car 
(Chamberlain et al., 2014) (Figure 4.5 A and B). 
A       B 
Figure 4.5: Cyp mRNA expression and Cyp2b activity in wild type and Car KO rats 
Figure 4.5 details the mRNA expression of PB responsive Cyp450 genes after 7 
days treatment in Car wild type (WT) and knockout (KO) rats (A), and Cyp2b activity, 
measured by PROD (B). Data were representative of 5 animals, with significance 
determined by Student’s t test. Data presented were from Chamberlain et al., 
(Chamberlain et al., 2014). 
 
MiR-182 and miR-96 are both time- and dose-dependently induced by PB in the rat 
(Koufaris et al., 2012, 2013) and are believed to play a role in the transition from 
hyperplasia to mitoinhibition (Koufaris et al., 2013). Interrogating the expression of 
these miRNAs in Car wild type and knockout samples will aid our understanding of 
their underlying molecular regulation. Figure 4.6 shows the expression of miR-182 
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was not significantly changed from control in Car wild type (A) or Car knockout (B) 
rats. Interestingly miR-96 expression was similar between PB (500ppm) and control 
in the wild type animals (C), whereas miR-96 was significantly increased with PB 
(500ppm) compared to control in the Car knock out individuals (D), suggesting miR-
96 was not regulated by Car. This implies that there could be a disparity in the 
regulation of the expression of miR-182 and miR-96, whereby miR-96 expression 
was not Car-mediated, but miR-182 may be. However, it is important to note that this 
study uses a lower dose of PB compared to previous work that demonstrates 
significant increases in these miRNAs (1000ppm PB) (Koufaris, 2011).  
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Figure 4.6: MiR-182 and miR-96 expression in wild type and Car KO rats 
Figure 4.6 miR-182 (A/B) and miR-96 (C/D) expression was measured from the 
livers of wild type and Car knockout rats treated with 500ppm PB or control diet for 7 
days. Data were mean + SD of 4-5 samples. Mann-Whitney was used to assess 
statistical significance of treatment to control in genotype matched samples. *p<0.05. 
 
 
4.3.1.3 Car as a regulator of miR-429/200b expression in PB treated Car wild type 
and knockout rats  
MiR-429 and miR-200b demonstrated similar expression changes as seen with miR-
182 and miR-96 when treated with 1000ppm PB in the rat (Koufaris et al., 2012, 
2013). Figure 4.7 shows that miR-429 was unchanged from control in wild type (A) 
and in the Car knockout model (B), as was miR-200b (C/D). Due to the lack of 
change in expression between control and PB treated samples it was not possible to 
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draw any conclusions from this dataset. The lack of a response was most likely due 
to the lower dose used in this study (500ppm PB) compared to previous data 
(1000ppm) (Koufaris, 2011).  
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Figure 4.7: MiR-429 and miR-200b expression in wild type and Car KO rats  
Figure 4.7 miR-429 (A/B) and miR-200b (C/D) expression was measured from the 
livers of wild type and Car knockout rats treated with 500ppm PB or control diet for 7 
days. Data were mean + SD of 4-5 samples. Mann-Whitney was used to assess 
statistical significance of treatment to control in genotype matched samples.  
 
Summary – The above data suggests that miR-96 expression was not controlled by 
PB-mediated activation of Car, suggesting that miR-96 was induced by PB through 
other mechanisms. Neither miR-182, nor miR-200b/429 were affected by PB 
treatment in either genotype within this timeframe (7 days), suggesting the low dose 
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used was not sufficient to stimulate their increased expression and the duration of 
the treatment may not have been appropriate. I next sought to confirm if miR-96 (and 
miR-182) also demonstrated Car independent expression in vitro.   
 
4.3.1.4 Inhibiting Car in the B13/H model 
Co-treating B13/H cells with 2mM PB and 5µM or 10µM androstenol (5α-androstan-
16-en-3α-ol) (Forman et al., 1998) for 72 hours significantly inhibited PB activation of 
Car, as determined by Cyp2b activity (Figure 4.8 A). Androstenol is a Car inverse 
agonist, an inhibitor of Car’s constitutive activity, through binding Car and stimulating 
release of co-activator proteins (Forman et al., 1998) via repositioning of Car’s co-
activation domain, AF2 (Suino et al., 2004), and aiding co-repressor, Smrt, 
recruitment (Dussault et al., 2002). To confirm androstenol-mediated suppression of 
Car, I repeated the experimental conditions and assessed Cyp2b1 mRNA 
expression (Figure 4.8 B). PB-induced (2mM) Cyp2b1 mRNA expression was not 
significantly inhibited by androstenol (5µM), suggesting that androstenol was unable 
to completely inhibit PB activation of Car. This has been noted before in HepG2 
cells, whereby 3α-androstenol did not alter nuclear localisation of GFP-Car in HepG2 
cells (Kawamoto et al., 1999), although human Car is not thought to be repressed by 
androstanes (H. Wang & Negishi, 2003). It has been suggested that PB and PB-like 
inducers are able to eliminate androstane-mediated inverse agonism of Car 
(Waxman, 1999), which would appear to be supported by the data shown here. 
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Figure 4.8: Cyp activity in B13/H cells treated with PB and androstenol 
Figure 4.8 B13/H cells were treated with 2mM PB for 72 hours in the presence of the 
Car inverse agonist, androstenol (A). In a separate experiment Cyp2b1 mRNA 
expression was analysed in cells co-treated with 2mM PB and 5µM androstenol for 6 
hours (B). Data were mean + SEM of 4 independent cultures. One way ANOVA with 
Dunnett’s multiple comparisons was used to compare PB + androstenol samples to 
PB alone (A), or Student’s t test to compare control with PB (A/B), or PB + 
androstenol to PB alone (B). 
 
As androstenol did not successfully inhibit PB-mediated activation of Car, I therefore 
attempted to inhibit Car in the B13/H cells using okadaic acid (OAA). OAA is a 
protein phosphatase (PP) 1 and 2A inhibitor, which inhibits PB-mediated de-
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phosphorylation, and subsequent activation, of Car (Kawamoto et al., 1999; Sidhu & 
Omiecinski, 1997). Sidhu and Omiecinski (Sidhu & Omiecinski, 1997) showed that 
pre-treating primary rat hepatocytes with >10nM OAA for 60 minutes could ablate 
PB-mediated (100µM) induction of Cyp2b1/2 mRNA.  Therefore B13/H cells were 
pre-treated with OAA (20nM and 200nM) for 60 minutes prior to PB (2mM) for 6 
hours. Unexpectedly, in this experiment Cyp2b1/2 mRNA were not detected by 
qPCR (data not shown), suggesting that the inhibitor vehicle, DMSO, may be 
contributing to this result; the mechanisms behind this are unknown. 
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4.3.2 Aim 2: Interrogate the activity of potential miRNA regulators using PB 
treated rat liver tissue. 
4.3.2.1 Hnf-4α as a regulator of miR-182/96 expression in PB treated rats  
MiR-96 and miR-200b have been shown to possess Hnf-4α binding sites in their 
promoter region (Koufaris, 2011). Under normal conditions, PB induces the nuclear 
translocation of Car where it binds nuclear cofactors to aid binding to gene regulatory 
elements and induce transcription (Honkakoski et al., 1998; Kodama et al., 2004; Q. 
Zhang, Bae, Kemper, & Kemper, 2006). PB treatment also induces nuclear 
translocation of Hnf-4α (Bell & Michalopoulos, 2006), but Hnf-4α is inhibited by Car 
through competition for binding gene regulatory elements and nuclear cofactors 
(Kachaylo, Pustylnyak, Lyakhovich, & Gulyaeva, 2011; Miao et al., 2006; Yarushkin, 
Kachaylo, & Pustylnyak, 2013). This has been corroborated by the finding that in 
primary hepatocytes from Car and Pxr knockout mice, Hnf-4α is activated by PB 
(Tamasi, Juvan, Beer, Rozman, & Meyer, 2009). Therefore, it is possible that the 
induction of miR-96 in Car KO rats (Figure 4.6 D) is controlled by Hnf-4α. This may 
also be true for miR-182 and the lack of concordance could be an issue of dose. This 
could also explain the delay in miRNA induction with PB treatment in the rat, 
whereby miRNAs are progressively significantly increased compared to control from 
14 days onwards ((Koufaris et al., 2013) Figure 4.4), mirroring the predicted increase 
in Hnf-4α activation at this time (Kakehashi et al., 2013). The Hnf-4α gene target, 
Cyp7a1 (Miao et al., 2006) was assessed by interrogating the previously published 
microarray data from Waterman et al., (Waterman et al., 2010) to explore if Hnf-4α 
was activated in a time-dependent manner. Cyp7a1 was not significantly induced 
over time with PB treatment (data not shown).  
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Summary – This suggests that Hnf-4α is unlikely to control PB-induced expression 
of miR-182/96.  
 
4.3.2.2 Methylation changes as a regulator of miR-182/96 expression in PB treated 
rats  
Methylation data were obtained in collaboration with Nahal Masrour (Department of 
Surgery and Cancer, Imperial College London). 
 
Analysis of the upstream region of miR-182/96 using USCS genome browser (Kent 
et al., 2002) (July 14 (RGSC 6.0/rn6) Assembly of Rattus norvegicus) identified a 
3,194 bp CpG island (highlighted in green in Figure 4.9) at 57,467,436-57,470,629 
bps on chromosome 4, which is approximately 3,500 bps upstream of the first 
miRNA of the cluster (Figure 4.9). 
 
Figure 4.9: Analysis of miR-182/96 upstream sequence 
Figure 4.9 shows the minus strand of Rattus norvegicus chromosome 4 orientated 3’ 
to 5’, upstream of the miR-182/96 (purple bar) cluster. The CpG island is shown 
(highlighted in green). 
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CpG islands are defined as >500bp in length, with G-C content >55% and a ratio of 
observed CpG / expected CpG >0.65 (Takai & Jones, 2002). The CpG island 
selected herein had a G-C content of 64% and a ratio of 0.7. Within this CpG island I 
identified a PB regulatory sequence known as a Barbie-box, which we designed 
PCR primers to amplify in order to sequence the 5 CpG sites around the Barbie-box. 
Barbie-boxes consist of a 10 bp PB consensus sequences (CCAAAGCNGG) that 
are bound by a barbiturate responsive protein(s) and found in the 5’-regulatory 
sequence of PB responsive genes, Cyp2b and α1-acid glycoprotein (Fournier et al., 
1994). Transfection of a promoter construct containing either functional, point 
mutated or deleted Barbie-box into primary rat hepatocytes showed that response to 
PB (2mM) was reduced in the latter two constructs (Fournier et al., 1994). 
Conversely, others have found that mutation of this sequence does not affect PB-
mediated gene expression (Park, Li, & Kemper, 1996). However, the authors do note 
that mutation of the sequence in a luciferase construct containing the Cyp2b 
upstream regulatory sequence results in a slight increase in activity, suggesting a 
potential role as a negative regulator of gene expression.  
 
RNA-sequencing identified miR-182 as significantly increased with PB treatment 
(1000ppm) compared to control at 28 days treatment in this sample set (Flores-
Torres – thesis in 2015). Therefore methylation levels were assessed at 28 days, but 
also 14 days due to previous data indicating global hypermethylation with PB 
treatment (1000ppm) at this time (Koufaris et al., 2013). Seven days were also 
chosen. Cyp2b1/2 mRNA were shown to be significantly induced by PB (100ppm) 
compared to control at the start and cessation of the study (days 1, 3 and 28) 
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(Flores-Torres – thesis in 2015). Figure 4.10 shows that at the 3 time points tested 
there was no change in percentage methylation of the targeted CpG sites with PB 
treatment (1000ppm) compared to control. 
 
Summary – These data suggest that methylation of the Barbie-box sequence within 
the CpG island upstream of miR-182/96 is unlikely to be involved in regulating the 
PB-mediated expression of these miRNAs. 
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Figure 4.10: Site-specific methylation 
levels after PB treatment in vivo 
Figure 4.10 shows percentage 
methylation levels of 5 sequential CpG 
sites upstream of the miR-182/96 
cluster with PB treatment (1000ppm) 
for 7 days (A), 14 days (B) and 28 days 
(C) as determined by pyro-sequencing.  
Data were mean + SD of 5 samples. 
Mann-Whitney was used to compare 
control against treatment.  
 
P e rc e n ta g e  m e th y la t io n  a t  in d iv id u a l C p G
s ite s  a fte r  2 8  d a y s  P B  tre a tm e n t in  v iv o
P
o
s
it
io
n
 1
P
o
s
it
io
n
 2
P
o
s
it
io
n
 3
P
o
s
it
io
n
 4
P
o
s
it
io
n
 5
0
5
1 0
1 5
2 0
C o n tro l
1 0 0 0 p p m
C p G  p o s it io n s  s u rr o u n d in g  B a rb ie -b o x
%
 m
e
th
y
la
ti
o
n
        4.  Regulation of phenobarbital-induced miRNAs 
 
154 
 
4.3.2.3 P53 as a regulator of miR-182/96 expression in PB treated rats  
To interrogate p53 as a regulator of miR-182/96, the downstream transcriptional 
target of p53, cyclin-dependent kinase inhibitor 1A (p21), was assessed. P21 inhibits 
cell cycle progression through inhibition of cyclin-dependent kinases (Harper, Adami, 
Wei, Keyomarsi, & Elledge, 1993). Expression of p21 was significantly decreased in 
the livers of PB treated (1000ppm) rats at 3 days treatment compared to control, and 
although decreased at 14 days, showed no significant change to control with PB 
treatment (1000ppm) (Figure 4.11 A and B). Three and 14 days were chosen as they 
reflect the time-dependent increase in miR-182 expression with PB treatment 
(1000ppm) (Figure 4.4).  
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Figure 4.11: p21 expression in PB treated rats 
Figure 4.11 depitcs p21 expression by qPCR after PB treatment (50ppm or 
1000ppm) for 3 (A) or 14 (B) days. Data were mean + SD of 3 samples, comparing 
treatment to control with Kruskal-Wallis and Dunn’s multiple comparison.  
 
Summary – These data suggest that p53 was not activated as a result of PB 
treatment and therefore is unlikely to be controlling the expression of miR-182/96. 
The significant decrease in p21 expression at 3 days PB treatment may reflect PB-
induced hyperplasia, due to p21’s role as an inhibitor of cell cycle progression. 
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4.3.2.4 ROS as a regulator of miR-182/96 expression in PB treated rats  
Increased expression of hypoxia-inducible factor- (Hif-)1α mRNA and protein have 
been reported as inducible by oxidative stress (Bonello et al., 2007; Pialoux et al., 
2009). Hif-1α is oxygen labile, resulting in protein levels increasing during hypoxic 
(low oxygen) and oxidative stress conditions. Stable Hif-1α associates with Hif-1β 
resulting in increasing expression of target genes involved in responding to oxidative 
stress, such as vascular endothelium growth factor (Vegf) (Pialoux et al., 2009). 
Therefore, it might be expected that if PB is inducing genes implicated in increasing 
oxidative stress (Dail et al., 2008; Elrick et al., 2005; Klepeisz et al., 2013), then Hif-
1α expression might also be increased as a counter measure. However, expression 
of Hif-1α at 3 and 14 days PB treatment in vivo showed no significant change 
compared to control, which was further confirmed by lack of significant change in Hif-
1α target, Vegf (Waterman et al., 2010). 
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Figure 4.12: β-Gal and Hif-1α expression in PB treated rats 
Figure 4.12 depitcs Hif-1α expression by qPCR after PB treatment (50ppm or 
1000ppm) for 3 (A) or 14 (B) days. Data were mean + SD of 3 samples, comparing 
treatment to control with Kruskal-Wallis and Dunn’s multiple comparison. 
 
Summary – These data suggest that increased ROS and subsequent oxidative 
stress are not likely to be involved in PB-mediated induction of miR-182/96. To 
confirm this, however, Hif-1α protein should also be assessed, as Hif-1α activity is 
determined by alteration in proteolytic degradation (Salceda & Caro, 1997).  
 
4.3.2.5 Tgf-β as a regulator of miR-182/96 expression in PB treated rats  
Expression of Tgf-β has been independently linked with PB treatment (Jirtle & 
Meyer, 1991) and increased miR-182 (Qiu et al., 2014). Although at 3 days, 50ppm 
PB appeared to induce Tgf-β1 expression, the response was not significant and 
demonstrated no clear dose effect (Figure 4.13 A). At 14 days PB treatment, no 
effect was seen (Figure 4.13 B).  
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Figure 4.13: Tgf-β expression in PB treated rats 
Figure 4.13 shows Tgf-β expression by qPCR after PB treatment (50ppm or 
1000ppm) for 3 (A) or 14 (B) days. Data were mean + SD of 3 samples, comparing 
treatment to control with Kruskal-Wallis and Dunn’s multiple comparison. 
 
Summary – These data suggest that increased Tgf-β expression is unlikely to be 
involved in the induction of miR-182/96 with PB treatment in the rat. 
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4.4 Conclusion 
Through previous work we have identified miR-182/96 and miR-429/200b as PB-
inducible miRNAs (Koufaris et al., 2012, 2013) (Figure 4.4). In this study we 
attempted to explore the expression of miR-182/96 and miR-429/200b in wild type 
and Car knockout rats in order to begin to interrogate the molecular changes 
underpinning the miRNA response.  
 
Car as a miRNA regulator I demonstrated that there was little difference in the 
expression of the miRNAs between control and 500ppm PB treatment in wild type 
and knockout rats (Figure 4.6 and Figure 4.7). However, it was shown that miR-96 
was significantly induced by PB (500ppm) compared to control in Car knockout rats 
(Figure 4.6 D), suggesting that this miRNA is not regulated by Car. MiR-96 and miR-
182 are expressed from the same cluster from the same promoter (S. Xu, Witmer, 
Lumayag, Kovacs, & Valle, 2007) and exhibited significant positive correlation with 
PB treatment in vivo (Figure 4.4 B). Therefore this would suggest that the lack of 
significant expression of miR-182 is likely a dose-dependent issue. Furthermore, lack 
of increased expression of the other miRNAs examined indicates that a higher dose 
of PB may confirm the claim that miR-96 (and its cluster partner miR-182) are not 
regulated by Car. 
 
B13/H cells Using the B13/H cells, which we have demonstrated are capable of 
increasing the expression of miR-182/96 in response to PB (chapter 2.3.3), I sought 
to confirm whether miR-182/96 were regulated by Car in the context of PB exposure 
in vitro. Unfortunately under the conditions used here to evaluate the effect of OAA, I 
        4.  Regulation of phenobarbital-induced miRNAs 
 
159 
 
was unable to stimulate PB-mediated induction of Cyp2b1/2, in the presence of 0.1% 
v/v DMSO. It is unclear why, but suggests that the presence of 0.1% v/v DMSO as 
the vehicle may have contributed to this. Future work to repeat this experiment using 
ethanol to solvate OAA are indicated.  
 
Hnf-4α as a miRNA regulator Car has been shown to exhibit an antagonistic 
relationship with Hnf-4α, despite Hnf-4α being sensitive to PB treatment (Bell & 
Michalopoulos, 2006; Miao et al., 2006). Due to the time-dependent expression of 
miR-182/96 and the apparent Car independent expression of miR-96 I hypothesised 
that the miRNA may be under the control of Hnf-4α. This was supported by the 
presence of Hnf-4α binding sites upstream of miR-96 (Koufaris, 2011). However, 
analysis of transcriptomic data from PB treated rats (Waterman et al., 2010) showed 
there was no change in the Hnf-4α regulated Cyp7a1 across the time when these 
miRNAs are induced, indicating that Hnf-4α is unlikely to control the expression of 
miR-182/96. 
 
Other regulators From the literature I identified a number of PB-responsive 
pathways, which are also associated with increased miR-182/96 expression (Figure 
4.1). However, transcriptomic or site-specific methylation analysis showed no 
changes to indicate regulation of miR-182/96 expression. Having only assessed one 
regulatory site by methylation analysis, it is possible that the key genomic regulatory 
region was overlooked and thus methylation could still play an important role in 
miRNA-mediated expression (Figure 4.14).  
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Figure 4.14: β-Catenin or methylation as miR-182/96 regulators 
Figure 4.14 Potential regulators of PB-mediated miR-182/96 expression. 
 
PB is reported as selecting for activating mutations in the β-catenin gene (Aydinlik et 
al., 2001) in mice treated with DEN (single intraperitoneal injection of 90µg/g body 
weight) followed by PB (on a diet of 0.05% PB) after 3 weeks rest, for 39 weeks. β-
Catenin has been shown to be required for PB-mediated tumour promotion in the 
mouse (Rignall et al., 2011). It has been reported that β-catenin may contribute to 
PB-mediated carcinogenesis through altering cell adhesion, and not through a direct 
transcriptional response in the mouse (Aydinlik et al., 2001). As well as undergoing 
nuclear translocation after PB treatment, Car has also been shown to associate at 
the cell membrane (Koike et al., 2005). It would be interesting to see if after PB 
treatment Car is involved in interacting with β-catenin as a signalling complex, and if 
this association is conserved between the rat and the mouse.  
 
Active β-catenin is also associated with increased expression of miR-182 in human 
breast cancer, although this is reported to be through a direct response (Chiang, 
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Hou, & Hung, 2013), suggesting that β-catenin could be involved in PB-mediated 
induction of miR-182/96 (Figure 4.14). Induction of miR-182/96 (and miR-
200a/b/429) by PB is a rat specific event (Koufaris et al., 2012, 2013) as similar 
responses are not reported in the mouse (Lempiäinen et al., 2013). If β-catenin does 
regulate miR-182/96, then it may be that miR-182/96 are protecting the rat from PB-
mediated tumour formation. This could be explored further through assessing 
associations of β-catenin with cell adhesion targets such as α-catenin (Aydinlik et al., 
2001), or even Car, in comparison between rat and mouse models, both in vivo and 
in vitro. If this hypothesis is true then the function of miR-182/96 would be to 
maintain hepatic homeostasis, and therefore understanding miRNA function is the 
focus of the following chapter.  
 
Chapter 4 Conclusions – In the rat, PB-mediated regulation of miR-182/96 could be 
through either epigenetic mechanisms or alteration of β-catenin activity state to 
maintain homeostasis. To explore if miR-182/96 are acting to preserve homeostasis, 
the function of these miRNAs will be interrogated next.  
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5. Function of phenobarbital-induced miRNAs 
5.1 Introduction  
In chapter 4 I explored potential regulators of the PB-inducible miR-182/96 cluster 
and suggest that β-catenin and methylation changes could potentially be involved. 
The function of these miRNAs have not been fully discussed however, and so will be 
the focus of this chapter. 
 
5.1.1 PB responsive miRNAs in the mouse 
One year PB treatment (0.05% w/v) of male B6C3F1 mice is known to induce liver 
tumours (Becker, 1982). It has also been reported that the same treatment over 13 
weeks induced expression of the noncoding RNA cluster, Dlk1-Dio3, which has been 
suggested as a candidate marker for hepatic tumour promotion in the mouse 
(Lempiäinen et al., 2013). The Dlk1-Dio3 cluster contains 53 miRNAs (Benetatos et 
al., 2013; Lempiäinen et al., 2013), which are reported to be involved in cell 
signalling, cell morphology and a variety of cancers (Benetatos et al., 2013). 
Furthermore, it was demonstrated that PB-mediated expression of the Dlk1-Dio3 
cluster was dependent on both Car and β-catenin, therefore implicating this ncRNA 
in PB-induced tumourigenesis (Lempiäinen et al., 2013), unlike miR-96 in the rat, 
which appears to be regulated independently of Car (chapter 4.3.1.2). In a separate 
study, male C3H/HeJ mice were treated with DEN (single intraperitoneal injection of 
90mg/kg body weight) for 2 weeks, followed by a diet of PB (0.05%w/w) for 39 
weeks (Unterberger et al., 2014). DEN/PB tumour promotion studies are known to 
induce growth of β-catenin activated tumours (Aydinlik et al., 2001; Rignall et al., 
2011; Unterberger et al., 2014), yet the data presented by Unterberger et al., 
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(Unterberger et al., 2014) identified different deregulated miRNAs following DEN/PB 
treatment compared to PB alone (by Lempiainen et al., (Lempiäinen et al., 2013)); 
although only three were detected as significantly changed.  
 
These data suggest that the different treatments used to induce tumours in rodents 
via PB result in disparate effects on the miRNAome; although it must be noted that 
different mouse strains were used. Nonetheless, miRNA expression as a result of PB 
treatment in the mouse appear representative of the tumour promoting phenotype. 
However in the rat, as PB does not induce tumours without pre-treatment with a DNA 
damaging agent, it is thought that PB-mediated miRNA expression changes may be 
involved in maintaining homeostasis (Koufaris et al., 2012, 2013).  
 
5.1.2 PB responsive miRNAs in the rat 
PB time- and dose-dependently induces miR-200a/b/429 and miR-182/96 in the rat 
(Koufaris et al., 2012, 2013). The miR-200 cluster are reported to be involved in 
antagonising tumourigenesis through inhibiting EMT in bladder cancer cells (Adam et 
al., 2009), breast cancer cells (Gregory et al., 2011) and in the context of PB 
exposure in rats (Koufaris et al., 2013). Interestingly, miR-96 has also been shown to 
inhibit EMT. In HCT116 colorectal cancer cells, over expression of the EMT 
transcription factor Zeb1 supressed miR-96 and miR-200a/b expression, which was 
reversed in Zeb1 knockdown experiments (X. L. Li et al., 2013). This confirmed 
previous work reporting a negative feedback loop between Zeb and miR-200 
expression (Bracken et al., 2008), but also demonstrated that miR-96 is sensitive to 
this regulation. Zeb1/2 protein expression has already been identified as down-
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regulated in the livers of PB treated rats (Koufaris et al., 2013) and so will not be 
discussed here. 
 
MiR-182/96 have been shown to act as oncomiRs in a number of cancers, including 
hepatocellular carcinoma (T.-H. Wang, Yeh, Ho, Ng, & Chen, 2015), prostate cancer 
(Tsuchiyama et al., 2013) breast cancer (Guttilla & White, 2009) and bladder cancer 
(Hirata et al., 2012). MiR-182 has also been reported as a tumour suppressor in 
some cancers, such as uveal melanoma (Yan et al., 2012) and renal cell carcinoma 
(Xin Xu et al., 2014), while miR-96 has been reported to act as a tumour suppressor 
in prostate cancer (Yu et al., 2010). This suggests that miRNA function is highly 
context dependent. In fact, miR-182/96 have been predicted to be involved in 
maintaining mitoinhibition in the livers of PB treated rats. This was reported due to 
predicted targets in pathways involved in growth factor signalling, such as 
MAPK/erbb, and the temporal induction of these miRNAs coinciding with the 
cessation of the hyperplastic response (Koufaris et al., 2013). However, no targets 
have been confirmed for miR-182/96 in the context of PB exposure. Here I identify a 
number of targets associated with miR-182/96, which are also deregulated as a 
result of PB treatment in vivo.  
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5.1.3 Hypothesis 
MiRNA targets can be identified using in silico analyses of the expression of miRNAs 
in in vivo PB treated samples. Identified targets will be context-specific and indicative 
of the PB phenotype. 
 
5.1.4 Aims 
1. Use in silico analyses to identify potential targets of miR-182/96. 
2. Confirm targets through selected targeted analysis. 
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5.2 Methods 
5.2.1 Tissue samples 
As described in chapter 3.2.1 
 
5.2.2 In silico analysis 
In silico analyses were performed using miRWalk (Dweep, Sticht, Pandey, & Gretz, 
2011) and TargetScan (B. P. Lewis, Shih, Jones-Rhoades, Bartel, & Burge, 2003) to 
identify miRNA targets. TargetScan identified putative miRNA targets based on 
sequence matches between the miRNA seed sequence and the 3’UTR of genes, 
and assessed surrounding sequences for added complementarity (B. P. Lewis et al., 
2003). MiRWalk identified putative targets in a similar manner but allowed 
comparison between other miRNA target prediction algorithms for miRNA binding to 
the 3’UTR of genes. MiRWalk also contained a curated database of experimentally 
validated targets from the literature (Dweep et al., 2011). 
 
5.2.3 qRT-PCR 
As described in chapter 2.2.6 
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5.3 Results and Discussion  
5.3.1 Aim 1: Use in silico analyses to identify potential targets of miR-182/96. 
5.3.1.1 miR-182/96 sequence 
Despite the fact that miR-182 and miR-96 both have the same seed sequence 
(nucleotides 2-7) they have been shown to exhibit unique target specification due to 
miR-96 containing a cytidine at position 8, and miR-182 with an adenosine (Jalvy-
Delvaille et al., 2012) (Figure 5.1). Others have reported that miR-182 and miR-96 
have overlapping targets (Guttilla & White, 2009). The work presented here 
assessed both unique and common targets between these two miRNAs. As 
discussed in chapter 1.3.1, functional miRNAs can be generated from the cleavage 
of double stranded pre-miRNA hairpin structures, and either the 5p or 3p end of the 
pre-miRNA hairpin becomes the mature miRNA; it is the 5p end of the miRNAs 
(Figure 5.1) that are referred to in this work and not the miRNA-3p form. However, as 
the 3p form of miRNAs also exhibits functional effects (J.-S. Yang et al., 2011) it 
would be interesting to explore miR-182/96-3p expression and potential targets in 
future work. 
Rno-miR-182            5’-UUUGGCAAUGGUAGAACUCACACCG-3’ 
Rno-miR-96-5p  5’-UUUGGCACUAGCACAUUUUUGCU-3’ 
 
Figure 5.1: MiR-182/96 sequence 
Figure 5.1 shows the seed sequence, 2-7+nt8 (shown in red with sequence 
differences underlined), for Rno-miR-182/96-5p (obtained from www.mirbase.org 
(Kozomara & Griffiths-Jones, 2014)). Rno, Rattus norvegicus. 
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5.3.1.2 Validated miR-182/96 targets 
Validated targets of miR-182 and/or miR-96 were identified using miRWalk (Dweep 
et al., 2011). This generated 30 high probability targets for rno-miR-182, and 39 for 
rno-miR-96. To further clarify these putative targets, they were then assessed for 
significant changes in expression with PB treatment in vivo, using published data 
from Waterman et al., (Waterman et al., 2010), whereby p<0.001 by two way 
ANOVA with Benjamini and Hochberg false discovery rate across 14 days PB 
treatment (0, 50, 500, 1000ppm). This concluded in 3 targets for miR-182: Egfr, 
Radixin and Slc12a2 (solute carrier family 12a2/sodium potassium chloride 
cotransporter (NKCC1)). In order to substantiate these targets, their expression at 3, 
7 and 14 days PB treatment (0, 50, 500, 1000ppm) from Waterman et al., 
(Waterman et al., 2010) were correlated with the expression of miR-96 using 
microarray data generated by Koufaris (Koufaris, 2011). MiR-182 expression could 
not be used in this instance as the expression level was too variable to be quantified 
by array (Koufaris, 2011), although both miRNAs demonstrated highly correlative 
expression (Figure 4.4). Furthermore, due to the data available, correlations 
compare average gene/miRNA expression over multiple time points and doses and 
therefore complicates data interpretation. Only one target passed these selection 
criteria: Slc12a2. 
 
Slc12a2 Using Spearman correlation, Slc12a2 significantly negatively correlated with 
miR-96 and was therefore identified as a potential target (Figure 5.2 A and B). 
Slc12a2 is a gene encoding for a cotransporter associated with increasing 
intracellular neuronal Cl- levels in neonates (Dzhala et al., 2005). Therefore, miRNA-
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mediated inhibition of Slc12a2 might be to modulate the chronic effects of PB 
exposure and Cl- influx.  
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Figure 5.2: In silico analysis of validated miRNA targets (1) 
Figure 5.2 shows median expression and miR-96 Spearman correlation with Slc12a2 
(A/B). mRNA data were obtained from Waterman et al., (Waterman et al., 2010), and 
miRNA expression from Koufaris (Koufaris, 2011). Data were representative of 4-5 
samples.  
 
MiR182/96 targets were also identified through literature searches in the same 
manner as described above. Through this method I determined a selection of miRNA 
targets whose expression were significantly altered by PB in vivo, and also 
significantly negatively correlate with miR-96 expression. 
 
Smad4 Mothers against decapentaplegic homolog 4 (Smad4) was identified as a 
validated target for miR-182 (Hirata et al., 2012) (Figure 5.3 A and B). Smad4 is a 
downstream component of Tgf-β signalling that is bound by receptor activated 
Smads (Smad2/3), which then translocate into the nucleus to modulate gene 
expression (Moustakas, Souchelnytskyi, & Heldin, 2001). Smad4 is also downstream 
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of bone morphogenetic protein signalling (Moustakas et al., 2001). Smad4 has been 
reported as decreased in prostate cancer, yet appears to be important in disease 
progression only in the presence of other gene dysregulation (Z. Ding et al., 2011). It 
has also been demonstrated that Smad4 is decreased in GST-P positive foci in the 
livers of rats treated with DEN-PB to promote tumourigenesis (Ichimura et al., 2010). 
Yet, Smad4 has also been shown to be increased in patients with hepatocellular 
carcinomas (Hernanda et al., 2014), demonstrating that Smad4 is associated with 
both tumour suppression and tumour growth. Interestingly, Smad4 knockdown has 
been reported to abrogate up-regulation of Zeb (Gregory et al., 2011), suggesting 
that miR-182 might be acting in concert with the miR-200 cluster to suppress EMT.  
 
Rb1 The retinoblastoma (Rb1) tumour-suppressor gene was also identified as a 
validated target for miR-182 (Krishnan, Steptoe, Martin, Wani, & Nones, 2012) 
(Figure 5.3 C and D). Rb1 is a regulator of cell cycle progression, cellular 
differentiation and survival; the loss of which is associated with myriad tissue defects 
and cancers (reviewed in (Goodrich, 2006)). Interestingly, loss of Rb1 function leads 
to the activation of multiple components of glycolysis, increasing lactate production 
(Clem & Chesney, 2012), which is also reported to be increased in the plasma of PB 
treated rats (Waterman et al., 2010).  
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Figure 5.3: In silico analysis of validated miRNA targets (2) 
Figure 5.3 shows median expression and miR-96 Spearman correlation with Smad4 
(A/B) and Rb1 (C/D). mRNA data were obtained from Waterman et al., (Waterman 
et al., 2010), and miRNA expression from Koufaris (Koufaris, 2011). Data were 
representative of 4-5 samples.  
 
FoxO1 FoxO1 has been reported as a validated target for miR-96 and miR-182 
(Guttilla & White, 2009), and is important in the regulation of gluconeogenic genes 
such as phosphoenolpyruvate carboxykinase (Pepck) and glucose-6-phosphatase 
(G6pase) (Puigserver et al., 2003), as well as acting as a co-activator for Car target 
genes (Kodama et al., 2004). Therefore FoxO1 was also interrogated as a potential 
miRNA target. Although FoxO1 was not reported as significantly changed by 
Waterman et al., (Waterman et al., 2010), my preliminary data showed that FoxO1 
significantly negatively correlated with miR-182 expression by qPCR (Figure 5.4), 
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suggesting that the above criteria used to select targets are quite stringent and are 
likely to be excluding other positive target matches. 
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Figure 5.4: In vivo FoxO1 correlation with miR-182 
Figure 5.4 shows the correlation between FoxO1 and miR-182 by qPCR at 3 and 14 
days PB treatment (0, 50 and 1000ppm) using Spearman correlation. 
 
Summary – These data demonstrate that the validated miRNA targets: Slc12a2, 
Smad4, Rb1 and FoxO1 exhibited expression changes and correlations indicative of 
miRNA regulation in the context of PB exposure in vivo. 
  
5.3.1.3 Predicted miR-182/96 targets  
I also explored predicted miRNA targets in the context of PB exposure. In order to 
limit the number of mRNA targets identified, through miRWalk, I first selected targets 
that were only consistently predicted (by at least 4 of the 8 programs searched by 
miRWalk). This generated 248 targets for rno-miR-182, and 231 targets for rno-miR-
96. Using a threshold of 3 matches between search programs would have selected 
629 potential targets of miR-182 and 578 for miR-96. Therefore using >4 programs 
concordance cut-off, produced a large, but not overwhelming number of targets. 
        5.  Function of phenobarbital-induced miRNAs 
173 
 
Targets were again assessed for significant change in expression with PB treatment 
using data from Waterman et al., (Waterman et al., 2010), and further stratified by 
significant negative correlation with miR-96 expression from Koufaris (Koufaris, 
2011). Only those that passed both criteria were selected, and are discussed below.  
 
Pc Pyruvate carboxylase (Pc) was identified as a putative target for both miR-182 
and miR-96 (Figure 5.5 A and B). Pc catalyses the carboxylation of pyruvate to 
oxaloacetate in gluconeogenesis (Jitrapakdee & Wallace, 1999). Therefore, miR-
182/96-mediated decrease of Pc might be predicted to decrease gluconeogenesis. 
Decreased hepatic glucose is a hallmark of PB treatment (Waterman et al., 2010), 
suggesting this may be mediated in part by miR-182/96.  
 
Slc12a2 Slc12a2 was identified as a potential target for miR-182 and miR-96, and as 
a validated target for miR-182 (Figure 5.2 A and B), suggesting this gene may be a 
common target for both miRNAs.  
 
Slc37a4 A second transporter was also identified as a putative target for miR-182; 
solute carrier family 37 (glycerol-6-phosphate transporter), member 4 (G6pt/Slc37a4) 
(Figure 5.5 C and D). Slc37a4 transports glucose-6-phosphate into the lumen of the 
endoplasmic reticulum to enable de-phosphorylation to glucose via glucose-6-
phosphatase (Chou & Mansfield, 2014). Therefore, miR-182 mediated suppression 
of Slc37a4, as with FoxO1 and Pc, may contribute to PB-mediated decrease in 
hepatic glucose.  
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Map2k1 mitogen-activated protein kinase kinase 1 (Mek1/Map2k1) was identified as 
a putative target for miR-96 (Figure 5.5 E and F). Map2k1 is an upstream kinase for 
the activation of Erk. Indeed inhibition of Map2k1 has been reported to potentiate 
PB-mediated Cyp induction, potentially through Erk inhibition (Florence Joannard et 
al., 2006). This suggests that miR-96 could be involved in modulating gene induction 
by PB through effecting Erk activation.  
 
Olr59 Olfactory receptor 59 (Olr59) was identified as a putative target for miR-96 
(Figure 5.5 G & H). The expression of rat Olr59 is reported to be male specific 
(Babelova et al., 2015), although there is very little else reported on this gene in the 
literature. Olr59 was shown to be expressed in rat mesenteric arterial tissue, as was 
the mouse homologue, Olfr78, in mouse arteries. Olfr78 was reported to bind short 
chain fatty acids to modulate vasodilation (Reho, Shetty, Dippold, Mahurkar, & 
Fisher, 2015). PB has been shown to increase the uptake of fatty acids in the livers 
of treated rats, potentially involved in endoplasmic reticulum growth (Waterman et 
al., 2010). It would be interesting to determine the role of Olr59 in this context, and 
whether miR-96 could be reducing expression of this gene to mediate Olr59’s 
response to the influx of fatty acids.  
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Figure 5.5: In silico analysis of predicted miRNA targets 
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Figure 5.5 shows median expression and miR-96 Spearman correlation with Pc 
(A/B), Slc37a4 (C/D), Map2k1 (E/F) and Olr59 (G/H). mRNA data were obtained 
from Waterman et al., (Waterman et al., 2010), and miRNA expression from Koufaris 
(Koufaris, 2011). Data were representative of 4-5 samples.  
 
Gnmt Glycine N-methyltransferase (Gnmt) was identified in preliminary work as 
significantly reduced by PB treatment in the rat (Figure 5.6 A). Using multiple 
comparisons in MiRWalk, Gnmt was not detected as a target for miR-182. Due to the 
stringent criteria selected for target identification, I also used TargetScan (B. P. 
Lewis et al., 2003) and found Gnmt was a predicted target for miR-182. Furthermore, 
Gnmt expression also correlated with the expression of miR-96 (Figure 5.6 B). Gnmt 
catalyses glycine methylation to sarcosine (and S-adenosylhomocysteine) using the 
methyl donor, S-adenosylmethionine. Gnmt is thought to be a major regulator of 
methylation of DNA/protein due to the use of S-adenosylmethionine in cellular 
methylation reactions (Luka, Mudd, & Wagner, 2009). Interestingly, Gnmt knockout 
mice present with hypoglycaemia due to decreased expression of fructose 1,6-
bisphosphatase, phosphoenolpyruvate carboxykinase, and Slc37a4, as well as 
showing hepatomegaly (Liu et al., 2007), all of which are associated with the PB 
phenotype (Waterman et al., 2010). These suggest that PB-mediated DNA 
methylation changes might be influenced by miR-182 inhibition of Gnmt expression, 
resulting in an increase in available methyl groups for DNA methylation, as well as 
affecting glucose metabolism.  
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Figure 5.6: In silico Gnmt correlation with miR-96 
Figure 5.6 shows the media expression of Gnmt (A) with PB treatment and 
Spearman correlation with miR-96 (B). mRNA data were obtained from Waterman et 
al., (Waterman et al., 2010), and miRNA expression from Koufaris (Koufaris, 2011). 
Data were representative of 4-5 samples.  
 
Summary - These data demonstrate that the predicted miRNA targets: Pc, Slc37a4, 
Map2k1, Olr59 and Gnmt displayed expression changes and correlations consistent 
with miRNA regulation in the context of PB exposure in vivo. 
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5.3.2 Aim 2: Confirm targets through selected targeted analysis. 
5.3.2.1 MiR-182/96 targets chosen for validation in vivo 
From the in silico analysis I have identified a number of validated and predicted 
targets for miR-182/96 (Table 5.1). 
 
Table 5.1: MiR-182/96 targets 
Gene Rno-miR-182 Rno-miR-96 
Slc12a2 Validated Predicted 
Smad4 Validated - 
Rb1 Validated - 
FoxO1 Validated Validated 
Pc Predicted Predicted 
Slc37a4 Predicted - 
Map2k1 - Predicted 
Olr59 - Predicted 
Gnmt Predicted - 
Table 5.1 shows validated (in green) and predicted (in blue) targets of miR-182 and 
miR-96. 
 
In order to assess the strength of the in silico analysis, I chose two targets to profile 
using qPCR across 1-90 days PB treatment in vivo, and correlated their expression 
to miRNA expression in matched samples. As the only validated target for both 
miRNAs as well as due to its role in gluconeogenesis, FoxO1 was selected for 
validation. Gnmt was also selected as a predicted target of miR-182 and due to its 
role in regulating methylation and glucose metabolism both of which are affected by 
PB treatment (Koufaris et al., 2013; Waterman et al., 2010). 
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FoxO1 mRNA The validated target FoxO1, showed a trend for decreased 
expression at all time-points tested with PB (1000ppm) compared to control (Figure 
5.7 A). Furthermore, in matched samples FoxO1 significantly negatively correlated 
with miR-182 (Figure 5.7 B), suggesting that FoxO1 could be a target of miR-182/96. 
It is interesting to note that FoxO1 expression appears decreased regardless of the 
time-dependent effect of PB on miR-182 (Figure 4.4). This could indicate that the 
miRNAs are working in concert with other factors to help maintain FoxO1 levels, or 
that the two may be independent. To further clarify this FoxO1 protein levels were 
assessed. 
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Figure 5.7: FoxO1 as a target for miR-182 
Figure 5.7 shows the expression of FoxO1 
mRNA in the livers of PB treated rats (A). 
Data shown were mean + SD of 3 samples. 
Y-axis is fold change to control using the 2-
ΔCt method. Kruskal-Wallis with Dunn’s 
multiple comparison to control was used to 
determine statistical significance, as well as 
Spearman’s correlation between FoxO1 
and miR-182 fold change from matched 
samples (B).  
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FoxO1 protein Immunoblots for FoxO1 protein were performed, which spanned the 
PB-mediated time-dependent change in miRNA expression. The data in Figure 5.8 
shows that PB (1000ppm) did not significantly change FoxO1 expression at either 
time point relative to control. However there does appear to be decreased FoxO1 
expression over time, which could be indicative of the miRNA expression changes. 
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Figure 5.8: In vivo FoxO1 protein expresion 
Figure 5.8 shows the expression of FoxO1 protein in the livers of PB treated rats at 
days 3 and 14 (A). Data shown were mean + SD of 3 samples, with Y-axis as fold 
change to control, after normalisation to β-tubulin. Mann-Whitney tests were used to 
compare control with treatment. Representative blot shown (B). 
 
Summary – The data presented suggests that PB does not significantly alter 
expression of FoxO1 mRNA or protein. However treatment with PB consistently 
lowers the mean FoxO1 mRNA levels and correlation analysis and change in protein 
Control 1000 ppm Control 1000 ppm 
Day 3  Day 14  
FoxO1 
β-tubulin 
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over time suggest that miR-182/96 may contribute to FoxO1 regulation in the context 
of PB exposure. 
 
Gnmt mRNA The predicted miR-182 target, Gnmt, was also shown to be 
consistently decreased throughout high dose PB (1000ppm) treatment in vivo 
(Figure 5.9 A), with significant suppression at 14 days. Significant negative 
correlation with miR-182 suggests Gnmt expression may be controlled by miR-182 
(Figure 5.9 B), in a similar manner to that described for FoxO1.  
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Figure 5.9: Gnmt as a target for miR-182 
Figure 5.9 shows the expression of Gnmt 
mRNA in the livers of PB treated rats (A). 
Data shown were mean + SD of 3 samples. 
Y-axis is fold change to control using the 2-
ΔCt method. Kruskal-Wallis with Dunn’s 
multiple comparison to control was used to 
determine statistical significance, as well as 
Spearman’s correlation between Gnmt and 
miR-182 fold change from matched 
samples (B). *p<0.05. 
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Gnmt protein Gnmt protein expression was then determined to further explore the 
potential effects of miR-182 on Gnmt. The data in Figure 5.10 A shows that Gnmt 
protein was decreased at both time points, and although not significant by Mann-
Whitney, was significantly decreased by t test at day 14 (p=0.0383). This would 
suggest that Gnmt may be a target for miR-182 (Figure 5.10 A & B). 
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Figure 5.10: In vivo Gnmt protein expression 
Figure 5.10 shows the expression of Gnmt protein in the livers of PB treated rats at 
days 3 and 14 (A). Data shown were mean + SD of 3 samples, with Y-axis as fold 
change to control, after normalisation to β-tubulin. Mann-Whitney tests were used to 
compare control with treatment. Representative blot shown (B). 
 
Summary – These data suggest that PB may influence expression of Gnmt through 
miR-182. 
Control 
Gnmt 
β-tubulin 
Control 1000 ppm 1000 ppm 
Day 3 Day 14 
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5.4 Conclusion 
From the in silico analysis I have identified a number of validated and predicted 
targets of miR-182/96. The assessment of 2 targets, FoxO1 and Gnmt, across a sub-
chronic PB treatment plan in vivo suggests that these targets may be regulated by 
miR-182/96. It is tempting to speculate that the remaining in silico identified targets 
are also likely to be regulated by miR-182/96.  
 
To verify the above targets I would need to perform transfection studies. Preliminary 
studies in B13/H (and B13 cells) demonstrated that 96 hours transfection increased 
both miR-182 and miR-96 expression levels but failed to affect the validated target 
FoxO1 (data not shown). These experiments suggested that further transfection 
optimisation is required. There are a number of miRNA targets that are predicted to 
be specific to either miR-182 or miR-96 (Table 5.1) and further transfection 
optimisation would enable these specific miRNA-mRNA interactions to be confirmed. 
 
Glycolysis FoxO1 was identified as a validated target for both miR-182/96, Rb1 as a 
validated target for miR-182, Pc as a novel predicted target for both, while Slc37a4 
and Gnmt were novel predicted targets of miR-182, and Map2k1 for miR-96. PB 
treatment has been shown to reduce hepatic glucose (Waterman et al., 2010), which 
could be due in part to miRNA-mediated glycolysis via suppression of Rb1, FoxO1, 
Pc, Slc37a4 and Gnmt (Table 5.2 and Figure 5.11). PB has been reported to 
increase malic enzyme activity (Waterman et al., 2010), which would result in the 
conversion of malate to pyruvate and the generation of NADPH (Jitrapakdee & 
Wallace, 1999) (Figure 5.11). Together, it might be that these miRNA targets 
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coupled with altered malic enzyme are involved in increasing NADPH generation for 
hepatic Cyp-mediated 
hydroxylation, which is 
significantly upregulated by PB 
treatment (Waterman et al., 
2010).  
 
Figure 5.11: MiRNA-mediated 
glycolysis 
Figure 5.11 demonstrates the 
predicted effect of miR-182/96 
targets on glycolysis based on 
target gene function from the 
literature, described in text. 
 
Table 5.2: Proposed function of miR-182/96 
Gene Rno-miR-182 Rno-miR-96 MiR function 
Slc12a2 Validated Predicted Modulating Cl- influx 
Smad4 Validated - Inhibit EMT 
Rb1 Validated - Glycolysis 
FoxO1 Validated Validated Glycolysis 
Pc Predicted Predicted Glycolysis 
Slc37a4 Predicted - Glycolysis 
Map2k1 - Predicted Car activation 
Olr59 - Predicted Lipid response 
Gnmt Predicted - Increased methylation 
Glycolysis 
Table 5.2 shows proposed gene functions related to the PB-phenotype: glucose 
metabolism (pale red). 
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Furthermore, miR-96-mediated targeting of Map2k1 could control downstream Erk 
activation. This might be predicted to modulate PB-induction of Cyp genes over 
extended treatments, as Erk has been shown to inhibit PB-induced gene expression 
in the rat (Florence Joannard et al., 2006). Reduced expression of the above miRNA 
target genes are indicative of increased glycolysis, which is a hallmark of cancer 
development (Hanahan & Weinberg, 2011). However in the rat PB does not induce 
cancer without an initiating event, therefore taken together it might be that the 
miRNA-mediated changes discussed here are involved in controlling PB-mediated 
Cyp induction and controlling glycolysis activity to allow production of NADPH for 
biotransformation.   
 
Methylation Gnmt was identified as a novel predicted target for miR-182. PB 
treatment has been shown to cause transient global hypermethylation in the rat 
(Koufaris et al., 2013). Interestingly, this methylation change in the rat is seen at 14 
days treatment and corresponds to the decrease in Gnmt mRNA and protein 
expression shown here (Figure 5.9 A, and Figure 5.10 A). Decreased Gnmt levels 
would result in an increased availability of methyl donor groups for DNA methylation 
(Figure 5.12). MiR-29b has also been identified as decreased at 14 days PB 
treatment in the rat (Koufaris, 2011). MiR-29b directly targets DNA methyltransferase 
enzymes (Dnmt)3a/3b, and indirectly targets Dnmt1 (Garzon et al., 2009), which 
might be expected to result in increased levels of Dnmts and subsequent DNA 
methylation. This suggests that miR-182 and miR-29b may work in concert to induce 
global hypermethylation in response to PB treatment (Table 5.2 and Figure 5.12). 
The function of this methylation change, and its transient nature are currently 
unknown.  
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Figure 5.12: MiRNA-mediated methylation 
Figure 5.12 demonstrates the predicted effect of the miR-182 target, Gnmt, in 
methylation patterns with another PB-sensitive miRNA, miR-29b based on target 
gene function from the literature, described in text. 
 
Other – Slc12a2 inhibition by miR-182 (and miR-96) could be involved in reducing 
PB-potentiated neuronal Cl- influx (Dzhala et al., 2005; Löscher & Rogawski, 2012). 
Smad4 suppression has been shown to inhibit increased Zeb expression (Gregory et 
al., 2011), therefore miR-182-mediated suppression of Smad4 may act in concert 
with miR-200a/b/429 and miR-96 on the suppressive effects on EMT (Figure 5.13). 
The role of Olr59, the novel putative target for miR-96, is uncertain but Olr59 
inhibition by miR-96 might be to reduce the receptor’s response to the influx of fatty 
acids as a result of PB treatment.  
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Figure 5.13: MiR-mediated effect on EMT 
Figure 5.13 demonstrates the predicted effect of the miR-182 target, Smad4, on cell 
transformation with other PB-sensitive miRNAs based on target gene function from 
the literature, described in text. 
 
Chapter 5 Conclusions – In conclusion the work presented here has identified 4 
validated miR-182/96 targets, and 5 novel targets (Table 5.2). Due to the functions of 
these genes and the PB-phenotype I propose that miR-182/96 are induced as a 
result of PB treatment in the rat in order to promote glycolysis and facilitate DNA 
methylation changes, as well as inhibiting cell transformation, and potentially 
modulating Car activation, neuronal Cl- influx, and lipid responses, and that miR-
182/96 accomplish this through shared and unique targets. 
 
Overall, I surmise that miR-182/96 work co-operatively with other miRNAs to 
maintain homeostasis during PB treatment in the rat. 
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6. Discussion  
6.1 General conclusions and future work 
The first 2 aims of this thesis were concerned with the use of a cell culture model of 
PB treatment. This was explored using the rat hepatocyte-like B13/H cell model. 
Aims 3 and 4 of this thesis pertained to the in vivo regulatory control and function of 
the PB inducible miR-182/96.  
 
6.1.1 Thesis aim 1: Characterise the B13/H cell line and its response to PB and PB-
like compounds. 
Background MiRNAs have been reported as being regulators of homeostasis, as 
well as contributing to disease when dysregulated (Ebert & Sharp, 2012). PB 
treatment in the rat progressively induced miRNA changes across a 90 day 
treatment study (Koufaris et al., 2012, 2013) (Figure 4.4). In order to begin 
understanding this response in vitro requires extended chemical treatments beyond 
the 2-3 days typically associated with optimal primary hepatocyte treatment 
(Soldatow et al., 2013). To circumvent the problem inherent with primary hepatocyte 
cultures, the hepatocyte-like B13/H cells were used, which are reported to maintain 
an hepatocyte-like phenotype up to 30 days (Marek et al., 2003). 
 
Results & Conclusion Generation of hepatocyte-like B13/H cells requires 
transdifferentiation from the pancreatic progenitor, B13, cell. This work confirmed 
that, in our hands, transdifferentiation to B13/H cells can be reliably performed 
through 2 weeks dexamethasone (10nM) treatment, with molecular and phenotypic 
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alteration towards an hepatocyte-like phenotype. Furthermore, B13/H cells 
responded to PB in an hepatocyte-like manner. However, the PB-responsive nuclear 
receptor, Car, appeared to reside in the nucleus, which is more representative of 
immortalised cells rather than primary hepatocytes; where Car can shuttle between 
the cytoplasm and the nucleus. Despite this caveat, I was able to use the 
transdifferentiated B13/H cells to reproduce PB-type responses. Finally, we showed 
that the in vivo PB-inducible miRNAs (miR-182/96) were also sensitive to PB 
treatment in vitro (B13/H cells) and demonstrated similar temporal expression 
patterns. 
 
Therefore, the B13/H cells are a useful model for exploring PB treatment in the rat, 
and offer a useful in vitro system for mechanistic studies that appear comparable to 
in vivo data.  
 
Future work Due to the nuclear localisation of Car in B13/H cells and the 
responsiveness of Car and Pxr to PB, understanding the extent of Car activation in 
the B13/H cells following PB treatment would be an important next step. This could 
be explored through the use of transient knock-down of Car in transdifferentiated 
B13/H cells using siRNA-mediated transfections. Additionally, I show that miR-122 
was decreased with PB treatment, and this has been reported to be involved in the 
activation of Car. Assessing dose- and time-dependent effects of PB on miR-122 
and Car-mediated gene expression would help to consolidate an interaction between 
miR-122 and Car. Furthermore, it would be necessary to perform a more extensive 
dose and time range of PB treatment to gain a better understanding of the miR-
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182/96 induction profile. This sample set would also allow one to explore the 
mechanistic effects of these miRNAs by assessing the expression of potential 
targets and regulators (such as those discussed below). 
 
6.1.2 Thesis aim 2: Explore the interaction with PB and growth factor signalling in 
vitro and in vivo. 
Background Mutoh et al., (Mutoh et al., 2013) report that PB indirectly activated Car 
through inhibition of the Egfr in the mouse. This is corroborated by previous work, 
which demonstrated that activation of the downstream Egfr signalling kinase, Erk, is 
inhibitory to Car activation in the mouse (Koike et al., 2007; Osabe & Negishi, 2011). 
Inhibition of Erk signalling has also been shown to increase expression of PB target 
genes in rat primary hepatocytes (F Joannard et al., 2000; Florence Joannard et al., 
2006). However, PB treatment in rat primary hepatocytes has also been reported to 
increase Erk activation (Florence Joannard et al., 2006). 
 
Results & Conclusion The data presented in this thesis suggests that B13/H cells 
respond to growth factors in a similar manner as rat primary hepatocytes, based on 
the literature, which is different to that of the mouse. B13/H cells respond to PB with 
increased Erk activation, as seen in rat primary hepatocytes (Florence Joannard et 
al., 2006), which is dependent on Egf. Joannard et al., (F Joannard et al., 2000; 
Florence Joannard et al., 2006) demonstrate suppression of PB-induced genes with 
Erk activation suggesting that Erk may act as a negative-feedback loop to control the 
magnitude of Car activation during PB exposure.  
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Egf or Hgf in combination with PB caused an increase in Akt activity compared to 
growth factors alone, which might suggest that PB augments pathway activity 
downstream of a growth factor receptor. Furthermore, through in vivo analysis I 
showed that changes in growth factor signalling appears to be a transient early effect 
with the most prominent changes taking place within 24 hours treatment, as 
indicated with the B13/H cells. However, the data also suggests that in vivo 
Akt/FoxO1 activity may be increased after 3 days PB (1000ppm) treatment 
compared to control, which indicates that Akt activation may be associated with the 
PB-induced transient hyperplasia reported at this time (Waterman et al., 2010). 
 
Future work In order to explore the function of Erk in PB-mediated activation of Car 
it would be necessary to assess expression of Car target genes following PB 
treatment in samples with increased or decreased Erk activation. It would be 
interesting to determine how PB affects Erk signalling. As Erk activation appears 
specific to Egf and not Hgf, it could be that this is a Egfr-mediated response. To 
determine the function of PB-induced Akt activation will be difficult as B13/H cells, 
like primary hepatocytes, are refractory to cell division (Cho, Berthiaume, Tilles, & 
Yarmush, 2008; Philip M E Probert et al., 2014), although analysis of downstream 
targets, such as FoxO1, could be used instead. Again, how PB interacts with Akt is 
unknown, but as this appears to be common between Egf and Hgf it suggests that 
PB affects the pathway downstream of the receptor. In order to begin to determine 
where PB interacts with both Erk and Akt signalling it would be necessary to perform 
a systematic study of the activation of the kinases within each pathway. 
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6.1.3 Thesis aim 3: Identify potential regulators of PB-induced miRNAs in vivo. 
Background Treatment with PB (1000ppm) in the rat for more than 14 days 
significantly increases 2 families of miRNAs (miR-182/96 and miR-200a/b/429) 
(Koufaris et al., 2013). There are many potential regulators of these miRNAs cited in 
the literature, but they appear to be highly context dependent. I identified a number 
of potential regulators that are associated with PB exposure. 
 
Results & Conclusion From the data presented, it is unlikely that miR-182/96 are 
regulated by Car, Hnf-4α, p53, ROS or Tgf-β. Changes in methylation patterns or 
through β-catenin-mediated alteration in cell adhesion signalling may contribute to 
the altered expression of miR-182/96 and miR-200a/b/429. PB is known to disrupt 
gap junction signalling to induce tumours in mice (Moennikes et al., 2000), and has 
been shown to stimulate cell membrane localisation of Car (Koike et al., 2005). 
Taken together it might be considered that PB induces cell membrane localisation of 
Car and alteration of β-catenin-mediated cell adhesion. Through altered β-catenin it 
might be that the PB-induced miRNAs are expressed, although the exact 
mechanisms behind this remain uncertain.  
 
Could it be possible that the induction of these miRNAs are a homeostatic response 
to PB treatment in the rat to inhibit tumourigenesis through β-catenin? This is an 
intriguing possibility as the mouse is more susceptible to PB-induced tumours than 
the rat, and the expression of miR-182/96 and miR-200a/b/429 are only increased 
after PB treatment in the rat (Koufaris, 2011) and not the mouse (Lempiäinen et al., 
2013). There are 3 main points to consider regarding this hypothesis:  
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(1) Does β-catenin only regulate the expression of miR-182/96 in the rat and not the 
mouse; as β-catenin is mutated in tumours from DEN/PB mouse studies (Aydinlik et 
al., 2001) and is in fact required for tumourigenesis in the mouse (Rignall et al., 
2011)? 
(2) Is β-catenin affected by PB in the rat? 
(3) Are β-catenin and miRNA expression differentially regulated between tumours 
and healthy tissue in the livers of DEN/PB treated rats?  
 
Future work Further methylation analysis of the upstream sequence of miR-182/96 
and miR-200a/b/429 would aid in determining the extent methylation changes play in 
the expression of these miRNAs. Identification of common regulatory sequences 
within these rat miRNAs that are not present in the mouse would be interesting to 
explore. It would also be important to assess the localisation of Car and β-catenin 
over time in correlation with these miRNAs to determine if the above proposed 
interaction is plausible.  
 
6.1.4 Thesis aim 4: Elucidate the potential function of PB-induced miRNAs in vivo. 
Background As with the regulators of these miRNAs, their function also appears to 
be highly context dependent. In order to identify putative mRNA targets I used in 
silico prediction programs as well as selecting validated targets from the literature. 
From here I screened targets based on (1) a significant change in expression with 
PB treatment in the rat in vivo, and (2) by significant negative correlation with miR-96 
over a 14 day PB treatment study in the rat.  
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Results & Conclusion By this approach I identified 4 validated targets for miR-182 
(Slc12a2, Smad4, Rb1, FoxO1), and 1 for miR-96 (FoxO1), as well as 3 predicted 
targets for miR-182 (Pc, Slc37a4, Gnmt) and 4 for miR-96 (Slc12a2, Pc, Map2k1, 
Olr59). Two targets, Gnmt and FoxO1, were analysed over an extended sample set 
to include up to 90 days PB treatment, and both targets maintained significant 
negative correlations with miR-182. Protein levels were also assessed and were 
suggestive of these targets being controlled by miRNA regulation. 
 
From the reported functions of these miRNA targets I proposed that miR-182/96 are 
involved in promoting glycolysis, possibly to allow production of NADPH through the 
tricarboxylic acid (TCA) cycle for Cyp450-mediated metabolism (Figure 5.11).  
 
Additionally, through miR-96 targeting of Map2k1, an upstream kinase involved in 
Erk activation, I suggest that miR-96 may be acting to modulate Erk activation and 
hence its purported target, Car. Data in Figure 3.10 demonstrated that in vivo Erk 
activity in response to PB (1000ppm), although variable, was not significantly 
changed from control, indicating that either miR-96 may not influence this pathway, 
or that the presence of miR-96 with PB treatment may be maintaining pathway 
activity relative to control. This distinction would be important to determine in future 
work and could be assessed by suppressing miR-96 and overexpressing its target, 
Map2k1, to determine the effect on Erk activity and Car phosphorylation and activity.  
 
MiR-182 is predicted to target the mRNA Gnmt, which is involved in regulating 
methylation, possibly by controlling availability of S-adenosylmethionine. As PB is 
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reported to alter methylation in the rat (Koufaris et al., 2013), it could be that this is in 
part mediated by miR-182 in concert with miR-29b, which Koufaris et al., (Koufaris et 
al., 2013) reported as decreased by PB treatment and has been identified as a 
regulator of the methylation enzymes Dnmt3a/3b (Garzon et al., 2009).  
 
PB treatment in the rat is reported to reduce expression of the EMT-associated 
transcription factors, Zeb1/2 (Koufaris et al., 2013). Both miR-200a/b/249 (Bracken 
et al., 2008; Gregory et al., 2008) and miR-96 (X. L. Li et al., 2013) have been 
reported to target Zeb1/2, suggesting these miRNAs may contribute to the 
maintenance of normal cell morphology through inhibiting EMT. This hypothesis is 
strengthened by the proposal that miR-182 targets Smad4. Knockdown of Smad4 
has been reported to suppress induction of Zeb1/2 mRNA (Gregory et al., 2011). 
Therefore these miRNAs may act in concert to prevent Zeb1/2 induction and 
suppress residual levels. 
 
PB potentiates Cl- influx in response to GABA (Löscher & Rogawski, 2012). The 
Na+/K+/2Cl- cotransporter, Scl12a2, is also reported to increase neuronal Cl- influx in 
neonates (Dzhala et al., 2005). Therefore, it could be that miR-182/96 targeting of 
Scl12a2 may act to modulate PB-induced neuronal Cl- influx. This is interesting as it 
could suggest that miR-182/96 may possess extra-hepatic effects.   
 
Finally, miR-96-mediated suppression of Olr59 could be involved in reducing the 
intracellular response to the influx of fatty acids associated with PB treatment, 
although the function of this is currently unknown.  
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Future work To confirm these proposed putative targets it would be necessary to 
perform miRNA transfection studies to experimentally manipulate the expression of 
the mRNAs. Furthermore, to identify the in vivo effects of these miRNAs, performing 
a miR-182/96 knockout study in the rat with PB treatment would help to determine if, 
for example, the miRNAs are acting to regulate Car activity or NADPH production for 
Cyp450 activities. Due to the proposed role in homeostasis and potential regulation 
by β-catenin it would be interesting to determine the expression of these miRNAs 
and their targets following a DEN/PB tumour initiation study in the rat.  
 
6.2 Consolidation – the big picture 
We demonstrated that the B13/H cell model appears to act in an hepatocyte-like 
manner and provide a model system with which we can begin to explore the 
molecular effects of PB in the rat and explore the roles and regulation of the PB-
inducible miRNAs; miR-182/96. Furthermore, we suggest that the mechanism by 
which PB indirectly activates Car in the rat is different to that of the mouse. While 
both organisms seem to involve Erk activity, PB in the mouse inhibits Erk activation, 
while in the rat PB appears to increase activation. 
 
The data presented in this thesis suggests that miR-182/96 may have a homeostatic 
role in the context of PB exposure in the rat, and through future work determining the 
effect of the loss of these miRNAs with PB treatment, I propose will identify these 
small ncRNAs as indicative of resistance to PB-induced tumourigenesis. 
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6.2.1 If not Egfr, what could be the rat PB receptor? 
The data presented in chapter 3 showed that Erk activity was increased with PB 
treatment in combination with Egf in B13/H cells, in agreement with primary rat 
hepatocytes (Florence Joannard et al., 2006). This suggests that PB does not 
antagonise the Egfr to activate Car, as reported in the mouse. I argued in chapter 1 
that Ampk activation may be involved in the full activation of nuclear Car, which is 
associated with decreased miR-122 expression shown in Figure 2.10, and by others 
(Kazantseva et al., 2015). PB-induced down regulation of miR-122 is reported to be 
a transient event occurring within the first 24 hours of treatment (Shizu et al., 2012). 
It has been suggested that PB reduces expression of miR-122 through nuclear Car-
mediated inhibition of Hnf-4α target gene transcription (of which miR-122 is a target) 
(Kazantseva et al., 2015); although PB-induced Pxr is also reported to inhibit Hnf-4α 
target gene transcription (Bhalla et al., 2004). Furthermore, miR-122 is also reported 
to be an indirect target of glycogen synthase kinase 3β (Gsk-3β) (Zeng et al., 2010). 
Gsk-3β is a kinase of high basal activity, reported to be involved in glucose 
metabolism and Wnt signalling (Aydinlik et al., 2001; Sakamaki et al., 2012). Gsk-3β 
is inhibited by Erk-mediated phosphorylation (Q. Ding et al., 2005), which is activated 
by PB treatment (Figure 3.6). Additionally, β-catenin levels increase as a result of 
Gsk-3β inhibition due to decreased β-catenin phosphorylation and ubiquitin-
proteaseomal degradation (Q. Ding et al., 2005). These suggest that PB may reduce 
miR-122 expression levels through Car/Pxr-mediated inhibition of Hnf-4α target gene 
transcription and/or through Erk activation and subsequent Gsk-3β inhibition, and 
that this process may also influence β-catenin (Figure 6.1).  
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Figure 6.1: Proposed PB signalling pathway in rat hepatocytes 
Figure 6.1 PB through GABAA, causes the nuclear translocation of Car. Due to Car’s 
structure it displays constitutive activity once in the nucleus, but is thought to require 
further molecular changes for full activation. Either inhibition of Hnf-4α, or Gsk-3β 
results in transiently reduced levels of miR-122 and subsequent activation of Ampk. 
Active Ampk provides the necessary signal for full activation of Car.  
Inhibition of Gsk-3β increases the stability of β-catenin, which may induce the miR-
182/96 cluster in association with cell membrane bound Car. 
Induction of miR-182/96 can feedback to regulate Erk activation, and glycolysis for 
NADPH generation for Cyp450 genes induced by Car. 
Blue colouration depicts increased activity/expression, while decreased 
activity/expression is shown in red. Discussed in text and adapted from: (Aydinlik et 
al., 2001; Kazantseva et al., 2015; Rignall et al., 2011; Shizu et al., 2012; Zeng et al., 
2010). 
 
Interestingly, increased Ampk activity is known to decrease gluconeogenesis in the 
liver (Lochhead, Salt, Walker, Hardie, & Sutherland, 2000), which is associated with 
PB exposure. This coincides with the data presented in chapter 5 suggesting that 
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miR-182/96 may also be involved in inhibiting gluconeogenesis, through targets such 
as Rb1, FoxO1, Pc, Slc37a4 and Gnmt (Figure 5.11). 
 
However, nuclear activation of Car by Ampk still does not explain what the cell signal 
is that causes Car translocation into the nucleus. If not Egfr in the rat, then what? PB 
is known to exert its anti-epileptic effects through the GABAA receptor (Löscher & 
Rogawski, 2012), which has been shown to be present in the liver (Sun et al., 2003). 
Interestingly, GABAA-β3 expression has been reported to be lost in certain human 
hepatocellular carcinoma cell lines (Sun et al., 2003), and the induction of Cyp2b by 
PB is also attenuated in preneoplastic lesions of rat livers (Numazawa et al., 2005). 
Taken together this implies that, in the rat, Car may be induced to translocate into 
the nucleus as a result of PB binding to GABAA, and that complete nuclear activation 
is controlled by Ampk activation (Figure 6.1). If this is the case, then GABAA 
activation in the liver might result in an influx of Cl- into hepatocytes following PB 
treatment. Therefore, miR-182/96 targeting of the K+/Na+/2Cl- cotransporter, 
Slc12a2, may be to modulate both neuronal and hepatic Cl- influx. The role of 
GABAA activation in the indirect activation of Car is an intriguing possibility and could 
be explored using the B13/H cell model.  
 
6.2.2 Thesis hypothesis 
“I hypothesise that the rat hepatocyte-like, B13/H, cell system can provide robust 
mechanistic insights into the PB phenotype. Additionally, that the regulation and 
function of PB-induced miRNAs can be explored using in vivo samples, and provide 
context-specific relationships relevant to chronic PB exposure.” 
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I believe that the work presented herein confirms my hypothesis and provides the 
necessary background to fully explore these miRNAs as a homeostatic response to 
the resistance of PB-induced tumours, as well as interrogating PB-mediated 
activation of Car, in the rat. 
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